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As	  you	  set	  out	  for	  Ithaka	  
hope	  your	  road	  is	  a	  long	  one,	  
full	  of	  adventure,	  full	  of	  discovery.	  
Laistrygonians,	  Cyclops,	  
angry	  Poseidon—don’t	  be	  afraid	  of	  them:	  
you’ll	  never	  find	  things	  like	  that	  on	  your	  way	  
as	  long	  as	  you	  keep	  your	  thoughts	  raised	  high,	  
as	  long	  as	  a	  rare	  excitement	  
stirs	  your	  spirit	  and	  your	  body.	  
Laistrygonians,	  Cyclops,	  
wild	  Poseidon—you	  won’t	  encounter	  them	  
unless	  you	  bring	  them	  along	  inside	  your	  soul,	  
unless	  your	  soul	  sets	  them	  up	  in	  front	  of	  you.	  
	  
Hope	  your	  road	  is	  a	  long	  one.	  
May	  there	  be	  many	  summer	  mornings	  when,	  
with	  what	  pleasure,	  what	  joy,	  
you	  enter	  harbors	  you’re	  seeing	  for	  the	  first	  time;	  
may	  you	  stop	  at	  Phoenician	  trading	  stations	  
to	  buy	  fine	  things,	  
mother	  of	  pearl	  and	  coral,	  amber	  and	  ebony,	  
sensual	  perfume	  of	  every	  kind—	  
as	  many	  sensual	  perfumes	  as	  you	  can;	  
and	  may	  you	  visit	  many	  Egyptian	  cities	  
to	  learn	  and	  go	  on	  learning	  from	  their	  scholars.	  
	  
Keep	  Ithaka	  always	  in	  your	  mind.	  
Arriving	  there	  is	  what	  you’re	  destined	  for.	  
But	  don’t	  hurry	  the	  journey	  at	  all.	  
Better	  if	  it	  lasts	  for	  years,	  
so	  you’re	  old	  by	  the	  time	  you	  reach	  the	  island,	  
wealthy	  with	  all	  you’ve	  gained	  on	  the	  way,	  
not	  expecting	  Ithaka	  to	  make	  you	  rich.	  
	  
Ithaka	  gave	  you	  the	  marvelous	  journey.	  
Without	  her	  you	  wouldn't	  have	  set	  out.	  
She	  has	  nothing	  left	  to	  give	  you	  now.	  
	  
And	  if	  you	  find	  her	  poor,	  Ithaka	  won’t	  have	  fooled	  you.	  
Wise	  as	  you	  will	  have	  become,	  so	  full	  of	  experience,	  
you’ll	  have	  understood	  by	  then	  what	  these	  Ithakas	  mean.	  
	  
Ithaka.	  KP	  Kavafis	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In	   this	   study	   I	   describe	   a	   novel	   mechanism	   by	   which	   increased	   levels	   of	   c-­‐Fos/AP-­‐1	  transcription	  factor	  in	  the	  epidermis	  promotes	  the	  development	  of	  epidermal	  preneoplastic	   lesions	   and	   eventually,	   upon	   7,12-­‐dimethyl-­‐benz[a]anthracene	   (DMBA)	  treatment,	  it	  contributes	  to	  the	  development	  of	  skin	  Squamous	  Cell	  Carcinomas	  (SCCs).	  To	  unravel	  the	  function	  of	  epidermal	  c-­‐Fos,	  we	  have	  generated	  a	  mouse	  model	  (c-­‐FosEp-­
tetON)	  in	  which	  we	  can	  inducibly	  activate	  the	  expression	  of	  c-­fos	  in	  the	  basal	  layer	  of	  the	  epidermis	  as	  well	  as	  in	  other	  stratified	  epithelia.	  I	  show	  that	  inducible	  c-­fos	  expression	  triggers	  innate	  and	  adaptive	  immune	  responses	  in	  the	  epidermis,	  particularly,	  transient	  recruitment	   of	   Gr1+	   cells	   and	   chronic	   recruitment	   of	   CD4	   T	   lymphocytes.	   In	   addition,	  broad	  genome-­‐wide	  expression	  analyses	  identified	  two	  direct	  and	  novel	  transcriptional	  target	   genes	   of	   c-­‐Fos,	   mmp10	   and	   s100a7a15.	   Both	   target	   genes	   are	   involved	   in	  inflammatory	  processes,	  being	  able	  to	  recruit	  Gr1+	  cells	  and	  CD4	  T	  lymphocytes,	  as	  well	  as	   in	   the	   development	   of	   cutaneous	   cancers.	   Importantly,	   using	   a	   broad	   matrix	  metalloprotease	   (MMP)	   inhibitor	   to	   reduce	   MMP10	   activity	   in	   the	   epidermis,	   we	  observed	   amelioration	   of	   the	   development	   of	   the	   preneoplastic	   lesions	   of	   the	   skin.	  	  Furthermore,	   in	  the	  absence	  of	  mature	  B	  and	  T	  cells	   in	  a	  Rag1-­‐deficient	  background,	  a	  drastic	   improvement	   of	   the	   disease	   in	   FosEp-­tetON	  mice	  was	   observed.	   Moreover,	   upon	  DMBA-­‐induced	  H-­‐Ras	  mutations,	  c-­‐Fos	  is	  sufficient	  to	  promote	  the	  development	  of	  skin	  SCCs.	   Interstingly,	   in	   this	   setting,	   tumor	   size,	   number	   and	   burden	   were	   significantly	  reduced	  upon	  blockade	  of	  inflammatory	  responses	  by	  means	  of	  a	  cyclooxygenase	  1	  and	  2	   (COX-­‐1/COX-­‐2)	   inhibitory	   treatment	   following	   DMBA	   treatment	   and	   inducible	  expression	  of	  c-­fos.	  Finally,	  I	  have	  seen	  a	  strong	  correlation	  between	  human	  c-­‐FOS	  and	  MMP10	  expression	  in	  human	  SCCs,	  where	  they	  are	  abundantly	  expressed,	  compared	  to	  BCCs,	   where	   no	   expression	   of	   these	   two	   proteins	   is	   observed.	   In	   addition,	   a	   strong	  correlation	  between	  c-­‐FOS	  expression	  and	  CD4	  T	  cell	  infiltrates	  were	  observed	  in	  human	  SCCs.	   This	   thesis	   has	   identified	   two	   novel	   and	   direct	   transcriptional	   targets	   of	   c-­‐Fos,	  MMP10	   and	   S100a7a15,	   clearly	   involved	   in	   mediating	   CD4	   T	   cell-­‐mediated	   immune	  responses	   in	   the	   epidermis	   and	   thereby	   contributing	   to	   the	   development	   of	  preneoplastic	  lesions,	  which	  upon	  oncogenic	  insults,	  eventually	  develop	  into	  SCCs.	  Here	  I	  propose	   two	  new	  candidate	  proteins	   that	  could	  be	  of	   therapeutic	   interest	   to	   treating	  cutaneous	  SCCs.	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   Los	   resultados	   de	  mi	   proyecto	   de	   tesis	   han	   dado	   lugar	   a	   la	   descripción	   de	   un	  nuevo	  mecanismo	  mediante	  el	   cual	   el	   factor	  de	   transcripción	  c-­‐Fos/AP-­‐1	  promueve	  el	  desarrollo	  de	  lesiones	  preneoplásicas	  en	  la	  epidermis	  y	  en	  combinación	  con	  la	  aplicación	  de	  DMBA,	  promueve	  el	  desarrollo	  de	  carcinomas	  epidermoides	  (SCCs).	  Para	  estudiar	  la	  función	  de	  c-­‐Fos	  en	  la	  epidermis,	  hemos	  generado	  un	  modelo	  genético	  de	  ratón	  (c-­‐FosEp-­
tetON)	  en	  el	  cual	  se	  puede	  inducir	  la	  expresión	  de	  c-­fos	  en	  la	  capa	  basal	  de	  la	  epidermis	  y	  en	   otros	   epitelios	   estratificados.	   Aquí	   demuestro	   que	   la	   expresión	   inducible	   de	   c-­fos	  promueve	  respuestas	   inmunes	  innatas	  y	  también	  adaptativas	  en	  la	  piel,	   fomentando	  la	  infiltración	   de	   células	   Gr1+	   transitoriamente	   y	   de	   linfocitos	   T	   CD4+	   de	   forma	   crónica.	  Mediante	   análisis	   de	   expresión	   genómica	   se	   identificaron	   dos	   nuevos	   genes	   diana,	  
mmp10	  y	  s100a7a15,	  ambos	  implicados	  en	  procesos	  inflamatorios	  así	  como	  también	  en	  cánceres	   de	   piel.	   La	   inhibición	   de	   metalloproteasas	   (MMPs)	   mediante	   el	   uso	   de	   un	  inhibidor,	  redujo	  significativamente	  la	  progresión	  de	  las	  lesiones	  preneoplásicas	  tras	  la	  inducción	  de	  la	  expresión	  de	  c-­fos	  en	  ratones	  c-­‐FosEp-­tetON.	  Además,	  una	  mejora	  drástica	  se	   observó	   en	   el	   80%	   de	   los	   casos	   al	   deplecionar	   las	   poblaciones	   de	   linfocitos	   T	   y	   B	  maduros,	  mediante	  el	  uso	  de	  un	  ratón	  knock-­‐out	  para	  Rag1.	  Asimismo,	  en	  esta	  tesis	  he	  demostrado	   que	   el	   factor	   de	   transcripción	   c-­‐Fos/AP-­‐1	   es	   suficiente	   para	   promover	   el	  desarrollo	  de	  carcinomas	  epidermoides	  en	  ratones	   tratados	  con	  el	  carcinógeno	  DMBA.	  En	   este	   mismo	   sistema,	   el	   bloqueo	   de	   procesos	   inflamatorios	   en	   la	   piel,	   mediante	   la	  inhibición	   de	   las	   enzimas	   COX1	   y	   COX2,	   en	   ratones	   inducidos	   con	   DMBA	   y	   c-­‐Fos	   se	  observa	   una	   disminución	   en	   el	   desarrollo	   de	   carcinomas	   epidermoides	   y	   aquellos	  desarrollados	   son	   más	   pequeños.	   Finalmente,	   los	   análisis	   de	   muestras	   humanas	   de	  carcinomas	   epidermoides	   y	   carcinomas	   basales	   de	   piel	   han	   descubierto	   la	   posible	  implicación	   de	   c-­‐FOS	   sólo	   en	   los	   carcinomas	   epidermoides	   dado	   que	   el	   80%	  de	   estos	  tumores	  presentaba	  altos	  niveles	  de	  c-­‐FOS,	  mientras	  que	   los	   carcinomas	  basales	  no	   lo	  expresaban.	  Finalmente,	  he	  observado	  una	  correlación	  entre	  la	  expresion	  de	  c-­‐FOS	  y	  de	  MMP10	  en	  carcinomas	  epidermoides,	  MMP10	  podría	  perfectamente	  ser	  un	  gen	  diana	  de	  c-­‐FOS	  en	  humano	  como	  observamos	  en	   ratón.	  Asimismo,	   se	  observó	  correlación	  entre	  los	  niveles	  de	  expresión	  de	  c-­‐FOS	  en	  los	  carcinomas	  epidermoides	  y	  los	  altos	  niveles	  de	  infiltración	   de	   células	   T	   CD4+.	   Esta	   tesis	   ha	   servido	   para	   identificar	   dos	   genes	  transcripcionalmente	  activados	  por	  c-­‐Fos,	  mmp10	  y	  s100a7a15,	   claramente	   implicados	  en	  el	  desarrollo	  de	  procesos	  inflamatorios	  mediados	  por	  células	  T	  CD4+	  en	  la	  piel	  y	  que	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promueven	   inicialmente	   el	   desarrollo	   de	   lesiones	   preneoplásicas	   y	   eventualmente	   el	  desarrollo	   de	   carcinomas	   epidermoides.	   	   El	   desarrollo	   de	   fármacos	   específicos	   para	  estas	  dos	  dianas	  puede	  ser	  de	  uso	  terapéutico	  en	  carcinomas	  epidermoides.	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ABBREVIATIONS	  ADAM	   A	  disintegrin	  and	  metalloproteinase	  ADAMTS	  	   A	  disintegrin	  and	  metallopreinase	  with	  thrombospoindin	  motifs	  AP-­‐1	   Activator	  Protein	  1	  ATF	   Activating	  transcription	  factor	  BCC	   Basal	  Cell	  Carcinoma	  BSA	   Bovine	  Serum	  Albumine	  ChIP	   Chromatin	  IP	  CTLS	   Cytotoxic	  T	  lymphocytes	  DC	   Dendritic	  cell	  DMBA	   7,12-­‐dimethyl-­‐benz[a]anthracene	  	  Dox	   Doxycycline	  ECM	   Extracellular	  matrix	  EdU	   5-­‐ethynyl-­‐2`-­‐deoxyuridine	  EGF	   Epidermal	  growth	  factor	  EGFR	   Epidermal	  growth	  factor	  receptor	  ERK	   Extracellular	  signal	  regulated	  kinase	  FBS	   Fetal	  bovine	  serum	  GM-­‐CSF	   Granulocyte	  monocyte	  colony	  stimulating	  factor	  HEK	   Human	  epidermal	  keratinocytes	  HF	   Hair	  follicle	  HPV	   Human	  papillomavirus	  IBD	   Inflammatory	  bowel	  disease	  IEL	   Intraepithelial	  lymphocyte	  IFE	   Interfollicular	  epidermis	  IHC	   Immunohistochemistry	  IP	   Intraperitoneal	  JNK	   Jun	  N-­‐terminal	  kinase	  K1	   Keratin	  1	  K10	   Keratin	  10	  K5	   Keratin5	  K6	   Keratin	  6	  KGF	   Keratinocyte	  growth	  factor	  LOH	   Loss	  of	  heterozigosity	  LOX	   Lysil	  oxidase	  MAPK	   Mitogen-­‐activated	  protein	  kinase	  MMP	   Matrix	  Metalloprotease	  NK	   Natural	  Killer	  NMSC	   Non	  melanoma	  skin	  cancer	  OCT	   Optimal	  cutting	  temperature	  PBS	   Phosphate	  buffered	  saline	  PDAC	   Pancreatic	  ductal	  adenocarcinoma	  PTCH1	   Patched1	  RT	   Room	  temperature	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1.	  THE	  SKIN	   	  The	  skin	  is	  the	  body´s	  largest	  organ.	  It	  serves	  as	  a	  protective	  barrier	  that	  protects	  against	   loss	   of	   fluids,	   physical	   trauma	   and	   invasion	   by	   harmful	  microbes.	   The	   skin	   is	  divided	   into	   two	   different	   compartments,	   the	   dermis	   and	   the	   epidermis.	   Interactions	  between	  epithelial	  and	  mesenchymal	  cells	  play	  a	  crucial	  role	  in	  the	  regulation	  of	  tissue	  morphogenesis,	  homeostasis	  and	  repair	  (Beck	  and	  Blanpain,	  2012).	  
1.1.	  The	  Dermis	  The	   dermis	   is	   the	   fibrous	   connective	   tissue	   between	   the	   epidermis	   and	   the	  subcutaneous	  fat	  and	  is	  responsible	  for	  providing	  nutrients	  and	  physical	  support	  to	  the	  epidermis	   (Burr	   and	  Penzer,	   2005).	   The	  most	   abundant	   cell	   type	   in	   the	   dermis	   is	   the	  fibroblast	   (McLafferty	  et	  al.,	  2012).	  Fibroblasts	  synthesize	   the	  extracellular	  matrix	  and	  collagen	  required	  for	  normal	  homeostasis.	  Type	  I	  collagen	  is	  by	  far	  the	  most	  abundant	  protein	   in	  human	  skin,	   comprising	  greater	   than	  90%	  of	   its	  dry	  weight	  and	   the	  unique	  physical	  properties	  of	  collagen	  fibers	   is	   to	  confer	  structural	   integrity	  to	  skin	  (Fisher	  et	  al.,	   2008).	   	   The	   dermis	   also	   contains	   blood	   and	   lymph	   vessels,	   nerve	   endings,	   hair	  follicles	   and	   glands.	   Immune	   cells	   also	   populate	   the	   dermis.	   Some	   immune	   cells	   like	  mastocytes,	   histiocytes	   and	   γ/δ	   T	   lymphocytes	   are	   resident	   in	   the	   skin,	   but	   other	  leukocytes	   like	   T	   cells	   migrate	   to	   the	   skin	   upon	   injury	   or	   infection	   (Gebhardt	   et	   al.,	  2011).	  
1.2.	  The	  Epidermis	  The	  epidermis	  is	  a	  stratified	  epithelium	  that	  contains	  a	  single	  inner	  (basal)	  layer	  of	  proliferative	  keratinocytes	   that	  adhere	   to	   the	  basement	  membrane,	  which	   is	   rich	   in	  extracellular	   matrix	   and	   growth	   factors,	   and	   separates	   the	   epidermis	   from	   the	  underlying	  dermis.	  Cells	   in	   the	  basal	   layer	  are	  responsible	   for	  generating	   the	   layers	  of	  non-­‐dividing	   cells	   that	   undergo	   a	   program	   of	   terminal	   differentiation	   as	   they	   move	  outward	  and	  are	  continually	  shed	   from	  the	  skin	  surface	  (Figure	  1)	  (Fuchs	  and	  Nowak,	  2008).	  The	  balance	  between	  proliferation	  and	  differentiation	  is	  tightly	  regulated,	  since	  the	   disruption	   of	   this	   balance	   causes	   several	   pathological	   conditions	   including	  inflammation	  and	  tumorigenesis	  (Blanpain	  and	  Fuchs,	  2009).	  Indeed,	  a	  disruption	  of	  the	  differentiation-­‐promoting	   Notch	   signaling	   pathway	   or	   a	   hyperactivation	   of	   the	   EGFR-­‐
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Ras-­‐MAPK	   signaling	   pathway	   in	   keratinocytes,	   leads	   to	   the	   development	   of	   epithelial	  tumors	  (Demehri	  et	  al.,	  2009;	  Brown	  et	  al.,	  1998).	  
Figure	  I1.	  	  	  	  	  	  	  	  	  	  	  	  	  
The skin and its appendages. Cross-section through mammalian skin and a hair follicle (Fuchs and Raghavan, 
2002)	   As	   epidermal	   keratinocytes	   exit	   the	   basal	   layer	   and	   cease	   to	   proliferate,	   they	  progress	   upward	   through	   three	   distinct	   differentiation	   stages:	   spinous	   layer,	   granular	  layer	   and	   stratum	   corneum.	   The	  major	   structural	   change	   at	   the	   basal-­‐to-­‐spinous-­‐layer	  transition	  is	  the	  switch	  from	  keratin	  5	  and	  keratin	  14	  intermediate	  filaments	  in	  the	  basal	  layer	   to	   Keratin	   1	   and	   Keratin	   10	   suprabasally.	   Additional	   changes	   occur	   in	   the	  basal/spinous	  transition,	  such	  as	  downregulation	  of	  p63,	  a	  member	  of	  the	  p53	  family	  of	  transcription	   factors	   (Dotto,	   2009).	   p63	   is	   expressed	   in	   basal	   cells	   of	   all	   stratified	  epithelia	   and	   is	   thought	   to	   represent	   a	   master	   regulator	   of	   the	   stratification	   process	  (Blanpain	   et	   al.,	   2007).	   Indeed,	   p63-­‐deficient	   mice	   die	   postnatally	   from	   severe	  developmental	  anomalies,	  including	  a	  lack	  of	  stratified	  epithelia	  (Mills	  et	  al.,	  1999).	  	  As	  cells	  enter	  the	  granular	  layer,	  the	  primary	  cornified	  envelope	  protein	  loricrin	  is	   expressed	   and	   lamellar	   granules	   packed	   full	   of	   lipids	   appear	   (Blanpain	   and	   Fuchs,	  2009).	   Profilaggrin	   is	   also	   expressed	   at	   this	   time,	   and	   soon	   afterwards,	   it	   is	  proteolytically	  processed	  to	  generate	  filaggrin,	  a	  protein	  that	  bundles	  keratin	  filaments	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into	   indestructible	   cables	   (Aho	   et	   al.,	   2012).	   As	   granular	   cells	   transit	   to	   the	   stratum	  
corneum,	  the	  metabolical	  activity	  ceases,	  and	  an	  influx	  of	  calcium	  results	  in	  activation	  of	  transglutaminases,	   that	   initiate	   glutamyl-­‐e-­‐lysine	   crosslinks	   to	   produce	   the	   cornified	  envelope,	   characteristic	   of	   this	   layer	   (Eckert	   et	   al.,	   2005).	   The	   cornified	   envelope	  surrounds	   cells	   in	   the	   stratum	   corneum	   and	   contributes	   to	   the	   skin's	   barrier	   function	  (Simpson	   et	   al.,	   2011).	   	   Eventually,	   keratinocytes	   in	   the	   stratum	   corneum	   undergo	  apoptosis	   and	   are	   released	   from	   the	   surface	   of	   the	   epidermis	   (Blanpain	   and	   Fuchs,	  2009).	  The	  epidermis	  also	  has	  the	  remarkable	  ability	  to	  elaborate	  the	  body	  surface	  with	  appendages,	  which	  range	  from	  hair	  follicles,	  nails,	  oil	  and	  sweat	  glands	  in	  mammals	  to	  scales	  and	  feather	  in	  lower	  vertebrates	  (Fuchs	  and	  Nowak,	  2008).	  	  Besides	   keratinocytes,	   three	   other	   cell	   types	   are	   found	   in	   the	   epidermis:	  melanocytes,	   Langerhans	   cells	   and	   Merkel	   cells.	   They	   are	   not	   abundant,	   but	   have	  important	  functions.	  Melanocytes	  are	  located	  in	  the	  lower	  part	  of	  the	  epidermis	  and	  they	  synthesize	  melanin,	   the	   pigment	   that	   gives	   skin	   the	   natural	   color	   (Haass	   and	   Herlyn,	  2005).	   Langerhans	   cells	   are	   dendritic	   cells	   (antigen-­‐presenting	   immune	   cells)	   of	   the	  epidermis	  and	  they	  are	  present	  in	  all	  layers	  of	  the	  epidermis,	  but	  are	  most	  prominent	  in	  the	  stratum	  spinosum	  where	  they	  take	  up	  and	  process	  microbial	  antigens	  to	  become	  fully	  functional	  antigen	  presenting	  cells	  (Romani	  et	  al.,	  2012).	  Merkel	  cells	  are	  oval	  receptor	  cells	   that	   have	   synaptic	   contacts	   with	   somatosensory	   neurons	   and	   these	   cells	   are	  involved	  in	  the	  sensation	  of	  light	  touch	  (Boulais	  and	  Misery,	  2007).	  
1.3.	  Epidermal	  and	  dermal	  crosstalk	  Interactions	   between	   mesenchymal	   and	   epithelial	   cells	   are	   responsible	   for	  complex	  events	  such	  as	  tissue	  development,	  homeostasis	  and	  repair	  (Werner	  and	  Smola,	  2001).	  This	  mutual	  crosstalk	  mainly	  involves	  growth	  factors	  and	  cytokines.	  	  Pioneering	  studies	   of	   Rheinwald	   and	   Green	   demonstrated	   that	   normal	   human	   epidermal	  keratinocytes	  depend	  on	  the	  presence	  of	  fibroblasts	  for	  efficient	  growth	  in	  tissue	  culture	  (Rheinwald	   and	   Green,	   1975).	   Later	   on	   Rubin,	   et	   al	   identified	   a	   fibroblast-­‐derived	  growth	  factor	  (FGF),	  termed	  Keratinocyte	  Growth	  Factor	  (KGF),	  that	  strongly	  stimulated	  the	   proliferation	   of	   keratinocytes	   (Rubin	   et	   al.,	   1989).	   Moreover,	   the	   group	   of	   Peter	  Angel	  described	  a	  paracrine	   loop	   in	  which	  by	  using	   immortalized	   fibroblasts	  deficient	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for	   c-­‐Jun	   and	   JunB,	   in	   combination	   with	   human	   primary	   keratinocytes	   in	   the	   three-­‐dimensional	  organotypic	  co-­‐culture	  system,	  observed	  that	  the	  lack	  of	  either	  one	  of	  these	  transcription	  factors	  in	  fibroblasts	  severely	  affected	  proliferation	  and	  differentiation	  of	  the	  overlying	  normal	  human	  keratinocytes	   (Szabowski	  et	  al.,	  2000).	  This	  was	  due	   to	  a	  direct	  transcriptional	  regulation	  of	  KGF	  and	  GM-­‐CSF	  by	  Jun/AP-­‐1	  proteins	  in	  fibroblasts.	  Furthermore,	   this	   crosstalk	   could	   also	   have	   an	   impact	   in	   epithelial	   tumorigenesis.	  Indeed,	  recent	  studies	  have	  shown	  that	  a	  disruption	  in	  the	  Notch	  signaling	  pathway	  in	  the	   mesenchymal	   compartment	   leads	   to	   the	   secretion	   of	   soluble	   factors	   in	   an	   AP-­‐1	  dependent	  manner	   (FGF7,	   FGF10,	   CSF1,	  MMP3	   and	  MMP13).	   These	   factors	   create	   an	  appropriate	  microenvironment	  in	  the	  dermis,	  also	  termed	  as	  "field	  cancerization",	  that	  promotes	  epithelial	  tumorigenesis	  (Hu	  et	  al.,	  2012).	  
1.4.	  Epidermal	  Stem	  Cells	  	   The	   adult	   epidermis	   and	   its	   appendages	   undergo	   continuous	   renewal	   and	  maintain	  reservoirs	  of	  multipotent	  stem	  cells	  (SC).	  Different	  stem	  cell	  pools	  have	  been	  found	  in	  the	  hair	  follicle	  (HF)	  as	  well	  as	  in	  the	  interfollicular	  epidermis	  (IFE).	  	  	   HF	   stem	   cells	   reside	   in	   a	   specialized	  microenvironment	   called	   the	  bulge.	  These	  cells	   cycle	   slowly,	   as	   revealed	   by	   their	   ability	   to	   retain	   a	   pulse	   of	   nucleotide	   label	  following	   weeks	   of	   chase	   (Alonso	   and	   Fuchs,	   2003).	   The	   bulge	   is	   composed	   of	   a	  heterogeneous	  population	  of	  self-­‐renewing	  multipotent	  cells.	  Stem	  cell	   subpopulations	  in	   the	   bulge	   exhibit	   different	   locations	   (basal	   versus	   suprabasal)	   and	   different	  characteristics,	   like	   slowly	   cycling	   (quiescent)	   versus	   rapidly	   cycling	   (Fuchs,	  2009).	   In	  contrast	   to	   the	  HF,	  much	   less	   is	   known	  about	   stem	   cells	   in	   the	   IFE.	  Although	   lineage-­‐tracing	  experiments	  have	  clearly	  demonstrated	  that	  homeostasis	  in	  mouse	  epidermis	  is	  fueled	   by	   an	   independent	   stem	   cell	   population,	   their	   origin	   and	   localization	   is	   still	   a	  matter	  of	  debate	  (Beck	  and	  Blanpain,	  2012).	  Stem	   cells	   in	   the	   basal	   layer	   of	   the	   epidermis	   can	   undergo	   symmetric	   and	  asymmetric	   cell	   division.	   The	   maintenance	   of	   a	   constant	   pool	   of	   stem	   cells	   can	   be	  accomplished	  by	  one	  of	  two	  distinct	  types	  of	  cell	  divisions	  during	  tissue	  homeostasis:	  in	  asymmetric	  division,	  where	  one	  daughter	  remains	  a	  SC	  throughout	  self-­‐renewal,	  and	  the	  other	  daughter	  becomes	   committed	   to	   enter	   a	  program	  of	   terminal	  differentiation.	  By	  contrast,	  symmetrical	  cell	  divisions	  result	  in	  both	  daughter	  cells	  adopting	  the	  same	  fate,	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which	   for	   SCs	   would	   result	   in	   the	   generation	   of	   two	   SCs	   (self-­‐renewal)	   or	   two	  differentiated	  cells	  (symmetric	  differentiation).	  	   	  
1.5.	  Human	  skin	  versus	  mouse	  skin	  
	  The	   stratification	   of	   mouse	   skin	   and	   human	   skin	   is	   similar—although	   distinct	  differences	  do	  exist,	  such	  as	  the	  increased	  thickness	  of	  human	  skin	  in	  comparison	  with	  that	   of	   mice	   (Lowes	   et	   al.,	   2007).	   Mouse	   skin	   is	   heavily	   populated	   by	   hair	   follicles,	  whereas	  the	  human	  epidermis	  is	  mainly	  interfollicular;	  the	  differences	  are	  less	  striking	  in	  skin	  from	  the	  ear	  and	  the	  tail	  of	  mice	  compared	  with	  the	  hairy	  back	  skin.	  Moreover,	  mouse	  skin	   lacks	  sweat	  glands	  and	  melanocytes	   in	  the	   interfollicular	  epidermis,	  but	   in	  contrast	  shows	  a	  synchronized	  hair	  cycle,	  rapid	  epidermal	  turnover	  and	  the	  presence	  of	  intra	   epidermal	   γδ	   T	   cells	   (Berking	   et	   al.,	   2002;	   Jameson	   et	   al.,	   2004;	   Khavari,	   2006;	  Wagner	  et	  al.,	  2010).	  The	  murine	  immune	  system	  contains	  particular	  subtypes	  of	  cells,	  including	  CD8+	  dendritic	  cells	  (DCs),	  dendritic	  epidermal	  T	  cells	  and	  natural	  killer	  (NK)	  1.1+	   T	   cells	   that	   are	   absent	   in	   human	   skin.	   Despite	   the	   obvious	   differences	   between	  mouse	  skin	  and	  human	  skin,	  mouse	  models	  have	  been	  successfully	  employed	  to	  mimic	  human	  skin	  disease	  in	  contact	  hypersensitivity,	  wound	  healing,	  inflammation	  as	  well	  as	  skin	   cancer	   to	  model	  monogenic	   hereditary	   skin	   diseases.	   Clearly,	  mouse	   and	   human	  skin	  have	  many	  aspects	  and	  molecular	  pathways	  in	  common.	  	  
2.	  SKIN	  CANCER	   	  
 Skin	  cancer	  is	  the	  third	  most	  common	  human	  malignancy	  and	  its	  occurrence	  has	  been	  increasing	  rapidly	  over	  the	  past	  decades.	  An	  estimated	  number	  of	  2-­‐3	  million	  non-­‐melanoma	   skin	   cancer	   patients	   and	   132,000	   patients	   of	  melanoma	   are	   counted	   every	  year	  (World	  Health	  Organization).	  Melanoma	  is	   the	  type	  of	  skin	  cancer	  that	  arises	   from	  the	  melanocytes,	  melanin-­‐producing	  cells	  located	  in	  the	  basal	  layer	  of	  the	  epidermis.	  It	  is	  the	  most	  dangerous	  type	  of	   skin	  cancer	  as	   it	   is	   the	   leading	  cause	  of	  death	   from	  skin	  disease	   (Tsao	  et	  al.,	  2012).	  	  10%	  of	  melanoma	  patients	  have	  a	   family	  history	  that	  confers	  approximately	  a	   twofold	  increase	   in	   probability	   to	   develop	   melanoma.	   Several	   genes	   have	   been	   identified	   to	  predispose	  to	  melanoma.	  Amongst	  others,	  mutations	  in	  CDKN2A	  (encoding	  p16),	  CDK4,	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RB1	   lead	   to	   the	  development	   of	  melanoma.	  Other	   genes	   such	   as	   PTEN	  or	  B-­‐RAF	  have	  been	  described	  to	  promote	  melanoma	  (Maubec	  et	  al.,	  2012;	  Rezze	  et	  al.,	  2012).	  Non-­‐Melanoma	  Skin	  cancer	  comprises	  two	  major	  types	  of	  Skin	  Cancers,	  Basal	  and	  Squamous	  Cell	  Carcinoma	  (BCC	  and	  SCC).	  Both	  tumors	  arise	  from	  keratinocytes,	  but	  are	  very	  different	  in	  morphology	  and	  in	  the	  underlying	  mechanisms	  (Colmont	  et	  al.,	  2012).	  	  	  
2.1.	  Basal	  Cell	  Carcinoma	  (BCC)	  It	   is	   the	  most	   common	   and	   least	   dangerous	   form	   of	   skin	   cancer	   (Kasper	   et	   al.,	  2012).	  It	  grows	  slowly,	  usually	  on	  the	  head,	  neck	  and	  upper	  torso.	  BCCs	  appear	  on	  skin	  exposed	  to	  UV	  light	  radiation	  and	  typically	  occur	  in	  the	  fourth	  decade	  of	  life	  and	  beyond	  (Kasper	  et	  al.,	  2012).	  Pathologically,	  it	  resembles	  the	  keratinocytes	  in	  the	  basal	  layer	  of	  the	   epidermis	   (Crowson,	   2006).	   The	   vast	   majority	   of	   BCCs	   occur	   sporadically,	   but	  patients	  with	   the	   rare	   heritable	   disorder	   “Basal	   cell	   nevus	   syndrome”	   have	   a	  marked	  susceptibility	  to	  developing	  BCCs.	  Several	  genes	  of	  the	  Sonic	  Hedgehog	  (SHH)	  signaling	  pathway	  are	  frequently	  mutated	  (Epstein,	  2008).	  Approximately	  90%	  of	  sporadic	  BCCs	  have	  identifiable	  mutations	  in	  at	  least	  one	  allele	  of	  PTCH1,	  and	  an	  additional	  10%	  have	  activating	   mutations	   in	   the	   downstream	   effector,	   smoothened	   (SMO)	   protein,	   which	  renders	   SMO	   resistant	   to	   inhibition	   by	   PTCH1	   (Epstein,	   2008).	   	   Several	   compounds	  targeting	  members	  of	  the	  SHH	  signaling	  pathway	  are	  being	  used	  in	  clinical	  trials	  (Kasper	  et	   al.,	   2012).	   Removal	   of	   tumors	   using	   surgery	   is	   widely	   established	   in	   less	   invasive	  BCCs.	  	  
2.2.	  Cutaneous	  Squamous	  Cell	  Carcinoma	  (SCC)	  Cutaneous	  Squamous	  cell	  carcinoma	  is	  the	  second	  most	  common	  type	  of	  human	  cancer	  with	  over	  250,000	  new	  cases	  annually	  in	  the	  USA	  and	  it	  is	  the	  second	  in	  incidence	  after	  BCC.	  It	  arises	  from	  keratinocytes	  of	  the	  epidermis	  and	  oral	  mucosa.	  Pathologically,	  keratinocytes	  in	  this	  type	  of	  cancer	  share	  features	  with	  the	  squamous	  cells	  seen	  in	  the	  outermost	   layers	  of	   the	  epidermis.	  Unlike	  BCCs,	   cutaneous	  SCCs	  are	   associated	  with	  a	  substantial	   risk	  of	  metastasis	   (Ratushny	  et	   al.,	   2012).	   SCC	   is	  most	   commonly	   found	   in	  sun-­‐exposed	  areas.	  Besides	  ultraviolet	  light,	  other	  risk	  factors	  have	  been	  associated	  with	  skin	   SCC,	   such	   as	   arsenic	   exposure,	   tobacco	   and	   human	   papilloma	   virus	   infection	  (Brantsch	  et	  al.,	  2008).	  SCC	  typically	  manifests	  as	  a	  spectrum	  of	  progressively	  advanced	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malignancies,	   ranging	   from	   a	   precursor	   lesion	   like	   actinic	   keratosis	   to	   SCC	   "in	   situ",	  invasive	  SCC	  and	  finally	  metastatic	  SCC	  (Figure	  4)	  (Ratushny	  et	  al.,	  2012).	  	  
Figure	  I2.	  	  	  	  	  	  
Histological	   features	   of	   the	   different	   stages	   of	   human	   SCC	   development,	   from	   healthy	   skin	   to	  metastatic	  SCC.	  	   Several	  syndromes	  like	  Xeroderma	  Pigmentosum	  or	  Epidermolysis	  bullosa	  have	  been	  associated	  with	  increased	  risk	  to	  develop	  SCCs.	  As	  with	  other	  cancers,	  SCCs	  exhibit	  impaired	   genomic	   maintenance	   that	   facilitates	   acquisition	   of	   new	   mutations.	   p53	   is	  commonly	   mutated	   in	   dysplastic	   lesions.	   40%	   of	   SCC	   in	   situ	   harbors	   p53	   mutations,	  indicating	   that	   p53	   loss	   occurrs	   prior	   to	   tumor	   invasion	   (Campbell	   et	   al.,	   1993).	  	  Aberrant	  activation	  of	  EGFR	  (Epidermal	  Growth	  Factor)	  and	  Fyn,	  a	  Src-­‐family	  tyrosine	  kinase,	  are	  seen	  in	  human	  SCCs.	  Furthermore,	  amplification	  and	  activating	  mutations	  of	  the	  Ras	  oncogene	  have	  been	  found	  in	  SCCs	  (Pierceall	  et	  al.,	  1991).	  21%	  of	  SCCs	  harbor	  activating	  Ras	  mutations.	  Of	  the	  three	  Ras	  genes,	  Harvey	  rat	  sarcoma	  virus	  oncogene	  (H-­
Ras)	  is	  preferentially	  mutated	  in	  SCCs.	  	  	  Skin	   SCC	   has	   been	   extensively	   modeled	   by	   either	   making	   use	   of	   genetically	  modified	  mice,	  such	  as	  K14-­‐HPV	  or	  the	  K5-­‐SOS	  mouse	  models	  (Arbeit	  et	  al.,	  1994;	  Sibilia	  et	  al.,	  2000),	  or	  by	  using	  the	  two-­‐step	  chemical	  carcinogenesis	  protocol	  (Kemp,	  2005).	  In	  this	  protocol,	  mutations	   in	  H-­Ras	   are	   induced	  by	  a	   single	   topical	  dose	  of	  a	   carcinogen,	  most	   commonly	   7,12-­‐dimethyl-­‐benz[a]anthracene	   (DMBA),	   applied	   on	   the	   back	   skin.	  Repeated	   topical	   applications	   of	   a	   tumor	   promoter,	   such	   as	   TPA	   give	   rise	   to	   benign	  neoplastic	   lesions,	  which	  causes	  sustained	  hyperplasia	  (papillomas)	  and	   inflammation.	  A	   small	   percentage	   of	   these	   papillomas	   progress	   to	  malignant	   invasive	   squamous	   cell	  carcinomas	   (SCC).	   In	   carcinomas,	   loss	   of	   heterozygosity	   (LOH)	   and	   mutations	   of	   the	  tumor	  suppressor	  p53	  are	   frequent.	  More	  aggressive	  carcinomas	  show	  additional	  LOH	  and	  mutations	  of	  the	  tumor	  suppressors	  p19/Arf	  and	  p16Ink4a	  (Kemp,	  2005).	  The	  use	  of	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these	  mouse	  models	  has	  allowed	  extensive	  analyses	  on	   the	  underlying	  mechanisms	  of	  cutaneous	  SCC	  development	  
3.	  THE	  ACTIVATOR	  PROTEIN	  1	  (AP-­1)	  TRANSCRIPTION	  FACTOR	   	  
3.1.	  	  Structure	  and	  function	  The	  transcription	  factor	  activator	  protein	  1	  (AP-­‐1)	  consists	  of	  dimers	  composed	  of	  members	  of	  the	  Jun	  and	  Fos,	  as	  well	  as	  activating	  transcription	  factor	  (ATF)	  and	  MAF	  protein	   families.	   In	   contrast	   to	   the	  Fos	   and	  Fos-­‐related	  proteins	   (Fos,	   FosB,	  Fra-­‐1	  and	  Fra-­‐1),	   which	   can	   only	   heterodimerize	   with	   members	   of	   the	   Jun	   family,	   Jun	   family	  members	  (Jun,	  JunB	  and	  JunD)	  can	  homodimerize	  or	  heterodimerize	  with	  Fos	  members	  (Jochum	   et	   al.,	   2001).	   A	   common	   feature	   of	   all	   these	   proteins	   is	   the	   evolutionarily	  conserved	   bZIP	   (basic	   DNA-­‐binding)	   domain	   combined	   with	   a	   leucine	   zipper	   region	  (Figure	  2).	  The	  leucine	  zipper	  is	  responsible	  for	  dimerization,	  which	  is	  a	  prerequisite	  for	  DNA	   binding	  mediated	   by	   the	   bZIP	   domain.	   AP-­‐1	   homo-­‐	   or	   heterodimers	   bind	   to	   the	  classic	   12-­‐O-­‐Tetradecanoylphorbol-­‐13-­‐acetate	   (TPA)-­‐responsive	   element	   or	   TRE	   with	  the	  consensus	  sequence	  TGAC/GTCA	  (Figure	  2)	  (Angel	  et	  al.,	  2001)	  
Figure	  I3.	  
AP-­1	  transcription	  factor.	  A.	  Schematic	  respresentation	  of	  the	  AP-­‐dimer	  binding	  to	  a	  TRE	  element	  on	  the	  DNA.	  B.	  Structure	  of	  mouse	  c-­‐Jun	  and	  c-­‐Fos	  proteins.	  Adapted	  from	  Eferl	  and	  Wagner,	  2003.	  Although	  members	   of	   the	   Jun	   and	   Fos	   families	   share	   high	   degree	   of	   structural	  homology,	  the	  individual	  AP-­‐1	  dimers	  show	  significant	  differences	  in	  their	  DNA	  binding	  affinity	  and	  their	  capability	  to	  activate	  or	  suppress	  gene	  expression.	  	  The	  different	  dimer	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combinations	   recognize	   different	   sequence	   elements	   in	   the	   promoters	   of	   target	   genes	  and	  exert	  different	  activities.	  
3.2.	  AP-­1	  signal	  transduction	  AP-­‐1	   controls	   distinct	   biological	   processes	   including	   cellular	   proliferation,	  differentiation,	   oncogenic	   transformation,	   apoptosis	   and	   inflammation	   (Zenz	   et	   al.,	  2008).	  AP-­‐1	   activity	   is	   regulated	   in	   a	   given	   cell	   by	   a	  broad	   range	  of	   physiological	   and	  pathological	  stimuli,	   including	  growth	   factors,	  neurotransmitters,	  hormones,	   infections	  as	  well	  as	  chemical	  stresses	  (Eferl	  and	  Wagner,	  2003).	  These	  stimuli	  activate	  a	  complex	  network	  of	  signaling	  cascades	  involving	  MAPK	  like	  ERK	  (Extracellular	  Signal-­‐Regulated	  Kinase),	   p38	   stress	   activated	   kinase	   and	   JNK	   (Jun	   Nuclear	   Kinase).	   In	   turn,	   these	  activated	   kinases	   modulate	   AP-­‐1	   activity	   by	   phosphorylating	   different	   substrates,	  including	   Jun	  and	  Fos	  proteins	   (Figure	  3).	  ERKs	  phosphorylate	  c-­‐Fos,	  Fra-­‐1	  and	  Fra-­‐2,	  thereby	  enhancing	   their	  DNA	  binding	  activity,	  as	   they	  heterodimerize	  with	  c-­‐Jun.	   JNKs	  phosphorylate	  c-­‐Jun	  very	  efficiently,	  JunD	  less	  efficiently,	  but	  they	  do	  not	  phosphorylate	  JunB.	  Effective	  JNK	  substrates	  require	  a	  separate	  docking	  site	  and	  specificity-­‐conferring	  residues	   flanking	   the	   phosphoacceptor.	   The	   docking	   site	   increases	   the	   efficiency	   and	  specificity	  of	  the	  phosphorylation	  reaction	  (Kallunki	  et	  al.,	  1996).	  	  
Figure	  I4.	  	  	  	  	  	  
	  
Transcriptional	   and	   post-­
translational	   modifications	   of	   AP-­1.	  
Adapted	  from	  Eferl	  and	  Wagner,	  2003.	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3.3.	  Biological	  functions	  of	  AP-­1	  in	  mice	  The	  use	  of	  broad	  or	  tissue-­‐specific	  gain-­‐	  and	  loss-­‐of-­‐function	  mouse	  models	  has	  been	  instrumental	  to	  understand	  the	  biological	  functions	  of	  the	  different	  AP-­‐1	  members	  in	  development	  and	  disease.	  Most	  members	  of	   the	  AP-­‐1	   family	  of	   transcription	   factors	  are	  essential	  for	  embryonic	  development,	  since	  c-­‐Jun,	  JunB	  and	  Fra-­‐1	  knock-­‐out	  fetuses	  die	  between	  E9.5	  and	  E12.5,	  whereas	  Fra-­‐2	  knock-­‐out	  pups	  die	  soon	  after	  birth	  (Fra-­‐2)	  (Hilberg	  et	  al.,	  1993;	  Schorpp-­‐Kistner	  et	  al.,	  1999;	  Eferl	  et	  al.,	  2007).	  Studies	  with	  knock-­‐out	   and	   transgenic	  mice	  have	  assigned	  distinct	   functions	   to	   c-­‐Fos	   and	  Fra-­‐1.	  Knock-­‐in	  mice	  that	  express	  Fra-­‐1	  in	  place	  of	  c-­‐Fos	  can	  rescue	  c-­‐Fos-­‐dependent	  functions	  such	  as	  bone	  development	  (Fleischmann	  et	  al.,	  2000).	  Moreover,	  JunB	  can	  substitute	  for	  absence	  of	  c-­‐Jun	  during	  mouse	  development	  since	  JunB	  can	  rescue	  both	  liver	  and	  cardiac	  defects	  in	   c-­‐Jun-­‐null	   mice	   (Passegue	   et	   al.,	   2002).	   For	   further	   information	   regarding	   specific	  functions	  of	  AP-­‐1	  in	  different	  tissues	  see	  Table	  S1.	  	  
3.3.1.	  Biological	  functions	  of	  AP-­1	  in	  skin	  	  	   Within	   the	   epidermis	  AP-­‐1	  proteins	   are	   found	   expressed	   in	   all	   layers,	   although	  with	   different	   patterns	   (Angel	   et	   al.,	   2001).	   None	   of	   the	   viable	   single	   knock-­‐out	  mice	  display	   dramatic	   skin	   phenotypes	   suggesting	   that	   individual	   AP-­‐1	   proteins	   are	   either	  dispensable	   or	   redundant	   during	   skin	   development	   (Zenz	   et	   al.,	   2008).	   However,	  keratinocyte-­‐specific	   single	   deletion	   of	   junB	   or	   combined	   constitutive	   or	   inducible	  deletion	   of	   both	   c-­jun	   and	   junB	   in	   the	   basal	   layer	   of	   the	   epidermis	   leads	   to	   the	  development	   of	   inflammatory	   skin	   diseases,	   such	   as	   Psoriasis	   (Meixner	   et	   al.,	   2008;	  Pflegerl	   et	   al.,	   2009;	   Zenz	   et	   al.,	   2005;	   Schonthaler	   et	   al.,	   2009).	   Interestingly,	   c-­‐Fos	  seems	  to	  be	  dispensable	  for	  epidermal	  development	  (Guinea-­‐Viniegra	  et	  al.,	  2012;	  Saez	  et	  al.,	  1995).	  
3.3.2.	  AP-­1	  functions	  in	  tumorigenesis	  Jun	  and	  Fos	  proteins	  were	  initially	  identified	  as	  the	  viral	  oncoproteins	  v-­‐Fos	  and	  v-­‐Jun	   in	   the	   Finkel-­‐Biskis-­‐Jenkins	   osteosarcoma	   virus	   and	   avian	   sarcoma	   virus	   17,	  respectively	  (Maki	  et	  al.,	  1987;	  Curran	  et	  al.,	  1983).	  	  A	   number	   of	   the	   AP-­‐1	   proteins,	   such	   as	   c-­‐Fos,	   FosB	   and	   c-­‐Jun,	   can	   transform	  several	   cell	   types	   efficiently	   in	   culture	   and	   have	   been	   linked	   to	   cancer	   (Jochum	   et	   al.,	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2001)).	  	  When	  widely	  overexpressed	  in	  mice,	  only	  some	  of	  these	  proteins	  can	  promote	  tumorigenesis.	   c-­fos	   transgenic	  mice	   develop	   osteosarcomas	   by	   the	   transformation	   of	  chondroblasts	  and	  osteoblasts	  (Wang	  et	  al.,	  1991;	  Grigoriadis	  et	  al.,	  1993).	  Moreover,	  c-­‐Fos	  can	  also	  display	  tumor	  suppressive	  functions,	  since	  combined	  deletion	  of	  c-­fos	  and	  
trp53,	   leads	   to	   the	   spontaneous	  development	   of	   rhabdomyosarcomas	   (Fleischmann	   et	  al.,	  2003b).	  The	  use	  of	  tissue-­‐specific	  promoters	  has	  shed	  light	  to	  specific	  roles	  of	  these	  proteins	   in	  cancer.	  Preliminary	  work	  performed	  in	  E.	  Wagner´s	   lab	  suggests	  that	  c-­‐Fos	  has	   an	  oncogenic	   role,	   since	   inducible,	   hepatocyte-­‐specific	   expression	  of	   c-­fos	   leads	   to	  increased	  HCC	  development	  8	  months	  after	  DEN	  treatment.	   Interestingly,	  c-­fos	   loss-­‐of-­‐function	   studies	   using	   a	   hepatocyte-­‐specific	   cre	   recombinase	   (Alfp-­‐cre)	   showed	  decreased	  tumor	  numbers	  and	  size	  8	  months	  after	  DEN	  treatment.	  These	  data	  suggest	  that	  c-­‐Fos	  primarily	  acts	  as	  an	  oncogene,	  but	  depending	  on	  the	  tissue	  context,	  it	  can	  act	  as	  a	  tumor	  suppressor.	  	  Contrary	  to	  c-­‐Fos,	  c-­‐Jun	  overexpression	  in	  transgenic	  mice	  does	  not	  result	  in	  the	  development	  of	  tumors,	  despite	  its	  oncogenic	  potential	  in	  vitro	  (Grigoriadis	  et	  al.,	  1993;	  Shaulian	  et	  al.,	  2000;	  Eferl	  et	  al.,	  1999).	   c-­‐Jun	   is	   important	   in	   the	  development	  of	   liver	  tumors,	  as	  conditional	  inactivation	  of	  c-­‐Jun	  in	  the	  liver	  interferes	  with	  the	  initiation	  and	  development	  of	  liver	  tumors,	  respectively	  (Eferl	  et	  al.,	  2003;	  Min	  et	  al.,	  2012).	  Additional	  studies	  have	   linked	  c-­‐Jun	   to	   intestinal	  cancer	   in	  mouse	  models.	   JNK-­‐phosphorylated	  c-­‐Jun	  was	  found	  to	  interact	  with	  TCF4	  to	  form	  a	  complex	  containing	  c-­‐Jun,	  β-­‐catenin,	  TCF4	  and	   nuclear	   Dishevelled.	   These	   interactions	   seem	   to	   enhance	   a	   feed-­‐forward	   loop	   in	  which	  the	  c-­‐Jun	  promoter	  is	  activated	  by	  TCF4	  and	  β-­‐catenin,	  and	  TCF4	  transcription	  is	  regulated	   by	   c-­‐Jun	   (Nateri	   et	   al.,	   2005;	   Sancho	   et	   al.,	   2009).	   Most	   importantly,	   in	   the	  APCMin	   mouse	   model	   of	   intestinal	   cancer,	   genetic	   abrogation	   of	   c-­‐Jun	   N-­‐terminal	  phosphorylation	   or	   gut-­‐specific	   conditional	   c-­jun	   inactivation	   reduced	   tumor	   number	  and	   size	   and	   prolonged	   lifespan	   (Nateri	   et	   al.,	   2005).	   c-­‐Jun	   involvement	   in	   intestinal	  cancer	   probably	   occurs	   via	   stimulation	   of	   progenitor	   cell	   proliferation	   and	  migration	  (Sancho	  et	  al.,	  2009).	  	  Not	  only	  do	  some	   Jun	  proteins	  promote	   tumorigenesis,	  but	  also	   they	  can	  act	  as	  tumor	   suppressor	   genes.	   Whereas	   c-­‐Jun	   is	   oncogenic,	   JunB	   and	   JunD	   can	   have	   anti-­‐oncogenic	   effects.	   The	   antioncogenic	   activity	   of	   JunB	   was	   confirmed	   in	   vivo	   by	   using	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JunB-­‐deficient	  mice	   that	  carry	  a	   JunB	   transgene.	  The	   transgene	  rescued	  the	  embryonic	  lethality	   of	   JunB-­‐deficient	   fetuses	   (Passegue	   et	   al.,	   2001),	   but	   its	   expression	   was	  epigenetically	   silenced	   in	   cells	   of	   the	   myeloid	   lineage.	   This	   resulted	   in	   progressive	  myeloid	  leukaemias,	  with	  increased	  proliferation	  of	  granulocytic	  progenitor	  cells.	   JunD	  acts	   as	   a	   tumor	   suppressor	   by	   reducing	   tumor	   angiogenesis	   by	   protecting	   cells	   from	  oxidative	   stress	   (Gerald	   et	   al.,	   2004).	   Altogether,	   these	   data	   indicate	   that	   although	  similar	  in	  structure,	  Jun	  proteins	  can	  have	  different	  roles	  in	  tumorigenesis.	  In	  contrast	  to	  c-­‐Fos,	  c-­‐Jun	  and	  Jun-­‐B,	  none	  of	  the	  Fra	  proteins	  have	  been	  linked	  to	  cancer	  in	  mouse	  models.	  
3.3.2.1.	  AP-­1	  functions	  in	  skin	  tumorigenesis	  	  AP-­‐1	  has	  been	  involved	  in	  a	  number	  of	  processes	  in	  the	  skin,	  including	  epidermal	  inflammation	  and	  carcinogenesis	  (Eferl	  and	  Wagner,	  2003).	  Expression	  of	  a	  dominant-­‐negative	   AP-­‐1	   transgene	   protects	   mice	   from	   UV-­‐,	   chemically-­‐	   and	   papillomavirus-­‐induced	   tumor	   formation	   indicating	   that	   AP-­‐1	   activity	   is	   essential	   for	   skin	   tumor	  development	  (Cooper	  et	  al.,	  2003;	  Young	  et	  al.,	  1999;	  Young	  et	  al.,	  2002).	  	  Furthermore,	  in	  papilloma-­‐prone	  mice	  (K5-­‐SOS)	  with	  a	  concomitant	  keratinocyte-­‐specific	  deletion	  of	  the	  c-­jun	   gene,	   skin	   tumor	  development	   is	   impaired	  due	   to	  reduced	  epidermal	  growth	  factor	  receptor	  (EGFR)	  expression	  and	  reduced	  proliferation	  (Zenz	  et	  al.,	  2003).	  c-­‐Fos	  is	  dispensable	   for	   mouse	   skin	   development	   and	   homeostasis	   (Guinea-­‐Viniegra	   et	   al.,	  2012),	   but	   it	   is	   required	   for	   the	   development	   of	   RAS-­‐induced	   malignant	   SCCs	   in	   the	  complete	  c-­fos	  knock-­‐out	  mouse	  (Saez	  et	  al.,	  1995).	  Moreover,	  tissue-­‐specific	  epidermal	  
c-­fos	  deletion	  in	  mouse	  tumor	  models	  or	  pharmacological	  FOS/AP-­‐1	  inhibition	  in	  human	  SCC	   cell	   lines	   induced	   epidermal	   cell	   differentiation	   and	   skin	   tumor	   suppression	   by	  inducing	   p53	   and	   subsequently	   TACE	   (TNFα	   converting	   enzyme).	   TACE,	   in	   turn,	  promotes	   keratinocyte	   differentiation	   by	   activating	   the	   Notch	   signaling	   pathway	  (Guinea-­‐Viniegra	   et	   al.,	   2012).	   Additionally,	   c.Jun	   and	   c-­‐Fos-­‐phoshorylation	   mouse	  mutants	   show	   altered	   papilloma	   formation	   in	   a	   papilloma-­‐prone	   backgroud	   (K5-­‐SOS)	  (Behrens	  et	  al.,	  2000;	  Bakiri	  et	  al.,	  2011).	  In	  contrast,	  transgenic	  mice	  broadly	  expressing	  exogenous	   c-­‐Fos	   are	   more	   sensitive	   to	   repeated	   DMBA	   treatment	   in	   the	   skin	   (Sakai,	  1990).	  On	   the	  other	  hand,	  overexpression	  of	   the	  viral	  homolog	  of	   c-­‐Fos	   (v-­‐Fos)	   in	   the	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spinous	   layer	   leads	   to	   long	   latency,	   wound-­‐associated	   epidermal	   hyperplasia	  (Greenhalgh	  et	  al.,	  1995).	  	  	  
4.	  TUMOR	  MICROENVIRONMENT	  	  Tumors	  are	   recognized	  as	  organs	  whose	  complexity	  approaches,	   and	  may	  even	  exceed,	  that	  of	  normal	  healthy	  tissues.	  Each	  tumor	  is	  composed	  by	  the	  cancer	  cells	  and	  by	  the	  tumor	  microenvironment	  or	  stroma.	  The	  tumor	  microenvironment	  is	  composed	  of	   fibroblasts	   (cancer	   associated	   fibroblasts),	   leukocytes,	   endothelial	   cells,	   soluble	  factors	   (cytokines,	   chemokines,	  matrix	  metalloproteases	   (MMPs),	   growth	   factors)	   and	  extracellular	   matrix	   (ECM)	   (Hanahan	   and	  Weinberg,	   2011).	   Interactions	   between	   the	  cancer	   cells	   and	   the	   microenvironment	   can	   foster	   an	   adequate	   environment	   for	   the	  cancer	   cells	   to	  proliferate,	   evade	   cell	   death,	   induce	  angiogenesis	   and	  activate	   invasion	  and	  mestastasis	  (Bhowmick	  et	  al.,	  2004).	  	  
4.1.	  Extracellular	  Matrix	  (ECM)	  A	  major	  component	  of	  the	  tumor	  stroma	  is	  the	  ECM.	  ECM	  remodeling	  is	  an	  active	  event	  during	  tumor	  progression.	  On	  one	  hand,	  the	  ECM	  serves	  as	  a	  niche	  for	  tumor	  cells	  to	   survive	   and	   proliferate.	   On	   the	   other	   hand,	   it	   is	   s	   a	   barrier	   that	   suppresses	   the	  spreading	   of	   tumor	   cells.	   Degradation	   of	   the	   ECM	   is	   one	   of	   the	   first	   steps	   in	   tumor	  invasion	  and	  metastasis	  (Lu	  et	  al.,	  2012).	  	  The	   ECM	   is	   composed	   of	   a	   large	   collection	   of	   biochemically	   distinct	   components	  including	   proteins,	   glycoproteins,	   proteoglycans	   and	   polysaccharides	   with	   different	  physical	  and	  biochemical	  properties	  (Bourboulia	  and	  Stetler-­‐Stevenson,	  2010).	  The	  ECM	  is	  composed	  of	  basement	  membrane	  and	  interstitial	  matrix.	  The	  ECM	  serves	  as	  well	  as	  a	  biochemical	  mediator	   in	  signal	   transduction	  because	   it	  binds	  growth	  factors	   like	  FGFs,	  vascular	  endothelial	  growth	  factors	  (VEGFs)	  and	  transforming	  growth	  factor	  β	  (TGF-­‐β)	  (Lu	  et	  al.,	  2012).	  	  Furthermore,	   ECM´s	   biomechanical	   properties	   also	   change	   in	   cancer.	   For	   example,	  tumor	   stroma	   is	   stiffer	   than	   normal	   stroma,	   indeed,	   in	   the	   case	   of	   breast	   cancer,	  diseased	  tissue	  can	  be	  10	  times	  stiffer	   than	  normal	  breast	   (Lopez	  et	  al.,	  2011).	  Part	  of	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the	   increase	   in	   tissue	   stiffness	   can	   be	   attributed	   to	   excess	   activities	   of	   Lysyl	   Oxidase	  (LOX),	  which	  crosslinks	  collagen	  fibers	  and	  other	  ECM	  components.	  Importantly,	  a	  study	  using	  mouse	  genetics	  has	  shown	  that	  overexpression	  of	  LOX	  increases	  ECM	  stiffness	  and	  promotes	  tumor	  cell	   invasion	  and	  progression	  (Levental	  et	  al.,	  2009).	  Thus,	  changes	  in	  the	  amount	  and	  composition	  of	  the	  ECM	  can	  greatly	  alter	  ECM	  biochemical	  properties,	  potentiate	   the	   oncogenic	   effects	   of	   various	   growth	   factor	   signaling	   pathways	   and	  deregulate	  cell	  behaviors	  during	  malignant	  transformation.	  
4.2.	  Matrix	  metalloproteases	  (MMPs)	  MMPs	  are	  a	   family	  of	  zinc-­‐dependent	  endopeptidases	   that	  play	  a	  crucial	   role	   in	  various	   physiological	   processes,	   such	   as	   tissue	   remodeling,	   organ	   development,	  inflammatory	   processes	   and	   cancer	   (Kessenbrock	   et	   al.,	   2010).	   MMPs	   are	   initially	  expressed	  as	  inactive	  zymogens	  and	  their	  activation	  depends	  on	  proteases,	  such	  as	  furin,	  plasmin	  or	  other	  MMPs	  (Bourboulia	  and	  Stetler-­‐Stevenson,	  2010).	  	  MMPs	   can	   be	   secreted	   either	   by	   cancer	   cells	   or	   by	   cells	   in	   the	   stroma,	   such	   as	  macrophages	   (Kessenbrock	   et	   al.,	   2010).	   The	   compartmentalization	   of	   MMPs	   under	  physiological	  conditions	  often	  dictates	  their	  biological	  function.	  For	  example,	  high	  levels	  of	  active	  MMP-­‐14	  at	  the	  cell	  membrane	  of	  metastatic	  cancer	  cells	  play	  important	  roles	  in	  cell	  migration	  (Friedl	  and	  Wolf,	  2008).	  Moreover,	  mice	  overexpressing	  MMP3,	  MMP7,	  or	  MMP14	   form	  mammary	   tumors	   (Sternlicht	   et	   al.,	   1999).	   MMPs	  may	   also	   be	   critically	  involved	  in	  disrupting	  the	  balance	  between	  growth	  and	  anti-­‐growth	  signals	  in	  the	  tumor	  microenvironment,	   as	   they	   potently	   influence	   the	   bioavailability	   or	   functionality	   of	  multiple	   important	   factors	   that	   regulate	  proliferation	  (Friedl	  and	  Wolf,	  2008).	  Ligands	  for	   the	   EGFR,	   which	   are	   MMP	   targets,	   are	   potent	   inducers	   of	   cell	   proliferation	   and	  important	  regulators	  of	  tissue	  homeostasis.	  	  Closely	   related	   to	   the	   MMPs	   are	   the	   so-­‐called	   ADAM	   (a	   disintegrin	   and	  metalloproteinase)	   and	   ADAMTS	   (a	   disintegrin	   and	   metallopreinase	   with	  thrombospoindin	  motifs)	  families	  of	  metzincing	  proteinases.	  ADAMs	  are	  also	  important	  in	   cancer	   (Edwards	   et	   al.,	   2008).	   ADAM-­‐10	   triggers	   the	   release	   of	   soluble	   EGF	  (Epidermal	  Growth	  Factor),	  whereas	  ADAM-­‐17	  is	  a	  major	  sheddase	  of	  TNFα,	  TGF-­‐α	  and	  epiregulin.	  Up-­‐regulation	  of	  EGFR	  signaling	  results	  in	  up-­‐regulation	  of	  MMP9,	  which	  in	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turn	   degrades	   E-­‐cadherin.	   The	   cleavage	   of	   E-­‐cadherin	   has	   an	   impact	   on	   cancer	   cell	  proliferation	  (Maretzky	  et	  al.,	  2005).	  MMP14	  and	  MMP2	  proteolytically	  activate	  TGF-­‐β1	  (Mu	  et	  al.,	  2002).	  Several	  MMPs	  have	  been	  shown	  to	  be	  upregulated	  in	  different	  types	  of	  cancer,	  such	  as	  MMP10,	  MMP1,	  MMP9,	  MMP3	  and	  MMP14	  (Liu	  et	  al.,	  2011;	  Stott-­‐Miller	  et	  al.,	  2011;	  Kerkela	  et	  al.,	  2001).	  In	   general,	  MMPs	   are	   not	   constitutively	   expressed	   in	   the	   skin,	   but	   are	   induced	  transiently	   in	   response	   to	   the	   abovementioned	   exogenous	   signals	   to	   trigger	   the	  proteolytic	  remodelling	  of	  the	  ECM	  in	  physiological	  and	  pathological	  situations,	  such	  as	  tissue	  morphogenesis,	   tissue	   repair	   and	   in	   tumor	   cells.	   For	   example,	   in	   acute	  murine	  excisional	   skin	   wounds	   MMP-­‐9,	   MMP-­‐3,	   MMP-­‐1	   and	   MMP-­‐13	   are	   strongly	   induced	  (Madlener	  et	  al.,	  1998).	  AP-­‐1	   plays	   a	   dominant	   role	   in	   the	   transcriptional	   activation	   of	   the	  majority	   of	  MMPs	   that	   are	   required	   for	   cell	   migration	   and	   ECM	   degradation	   (Angel	   et	   al.,	   2001).	  Tissue	  culture	  as	  well	  as	  mouse	  studies	  have	  provided	  evidence	   for	   the	   importance	  of	  the	   AP-­‐1	   target	   genes	   MMP-­‐1	   and	   MMP-­‐3	   during	   wound	   healing	   in	   keratinocyte	  migration	   and	  wound	   contraction	   respectively	   (Lund	   et	   al.,	   1999).	  MMP13	   is	   another	  well-­‐known	  target	  of	  c-­‐Fos	  and	  was	  initially	   identified	  in	  c-­‐Fos	   induced	  osteosarcomas	  (Tuckermann	  et	  al.,	  2001).	  
4.3.	  Cancer	  Associated	  Fibroblasts	  (CAFs)	  	   Fibroblasts	   synthesize	  many	  of	   the	   constituents	   of	   the	  ECM	  contributing	   to	   the	  formation	  of	  the	  basement	  membrane	  by	  secreting	  type	  IV	  collagen	  and	  laminin,	  and	  are	  also	  a	  source	  of	  MMPs.	  Fibroblasts	  at	  the	  site	  of	  a	  tumor	  remain	  constantly	  activated	  and	  within	   the	   tumor	   stroma	   acquire	   a	   modified	   phenotype.	   Such	   activated	   fibroblasts	  within	  the	  tumor	  stroma	  have	  been	  termed	  CAFs.	  These	  CAFs	  support	  tumorigenesis	  by	  stimulating	   angiogenesis,	   cancer	   cell	   proliferation	   and	   invasion.	   Several	   studies	   using	  mouse	  models	  have	  shown	  that	  cancer	  cells	  can	  educate	  surrounding	  CAFs	  to	  promote	  tumorigenesis	  by	  secreting	  pro-­‐survival	   factors,	  such	  as	   IL-­‐6	  or	  secrected	  glycoprotein	  stanniocacin-­‐1	  (STC1)	  (Erez	  et	  al.,	  2010)	  (Pena	  et	  al.,	  2012).	  Interestingly,	  recent	  studies	  show	   that	  genetic	   changes	   in	   the	  Notch	  pathway	   in	   fibroblasts	   can	  have	  an	   impact	  on	  neighboring	  epithelial	  cells,	  thus	  promoting	  them	  to	  proliferate	  and	  give	  rise	  to	  tumors	  (Hu	  et	  al.,	  2012).	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4.4.	  Inflammation	  and	  Cancer	  Links	   between	   cancer	   and	   inflammation	   were	   first	   made	   in	   the	   19th	   century	  (Balkwill	  and	  Mantovani,	  2001)	  on	  the	  basis	  of	  observations	  that	  tumors	  often	  arise	  at	  sites	   of	   chronic	   inflammation	   and	   that	   leukocytes	   were	   present	   in	   biopsied	   samples	  from	  tumors	  (DiDonato	  et	  al.,	  2012).	  In	  homeostatic	  tissue,	  resident	  immune	  cells	  serve	  as	  sentinels	   to	  safeguard	   tissue	  and	  organ	   integrity.	  Following	  acute	  damage,	  e.g.	  after	  infection	   or	   physical	   trauma,	   resident	   leukocytes	   limit	   tissue	   damage,	   while	   engaging	  tissue	  repair	  programs	  and	  facilitate	  reepithelialization.	  	  In	  cancer,	   immune	  cells	  play	  dual	  roles	  with	  the	  potential	  to	  either	  eliminate	  or	  promote	   malignancy	   (Balkwill	   and	   Mantovani,	   2001).	   Premalignant	   tissues	   contain	  proliferating	   cells	   harboring	   genomic	   damage	   that	   typically	   activate	   critical	  proliferation/survival	   signals.	   In	   these	   tissues,	   chronic	   engagement	   of	   immune	   cells	  foster	  survival	  of	  "initiated"	  cells,	  culminating	  in	  mitotic	  cell	  expansion	  and	  development	  of	  premalignant	  lesions	  via	  a	  similar	  process	  like	  upon	  tissue	  injury.	  When	  these	  chronic	  inflammatory-­‐type	  events	  are	  sustained,	  neoplastic	  progression	  can	  ensue	  (Figure	  6).	  
4.4.1.	  Tumor-­protective	  inflammation	  Initially	   it	  was	  believed	  that	   leukocytic	   infiltrates	  in	  developing	  tumors	  were	  an	  attempt	  by	  the	  host	  to	  eradicate	  formation	  and	  progression	  of	  incipient	  neoplasias,	  late-­‐stage	   tumors	   and	   micrometastasis	   (de	   Visser	   et	   al.,	   2006).	   The	   role	   of	   defective	  immunological	  monitoring	  of	   tumors	  seems	   to	  be	  validated	  by	   the	  striking	   increase	   in	  certain	   cancers	   in	   immuno-­‐compromised	   individuals	   (Vajdic	   and	  van	  Leeuwen,	  2009).	  However,	  the	  great	  majority	  of	  these	  are	  virus-­‐induced	  cancers,	  suggesting	  that	  much	  of	  the	   control	   of	   this	   class	   of	   cancers	   normally	   depends	   on	   reducing	   viral	   burden	   in	  infected	  individuals,	  in	  part	  through	  eliminating	  virus-­‐infected	  cells	  (Pages	  et	  al.,	  2010).	  Patients	  with	  colon	  and	  ovarian	  tumors	  that	  are	  heavily	  infiltrated	  with	  Cytotoxic	  T	  Lymphocytes	  (CTLS)	  and	  Natural	  Killer	  (NK)	  cells	  have	  a	  better	  prognosis	  than	  those	  that	  lack	  such	  abundant	  killer	  lymphocytes.	  Indeed,	  extensive	  infiltration	  of	  NK	  cells	  in	  human	  gastric	  or	  colorectal	  carcinoma	  is	  associated	  with	  favorable	  prognosis	  (Ishigami	  et	  al.,	  2000).	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In	  recent	  years,	  an	  increasing	  body	  of	  evidence,	  both	  from	  genetically	  engineered	  mice	   and	   from	   clinical	   epidemiology,	   suggests	   that	   the	   immune	   system	   operates	   as	   a	  significant	  barrier	   to	   tumor	   formation	  and	  progression,	  at	   least	   in	  some	   forms	  of	  non-­‐virus-­‐induced	  cancer.	   In	  mouse	  models	  of	  skin	  cancer,	  CD4+	  and	  CD8+	  T	  cells	  can	  have	  different	  roles.	  Kopan	  and	  colleagues	  have	  recently	  shown	  that	  CD4+T	  cells	  are	  tumor-­‐protective	  in	  skin	  cancers	  by	  using	  mouse	  models	  in	  which	  the	  Notch	  signaling	  pathway	  is	  impaired	  (Demehri	  et	  al.,	  2012).	  Moreover,	  Radtke	  and	  colleagues	  have	  demonstrated	  that	  CD8+T	  responses	  are	  important	  in	  protecting	  from	  skin	  carcinogenesis	  (Di	  Piazza	  et	  al.,	  2012).	  Genetic	  elimination	  of	  CD4+T	  lymphocytes	  in	  female	  HPV16	  mice	  that	  undergo	  estrogen	  treatment	  to	  predispose	  them	  to	  cervical	  carcinogenesis	  resulted	   in	  a	  10-­‐fold	  increased	   tumor	   burden	   and	   a	   20%	   increase	   in	   carcinoma	   incidence	   with	   estrogen-­‐treated	   HPV16	   controls	   (Daniel	   et	   al.,	   2005).	   Altogether,	   these	   data	   suggest	   a	   tumor-­‐protective	  function	  of	  the	  adaptive	  immune	  responses	  in	  epithelial	  tumors.	  
4.4.2.	  Tumor-­promoting	  inflammation	  
	  It	   is	   well	   established	   that	   inflammatory	   processes	   both	   hinder	   and	   facilitate	  cancer	   by	   fostering	   infiltration	   of	   leukocytes	   and	   promoting	   stromal	   remodeling	  (Demaria	   et	   al.,	   2010).	   Inflammatory	   cells	   are	   an	   important	   source	   of	   cytokines	   and	  growth	  factors,	  such	  as	  IL-­‐6	  and	  EGF	  as	  well	  as	  metalloproteases	  that	  foster	  immune	  cell	  survival	  and	  tumorigenesis	  (DiDonato	  et	  al.,	  2012).	  A	   clear	   example	   is	   evident	   in	   patients	  with	   ulcerative	   colitis	   and	   patients	  with	  Chrohn´s	  disease,	  the	  two	  major	  forms	  of	  inflammatory	  bowel	  disease	  (IBD).	  There	  is	  a	  strong	   correlation	   between	   patients	   bearing	   IBD	   and	   the	   risk	   of	   colon	   cancer	  (Monteleone	   et	   al.,	   2012).	   In	   the	   case	   of	   pancreatic	   cancer	   (or	   Pancreatic	   Ductal	  Adenocarcinoma	   or	   PDAC)	   there	   is	   a	   strong	   correlation	   between	   inflammation	   in	   the	  pancreas	   and	   the	   risk	   of	   developing	   a	   PDAC	   in	   human	   and	  mouse	  models	   (Dite	   et	   al.,	  2012;	  Greer	  and	  Whitcomb,	  2009;	  Grote	  et	  al.,	  2012;	  Carriere	  et	  al.,	  2011)	  Several	   epidemiological	   studies	   have	   shown	   that	   patients	   with	   autoimmune	  disease,	  in	  particular,	  rheumatoid	  arthritis,	  Systemic	  Lupus	  Erythematosus	  (SLE),	  celiac	  disease	  and	  inflammation-­‐induced	  pulmonary	  fibrosis,	  are	  predisposed	  to	  certain	  types	  of	  non-­‐hematogenous	  malignancies,	  e.g.,	  lung	  carcinoma,	  non-­‐melanoma	  skin	  cancer	  and	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cervical	   atypia	   (Mellemkjaer	   et	   al.,	   1996).	   Overall,	   these	   data	   indicate	   inflammatory	  responses	  may	  be	  detrimental	  to	  the	  development	  of	  certain	  cancers.	  	  
4.4.3.	  Skin	  inflammation	  and	  cancer	  
"Cancers	  are	  wounds	  that	  never	  heal"	  Harold	  Dvorak.	  1984.	  	  To	   understand	   the	   contribution	   of	   the	   inflammatory	  microenvironment	   to	   the	  development	   and	   progression	   of	   epithelial	   skin	   cancer,	   it	   is	   important	   to	   understand	  how	   it	   contributes	   to	   physiological	   processes,	   such	   as	   epidermal	   wound	   healing	   and	  infection.	  	  
Figure	  I5.	  	  	  	  	  	  	  	  
Wound	   healing	   versus	   invasive	   tumor	   growth.	   Comparison	   between	   wound	   healing	   and	   invasive	  carcinoma.	  Adapted	  from	  Mueller	  et	  al.	  2006.	  	  The	  human	  adult	  epidermal	  wound	  healing	  process	  can	  be	  divided	  into	  3	  distinct	  phases:	   inflammatory,	   proliferative	   and	   remodeling	   (Balkwill	   and	   Mantovani,	   2001).	  After	   injury	   a	   blood	   clot	   is	   formed	   and	   a	   cascade	   of	   events	   starts.	   First	   there	   is	  inflammation,	  to	  prevent	   infection	  and	  remove	  debris.	  Then,	   fibroblast	  proliferation	  as	  well	  as	  ECM	  remodeling,	  angiogenesis	  and	  finally,	  deposition	  of	  new	  connective	  tissue,	  which	   is	   known	   as	   granulation	   tissue.	   Keratinocytes	   are	   stimulated	   to	   proliferate	   and	  migrate	  over	  the	  granulation	  tissue	  to	  repair	  the	  epidermis	  (Arwert	  et	  al.,	  2012).	  Once	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the	  epidermis	  has	  re-­‐epithelized,	  keratinocytes	  and	  fibroblasts	  synthesize	  ECM	  proteins	  that	  are	  incorporated	  into	  the	  new	  basement	  membrane.	  When	   tissue	   homeostasis	   is	   chronically	   perturbed,	   interactions	   between	   innate	  and	   adaptive	   immune	   cells	   can	   be	   disturbed.	   A	   failure	   to	   appropriately	   engage	   or	  disengage	  either	  arm	  of	   the	   immune	  system	  can	  result	   in	  excessive	   tissue	  remodeling,	  loss	  of	  tissue	  architecture	  due	  to	  tissue	  destruction,	  protein	  and	  DNA	  alterations	  due	  to	  oxidative	  stress	  and	  finally	  increase	  the	  risk	  of	  cancer	  development.	  Tumors	  have	  often	  been	  referred	  to	  as	  'wounds	  that	  never	  heal'.	  Indeed,	  gene-­‐expression-­‐profiling	  analyses	  were	  performed	  to	  make	  a	  direct	  comparison	  between	  wounds	  and	  tumors,	  and	  it	  was	  found	   that	   a	   wound-­‐response	   gene	   expression	   pattern	   can	   predict	   metastasis	   and	  survival	  likelihoods	  in	  patients	  with	  breast	  cancer	  (Chang	  et	  al.,	  2005)	  In	  humans,	  certain	   inflammatory	  diseases,	  such	  as	  actinic	  keratosis	  (Berhane	  et	  al.,	   2002)	   of	   the	   skin	   predispose	   patients	   to	   develop	   cutaneous	   SCCs	   suggesting	   the	  inflammatory	   cell	   infiltrate	   is	   promoting	   skin	   tumor	   development	   (Gronhagen	   et	   al.,	  2012).	  Mouse	  models	  have	  been	   important	   tools	   to	   study	   the	   contribution	  of	  different	  inflammatory	  cell	  types	  in	  the	  development	  of	  cutaneous	  SCCs.	  Hanahan	  et	  al	  generated	  a	  transgenic	  mouse	  model	  of	  epithelial	  carcinogenesis	   in	  which	  Human	  Papillomavirus	  type	  16	  was	  expressed	  from	  the	  control	  of	   the	  keratin	  14	  promoter	  (basal	   layer	  of	  the	  epidermis)	  (Arbeit	  et	  al.,	  1994).	  These	  mice	  develop	  by	  1	  month	  of	  age	  hyperplasias	  with	  100%	  penetrance	  and	  by	  1	  year	  of	  age,	  60%	  of	  these	  mice	  develop	  skin	  cancers,	  50%	  of	  which	  are	  SCCs	   (Junankar	  et	   al.,	   2006).	  Using	   this	  mouse	  model	   the	   inflammatory	   cell	  infiltrate	  was	  characterized	  throughout	  the	  different	  stages	  of	  epithelial	  carcinogenesis	  (Junankar	  et	  al.,	  2006).	  Moreover,	  the	  contribution	  of	  different	  leukocytes	  was	  analyzed	  in	  the	  promotion	  of	  SCCs	  by	  genetically	  depleting	  different	  subsets	  of	  inflammatory	  cells	  (Table	   I1).	   In	   fact,	   certain	   populations	   of	   leukocytes	   are	   important	   promoters,	   since	  CD4+T	  or	  Mast	  cell	  depletion	  caused	  a	  delay	  in	  the	  appearance	  of	  tumors	  in	  a	  skin	  SCC-­‐prone	  genetic	  mouse	  model	  (K14-­‐HPV16	  mice,	  Table	  I1)	  (Daniel	  et	  al.,	  2003;	  Coussens	  et	  al.,	  1999).	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Table	  I1.	  	  	  	  	  	  	  	  	  	  
Immunomodulation	   of	   skin	   cancer	   by	   selectively	   depleting	   different	   immune-­cell	   types.	  Adapted	  
from	  Coussens	  et	  al.	  2011.	  	  	   Carcinogens	  such	  as	  DMBA/TPA	  have	  also	  been	  widely	  employed	  to	  mimic	  the	  multifaceted	  steps	  in	  the	  development	  of	  SCCs.	  DMBA/TPA	  treatment	  performed	  in	  SCID	  mice	  (deficient	  for	  mature	  CD4+	  and	  CD8+	  T	  cells)	  showed	  a	  five	  fold	  decrease	  in	  the	  penetrance	  of	  skin	  tumor	  development.	  However,	  when	  used	  in	  Rag1	  or	  Rag2	  knock-­‐out	  mice	  (also	  deficient	  in	  mature	  T	  cells)	  no	  difference	  in	  skin	  tumor	  penetrance	  was	  observed	  compared	  to	  wild-­‐type	  littermates	  (Kemp	  et	  al.,	  1999)	  	  It	  is	  known	  that	  the	  epidermis	  harbors	  distinct	  subsets	  of	  T	  cells,	  which	  comprise	  resident,	   interaepithelial	   lymphocytes	   (IELs)	   and	   infiltrating	   systemic	   T	   cells,	  respectively	  (Hayday	  et	  al.,	  2001).	  These	  two	  populations	  have	  different	   functions	  and	  display	  highly	  distinct	  gene	  expression	  profiles	  and	  T	  cell	  receptor	  usage.	  Whereas	  the	  murine	  and	  human	   systemic	  T	   cell	   compartments	   are	  dominated	  by	  TCRαβ+	   cells,	   the	  IEL	  repertoires	  are	  disproportionately	  enriched	  in	  TCRγδ+	  cells.	  TCRδ-­‐/-­‐	  mice	  are	  highly	  susceptible	   to	   the	   development	   of	   SCCs	   induced	   by	   different	   methods	   (Girardi	   et	   al.,	  2001).	  However,	  TCRαβ-­‐/-­‐	  mice	  after	  DMBA	  and	  high	  doses	  of	  TPA	  are	  more	  resistant	  to	  tumor	   development	   compared	   to	   wild-­‐type	   littermates	   (Girardi	   et	   al.,	   2003).	   Overall	  these	  data	   indicate	   that	   the	   innate	   immune	  system,	   is	  an	   important	   contributor	  of	   the	  development	  of	  SCC	  
	  	  
	  	  	  	  	  	  	  	  	  	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  





















	   Objectives	   	  
	   43	  
Little	  is	  known	  about	  the	  contribution	  of	  skin	  inflammation	  and	  the	  inflammatory	  cell	  component	  to	  the	  development	  of	  cutaneous	  Squamous	  Cell	  Carcinomas.	  The	  main	  objective	  of	  this	  thesis	  was	  to	  analyze	  the	  function	  of	  c-­‐Fos/AP-­‐1	  transcription	  factor	  in	  epidermal	   homeostasis	   and	   carcinogenesis,	   and	   to	   study	   whether	   c-­‐Fos	   mediates	  inflammatory	  responses	  in	  the	  skin	  that	  promote	  skin	  cancer	  development.	  	  	   Therefore,	  the	  specific	  goals	  for	  this	  thesis	  project	  were:	  1. Generate	  a	  mouse	  model	   to	   inducibly	  express	  c-­fos	   in	   the	  epidermis	   to	  uncover	  deregulated	   pathways	   that	   may	   interfere	   with	   epidermal	   homeostasis,	   affect	  inflammatory	  processes	  and	  eventually	  impact	  on	  skin	  cancer.	  2. Investigate	   the	   underlying	  molecular	  mechanisms	   through	   the	   identification	   of	  novel	  c-­‐Fos	  target	  genes	  and	  perform	  functional	  assays	  to	  address	  the	  relevance	  of	  these	  genes	  in	  skin	  inflammation	  and	  cancer	  development	  3. Dissect	  whether	  c-­‐Fos	  and	  the	  downstream	  transcriptional	  target	  genes	  could	  be	  used	   as	  potential	   targets	   for	   the	  development	   of	   therapies	   to	   treat	   human	   skin	  cancer.	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Actualmente	  se	  sabe	  poco	  acerca	  del	  papel	  que	  ejercen	  los	  procesos	  inflamatorios	  de	  la	  piel	  en	  el	  desarrollo	  de	  carcinomas	  epidermoides.	  Por	  esto,	  el	  principal	  objetivo	  de	  esta	   tesis	   fue	   analizar	   las	   funciones	   del	   factor	   de	   trascripción	   c-­‐Fos/AP-­‐1	   en	   la	  homeostasis	   de	   la	   piel	   y	   en	   la	   carcinogénesis	   para	   entender	   cómo	   c-­‐Fos	   regula	   las	  respuestas	  inflamatorias	  de	  la	  piel	  que	  pueden	  promover	  del	  desarrollo	  de	  carcinomas	  epidermoides.	  	  	  Por	  lo	  tanto,	  los	  objetivos	  específicos	  de	  este	  projecto	  de	  tesis	  fueron:	  1. Generar	   un	   modelo	   de	   ratón	   que	   exprese	   de	   manera	   inducible	   el	   factor	   de	  transcription	  c-­fos	  en	  la	  epidermis	  para	  descubrir	  las	  vias	  de	  señalización	  que	  se	  alteran	   cuando	   los	   niveles	   de	   c-­‐Fos	   son	   elevados	   y	   pueden	   interferir	   con	   la	  homeostasis	   epidérmica,	   mediar	   	   procesos	   inflamatorios	   en	   la	   piel	   y	   tener	   un	  impacto	  en	  el	  desarrollo	  de	  cancer	  de	  piel.	  2. Investigar	  el	  papel	  de	  c-­‐Fos	  mediante	  el	  descubrimiento	  de	  nuevos	  genes	  diana	  cuya	  expresión	  está	   controlada	  por	   c-­‐Fos.	  Desarrollar	   ensayos	   funcionales	  para	  evaluar	  el	  papel	  de	  estos	  genes	  diana	  en	  el	  desarrollo	  de	  procesos	  inflamatorios	  de	  la	  piel	  y	  finalmente	  cancer.	  3. Investigar	   si	   c-­‐Fos	   y	   sus	   genes	   diana	   pueden	   ser	   dianas	   para	   el	   desarrollo	   de	  fármacos	  para	  tratar	  los	  carcinomas	  epidermoides.	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1.	  MICE	   	  
1.1.	  Study	  approval	  Mice	  were	  kept	  in	  the	  animal	  facility	  in	  accordance	  with	  institutional	  policies	  and	  federal	   guidelines.	   Animal	   experiments	   were	   approved	   by	   the	   Animal	   Experimental	  Ethics	   Committee	   of	   the	   Instituto	   de	   Salud	   Carlos	   III	   (Madrid,	   Spain).	   Human	   tumor	  samples	  were	   obtained	   after	   approval	   from	   the	   Ethics	   Comittee	   of	   Instituto	   de	   Salud	  Carlos	  III	  (Madrid,	  Spain).	  
1.2.	  Generation	  of	  the	  tet-­switchable	  c-­fos	  allele	  	  To	  generate	  inducible,	  titrable	  and	  switchable	  expression	  of	  c-­fos	  we	  made	  use	  of	  the	  Tetracycline-­‐Controlled	  Transcriptional	  Activation	  method.	  This	  system	  permits	  the	  switchable	   expression	   of	   a	   specific	   gene	   upon	   the	   presence	   or	   abscence	   of	   the	  tetraycline	  antibiotic	  or	  one	  of	  its	  derivatives	  (Doxycycline)	  (Gossen	  and	  Bujard,	  1992).	  	  The	  tetracycline	  (tet)-­‐switchable	  c-­fos	  allele	  was	  introduced	  3’	  of	  the	  col1a1	  locus	  using	  a	  recombinase-­‐mediated	  single-­‐copy	  transgene	  integration	  strategy	  in	  Embryonic	  Stem	  cells	  (Beard	  et	  al.,	  2006).	  Southern	  blot	  analyses	  confirmed	  correct	  recombination	  in	  ES	  cells	  and	  correct	  germline	  transmission.	  Doxycycline-­‐switchable	  expression	  of	  the	  flag	  tagged	  mouse	  c-­fos	  cDNA	  sequence	  and	  the	  flag	  tag	  were	  confirmed	  in	  ES	  cells	  and	  in	   mice	   with	   a	   tetracycline	   activator	   expressed	   from	   the	   Rosa26	   locus	   (Bakiri	   and	  Wagner,	  unpublished).	  	  	  
1.3.	  Mouse	  lines	  
1.3.1.	  c-­FosEp-­tetON	  	  and	  c-­FosEp-­tetOFF	  mouse	  lines	  c-­‐FosEp-­tetON	  mice	  were	  generated	  by	  crossing	  the	   tet-­‐switchable	  c-­fos	  allele	  with	  K5-­‐rtTA	   allele	   obtained	   from	   Sylvio	  Gutkind	   (NIH,	   Bethesda,	   USA).	   The	  K5-­‐rtTA	   allele	  enables	  expression	  of	   the	   reverse	   transactivator	   (rtTA)	  under	   the	  control	  of	  Keratin	  5	  promoter	   (Vitale-­‐Cross	   et	   al.,	   2004).	   Mice	   were	   kept	   in	   a	   C56BL/6	   background.	   To	  generate	   c-­‐FosEp-­tetOFF	   mice	   the	   tet-­‐switchable	   c-­fos	   allele	   was	   crossed	   to	   the	   K5-­‐tTA	  allele	  (Diamond	  et	  al.,	  2000).	  The	  K5-­‐tTA	  allele	  enables	  expression	  of	  the	  transactivator	  (tTA)	   obtained	   from	  Elaine	   Fuchs	   (Rockefeller	  University,	  New	  York	   City,	   USA)	   under	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the	  control	  of	  the	  K5	  promoter.	  c-­‐FosEp-­tetOFF	  mice	  were	  kept	  in	  a	  mixed	  background	  (mix	  of	   pure	   C57BL/6.	   Double	   transgenic	   mice	   are	   referred	   to	   as	   c-­‐FosEp-­tetON/c-­‐FosEp-­tetOFF	  mice	  or	  mutants.	  Wild-­‐type	  or	  single	  transgenic	  littermates	  are	  always	  used	  as	  controls.	  	  	  
1.3.2.	  c-­FosEp-­tetON;	  Rag1-­/-­	  mouse	  line	  To	  generate	  c-­‐FosEp-­tetON	  mice	  lacking	  mature	  T	  and	  B	  cells	  we	  crossed	  the	  c-­‐FosEp-­
tetON	   inducible	  mouse	   line	  to	  a	  Rag1	  knock	  out	  mice,	  obtained	  from	  A.	  Ramiro	  (Spanish	  National	  Cardiovascular	  Research	  Centre,	  Spain)	  (Mombaerts	  et	  al.,	  1992).	  	  
1.4.	  Mouse	  Genotyping	  Genotyping	  was	  performed	  by	  PCR	  analyses	  of	  genomic	  DNA	   from	   tail	  biopsies	  (see	  table	  M1).	  A	  single	  PCR	  reaction	  was	  prepared	  in	  a	  final	  volumen	  of	  24	  µl	  using	  2.5	  
µl	  of	  Buffer	   (Sigma-­‐Aldrich®)	  with	  Mg2+,	  2µl	  of	  10µM	  primers	  diluted	   in	  water,	  2µl	  of	  2.5mM	  dNTPs	   (Sigma-­‐Aldrich®),	  17.5	  µl	   of	  DEPC	  water	   and	  0.1	  µl	   of	  Taq	  polymerase	  (Sigma-­‐Aldrich®).	  For	  the	  K5-­‐rtTA	  PCR,	  2ul	  of	  DMSO	  were	  used	  per	  reaction.	  	  
Table	  M1.	  	  
Allele	  Name	   Primer	   Sequence	  (5´-­-­>3´)	  Sense	  	   GCGAAGAGTTTGTCCTCAACC	  Antisense	  #1	   GGAGCGGGAGAAATGGATATG	  Rosa	  26-­rtTA	   Antisense	  #2	   AAAGTCGCTCTGAGTTGTTAT	  Sense	  	   GCACAGCATTGCGGACATGC	  Antisense	  #1	   CCCTCCATGTGTGACCAAGG	  Col-­Fos	   Antisense	  #2	   GCAGAAGCGCGGCCGTCTGG	  Sense	  	   CCGGATCCACCATGCCTAAGAGCCCACGACCGTCTAGATTAGATAAAAGT	  K5-­rtTA	   Antisense	   ATCTG TGTACTTTTGCTCCATTGCGATGACT	  Sense	  	   ATGCTACCATAGTCATATCGTCATGCATGCAT	  
K5-­tTA	   Antisense	   TATCGTCATGCATGCATATGCTACCATAGTCA	  Sense	  	   CCCGGACAAGTTTTTCATCGT	  Antisense	  #1	   GAGGTTCCGCTACGACTCTG	  Rag1	   Antisense	  #2	   TGGATGTGGAATGTGTGCGAG	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1.5.	  Mouse	  treatments	  
1.5.1.	  Doxycycline	  treatment	  Doxycycline	   (Sigma-­‐Aldrich®-­‐Aldrich®).	   	   was	   used	   to	   activate	   inducible	   c-­fos	  expression.	   Initially	   it	  was	   supplied	   in	   drinking	  water	   in	   concentrations	   varying	   from	  0.25-­‐0.5g/l	   in	   the	   presence	   of	   sucrose	   (Sigma-­‐Aldrich®).	   However,	   for	   most	   of	   the	  experiments,	  doxycycline	  was	  supplied	  in	  food	  pellets	  ad	  libidum	  (Harlan	  laboratories).	  
1.5.2.	  Chemical	  carcinogenesis	  	  For	  DMBA/TPA-­‐induced	  skin	  carcinogenesis,	  cohorts	  of	  c-­‐FosEp-­tetON,	  c-­‐FosEp-­tetOFF,	  at	  6-­‐8	  weeks	  of	  age	  were	  shaved	  and	  2-­‐3	  later	  received	  a	  single	  application	  of	  100	  μL	  of	  an	   acetone	   solution	   containing	   0.5%	   DMBA	   (7,12-­‐dimethylbenz[a]anthracene,	   Sigma)	  applied	   to	   the	   dorsal	   surface.	   10-­‐4M	   TPA	   in	   acetone	  was	   applied	   twice	   a	  week	   to	   the	  dorsal	   surface.	   This	   treatment	   was	   combined	   (or	   not)	   with	   doxycycline	   and	   with	  Sulindac	  (Sigma-­‐Aldrich®).	  	  
1.5.3.	  Anti-­inflammatory	  treatment	  	   COX1/COX2	  inhibitor	  Sulindac	  (Sigma-­‐Aldrich®)	  was	  supplied	  in	  drinking	  water	  in	  a	  concentration	  of	  1.8mg/l	  diluted	  in	  autoclaved	  water.	  This	  treatment	  was	  combined	  with	  Doxycycline	  in	  the	  food	  pellets	  and	  with	  0.5%	  DMBA	  applied	  topically	  only	  once.	  
1.5.4.	  MMP	  inhibitory	  treatment	  	   6-­‐8	  week	  old	  control	  and	  c-­‐FosEp-­tetON	  mice	  were	  treated	  with	  Dox	  for	  four	  weeks.	  TAPI-­‐1	   (MMP10	   inhibitor,	   Peptides	   International)	   was	   injected	   intraperitoneally	   (IP)	  every	  other	  day	   three	   times	   a	  week	  during	  4	  weeks.	  TAPI	  was	  diluted	   in	  5%DMSO	   in	  saline.	  The	  final	  concentration	  used	  was	  10mg/kg.	  	  
1.6.	  Skin	  barrier	  assays	  
1.6.1.Transepidermal	  water	  loss	  (TEWL)	  in	  vivo	  epidermal	  barrier	  assay	  
	   Measurements	   in	   pups	   at	   P1	   were	   performed	   with	   Tewameter	   TM300	  (EnviroDerm	   Services)	   following	   the	   manufacturer´s	   instructions.	   Units	   are	   given	   in	  gram	  per	  hour	  per	  square	  meter.	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1.6.2	  Toluidine	  Blue	  in	  vivo	  epidermal	  barrier	  assay	  	   This	  assay	  modifies	  skin	  to	  permit	  barrier-­‐dependent	  penetration	  by	  histological	  dyes.	  Euthanized	  newborn	  pups	  were	  rinsed	   in	  PBS	   (1X)	  and	   immersed	   in	  25%,	  50%,	  75%	  and	  100%	  methanol	  for	  1	  minute	  each	  successively;	  pups	  were	  then	  rehydrated	  in	  PBS	  and	  stained	  in	  0.1%	  toluidine	  blue	  for	  10	  minutes	  at	  room	  temperature.	  They	  were	  washed	  briefly	  in	  PBS	  (1X)	  and	  photographed	  immediately.	  
	  
2.	  HISTOLOGICAL	  ANALYSIS	   	  
2.1.	  Fresh	  frozen	  tissue	  Tissues	   were	   embedded	   in	   optimal	   cutting	   temperature	   (OCT)	   compound	  (Sakkura	  Finetek,	  Torrance,	  CA),	  snap-­‐frozen	  in	  dry	  ice,	  and	  6µm	  cryostat	  sections	  were	  cut.	   Immunofluorescence	   analyses	   were	   performed	   as	   described	   previously	   (Perez-­‐Moreno	   et	   al.,	   2006),	   using	   the	   following	   antibodies:	   s100a7a15	   (home-­‐made,	   kindly	  provided	   by	   Ronald	   Wolf,	   Ludwig-­‐Maximilian	   University,	   Munich,)	   and	   Alexa488-­‐	   or	  Alexa594-­‐coupled	  secondary	  antibodies	  (Invitrogen).	  DAPI	  (Invitrogen).	  
2.2.	  Formalin-­fixed	  paraffin-­embedded	  tissue	  Tissues	  were	   fixed	   in	  10	  %	   formalin,	  embedded	   in	  paraffin,	  4µm	  sectioned	  and	  dried	   at	   37ºC	   overnight	   for	   further	   processing.	   Immunohistochemical	   detection	   was	  performed	   using	   antibodies	   against	   different	   epitopes:	   c-­‐Fos	   (sc-­‐52,	   Santa	   Cruz	  Biotechnology	   Inc.),	   Flag	   (Cell	   Signaling),	   CD3	   (Santa	   Cruz	   Biotechnology	   Inc.),	   Ki-­‐67,	  MMP10	   (DAKO),	   p-­‐Stat3	   (Cell	   Signaling),	   Keratin	   1,	   5,	   6,	   10,	   14,	   Filaggrin,	   Loricrin	  (Covance),	   human	   CD4	   (IF6	   clone,	   Novocastra).	   Sections	   were	   subjected	   to	   antigen	  retrieval	  using	  citrate	  buffer	  pH6	  (1mM	  sodium	  citrate,	  0.05%Tween	  20)	  and	  cooked	  in	  a	   pressure	   cooker.	   	   Immunohistological	   stainings	   were	   performed	   according	   to	   the	  manufacturer´s	   protocol	   (either	   the	   EnVision	   DAB+	   kit	   (DAKO)	   for	   rabbit	   IgG	   or	   the	  VECTASTAIN	  Elite	  ABC	  Kit	  (Vector	  Labs)	  for	  rat,	  goat	  or	  mouse	  IgG).	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2.3.	  Human	  samples	  and	  Tissue	  Microarray	  (TMA)	  preparation	  	   Human	  skin	  SCC	  samples	  obtained	  after	  informed	  consent	  (ethics	  permission	  number	  is	  125/10/2012	  EK	  405/2006) and	  approval	  were	  provided	  and	  evaluated	  by	  Dr.	  Peter	  Petzelbauer	  (Medical	  University	  of	  Vienna,	  Austria).	  Production	  of	  tissue	  arrays	  from	  paraffin	  blocks	  from	  BCC	  and	  SCC	  lesions	  (from	  the	   dermato-­‐pathological	   data	   bank)	   according	   to	   ethics	   committee	   permission	  405/2006	  and	  extension	  125/10/2012).	  In	  brief,	  by	  this	  technique	  0.5	  mm	  punches	  are	  taken	   out	   of	   the	   paraffin-­‐embedded	   material	   by	   parallel	   viewing	   of	   H&E-­‐stained	  sections.	  	  
2.4.	  Nile	  Red	  staining	  Nile	  red	  (Sigma-­‐Aldrich®)	  staining	  was	  performed	  on	  frozen	  sections	  for	  2	  min	  with	  0.15mg/ml	  Nile	  Red	  in	  75%	  glycerol.	  Stock	  solution	  of	  nile	  red	  at	  0.5	  mg/ml	  was	  prepared	  in	  acetone.	  To	  prepare	  the	  working	  solution,	  0.05ml	  of	  stock	  solution	  is	  added	  to	   50ml	   of	   a	   75:25	   glycerol-­‐water	   mixture.	   To	   stain	   the	   sections,	   a	   drop	   of	   working	  solution	  was	  added	  on	  the	  frozen	  tissue	  and	  it	  was	  covered	  with	  a	  coverslip.	  The	  section	  was	  analyzed	  in	  a	  Nikon	  fluorescence	  microscope.	  	  	  
3.	  PROTEIN	  ANALYSES	   	  
3.1.	  Protein	  extraction	  and	  quantification	  	   Protein	   isolation	   for	  Western	   blot	   was	   performed	   in	   RIPA	   buffer	   (50mM	   Tris,	  150mM	  NaCl,	  0.1%	  SDS,	  0.5%	  deoxycholate,	  1%	  NP-­‐40)	  containing	  a	  protease	  inhibitor	  cocktail	   (Sigma-­‐Aldrich®),	   0,1mM	   Na3VO4,	   40mM β-­‐glycerophospate,	   40mM	   NaPPi,	  1mM	  NaF	  and	  tissues	  were	  homogenized	  using	  Precellys	  24	  (Bertin	   technologies).	  For	  protein	  lysates	  from	  cultured	  keratinocytes,	  cells	  were	  scraped	  with	  100ul	  (for	  each	  well	  in	  a	  6	  well	  plate)	  with	  a	  cell	  scraper	  and	  kept	  in	  ice	  for	  15	  minutes.	  The	  cell	  lysate	  was	  spun	   down	   at	   maximum	   speed	   and	   supernatant	   was	   collected.	   Protein	   lysates	   were	  quantified	  by	  using	  Pierce	  BCA	  Protein	  Assay	  Reagent	  (Thermo	  Scientific).	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3.2.	  Immunoblotting	  	   Equal	   amounts	   of	   protein	   (20-­‐50ug)	   were	   separated	   by	   SDS-­‐PAGE	   on	   4-­‐12	  Western	   blot	   analysis	   was	   performed	   according	   to	   standard	   procedures	   using	   the	  following	  antibodies:	   c-­‐Fos	   (BD-­‐Pharmingen),	   Flag	   (Sigma-­‐Aldrich®),	  Vinculin	   (Sigma-­‐Aldrich®),	  MMP10	  (DAKO),	  S100a7a15	  (provided	  by	  Dr.	  Ronald	  Wolf), β-­‐Actin	  (Sigma-­‐Aldrich®),	  GAPDH	  (Sigma-­‐Aldrich®).	  	  	   The	   blots	   were	   incubated	   with	   the	   appropriate	   secondary	   horseradish	  peroxidase-­‐coupled	  antibodies	  (GE	  Healthcare)	  and	  developed	  using	  the	  Amersham	  ECL	  Plus	   Western	   Blotting	   Detection	   Reagent	   (GE	   Healthcare)	   and	   Amersham	   ECL	  Hyperfilms	   (GE	  Healthcare).	   Alternatively,	   blots	  were	   incubated	  with	   Alexa-­‐Fluor	   680	  coupled	  secondary	  antibodies	  (Invitrogen)	  and	  visualized	  using	  the	  Odyssey	  Imaging	  system	  (Li-­‐Cor).	  	  
3.3.	  Chromatin	  Immunoprecipitation	  (ChIP)	  	   ChIP	   analysis	  was	   performed	  with	   a	   ChIP	   Assay	   Kit	   (Upstate)	   according	   to	   the	  manufacturer’s	   instructions.	   Antibodies	   used	   were	   c-­‐FOS	   (Santa	   Cruz	   Biotechnology	  Inc.).	  Cells	  were	  plated	  as	  for	  keratinocyte	  culture	  in	  order	  to	  exclude	  any	  other	  cell	  type	  in	   the	   sample.	   Isotype	   antibodies	  were	   used	   as	   controls	   (BD	  Biosciences).	   Bound	   and	  unbound	   fragments	   were	   run	   in	   agarose	   gels	   or	   quantified	   by	   real-­‐time	   PCR	   when	  indicated.	  	  	  
4.	  RNA	  ANALYSES	   	  
4.1.	  RNA	  extraction	  from	  tissues	  or	  cells	  Total	   RNA	   was	   isolated	   using	   Trizol	   (Sigma-­‐Aldrich®)	   according	   to	   the	  manufacturarer´s	  instructions.	  Complementary	  DNA	  was	  synthesized	  using	  1µg	  of	  RNA,	  Ready-­‐To-­‐Go-­‐You-­‐Prime-­‐First-­‐Strand	  Beads	  (GE	  Healthcare)	  and	  random	  primers	  	  were	  used	   (Sigma-­‐Aldrich®)	   as	   described	   in	   the	   manufacturer´s	   protocol.	   Quantitative	  reverse	   transcriptase	   PCR	   reactions	   were	   performed	   using	   GoTaq®	   RT-­‐qPCR	   Master	  Mix	   (Promega)	   and	   Eppendorf	   fluorescence	   thermocyclers	   (Eppenddorf).	   The	   2-­‐∆∆CT	  method	  was	  used	   to	  quantify	   amplified	   fragments.	   Expression	   levels	  were	  normalized	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using	   at	   least	   two	   housekeeping	   genes	   (gapdh,	   hprt).	   Primer	   sequences	   are	   shown	   in	  Table	  M2,	  and	  M3.	  
4.2.	  RNA	  extraction	  from	  FACS-­sorted	  cells	  	   This	  protocol	  was	  used	  to	  extract	  RNA	  from	  a	  very	  low	  number	  of	  cells	  (down	  to	  10.000	  cells).	  Cells	  were	  collected	  in	  either	  FACS	  tube	  (when	  using	  the	  BD	  Influx	  Sorter)	  or	  1.5ml	  eppendorf	  tubes	  (when	  using	  the	  BD	  FACSAria	  III).	  Cells	  were	  spun	  down	  and	  resuspended	   in	   350µl	   of	   RLT	   buffer	   (Qiagen)	   +	   3.5	   µl	   of	   B-­‐Mercaptoethanol	   (Sigma-­‐Aldrich®).	  The	   cells	  were	  disrupted	  with	   an	   insulin	   syringe	  10	   times	  up	  and	  down.	  A	  150µl	  of	  chloroform	  was	  added	  and	  the	  whole	  suspension	  was	  carefully	  mixed	  and	  spun	  down	  at	  13000rpm	  for	  10	  min	  at	  4C.	  Carefully,	  the	  upper	  layer	  phase	  was	  transfered	  to	  a	  clean	   1.5ml	   Eppendorf	   tube.	   400	   µl	   of	   isopropanol	   with	   4µl	   of	   Ambion®	   linear	  acrylamide	  (Invitrogen™)	  was	  added	  on	  top.	  This	  mix	  was	  left	  to	  precipitate	  overnight	  at	   -­‐20C.	   Next	   morning,	   the	  mix	   was	   spun	   down	   30	  minutes	   at	   13200rpm	   at	   4C.	   The	  pellet	  was	  washed	  twice	  with	  70%	  EtOH	  in	  DEPC	  water.	  The	  mix	  was	  spun	  down	  and	  the	  pellets	  were	   left	   to	   air	   dry	   for	   a	   couple	  minutes.	   Finally,	   pellets	  were	   resuspended	   in	  15ul	  of	  Rnase-­‐free	  water.	  	  Complementary	   DNA	   was	   synthesized	   using	   100ng	   of	   RNA	   and	   following	   the	  instructions	  of	  the	  SuperScript®	  	  VILO™	  	  cDNA	  Synthesis	  Kit	  (Invitrogen).	  
Table	  M2.	  	  
Allele	  Name	   Primer	   Sequence	  (5´-­-­>3´)	  Sense	   CTGTCACCGTGGGGATAAAG	  
c-­fos	   Antisense	   CCTACTACCATTCCCCAGCC	  Sense	   ATGGGGCTCTCCTGTCAACACAC	  
c-­Fos-­flag	   Antisense	   TGTCGTCGTCGTCCTTGTAG	  Sense	  	   TATGTGTGTCACCGTCCTGG	  
mmp10	   Antisense	   AGCCACAAGTTGATGCTGTG	  Sense	  	   TGA	  AGG	  GTC	  CAT	  CAG	  TCA	  
s100a7a15	   Antisense	   CTA	  GTA	  GAG	  GCT	  GTG	  CT	  Sense	  	   ATCGTCTACTGCTATCTGCGT	  
hprt	   Antisense	   GCTATCTGCGTATCGTCTACT	  Sense	  	   TTGATGGCAACAATCTCCAC	  
gapdh	   Antisense	   CGTCCCGTAGACAAAATGGT	  Sense	  	   TCTTACACGGTGTGCTGAGG	  
notch-­1	   Antisense	   GAATGGAGGTAGGTGCGAAG	  Sense	  	   GTCACCTCGTTCATGCACTC	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Sense	  	   GTCACCTCGTTCATGCACTC	  
hes-­1	   Antisense	   TCTGGAAATGACTGTGAAGCA	  Sense	  	   CAGTGTGCCAACCTCCAGAACG	  keratin	  5	   Antisense	   AGCCCGCTACCCAAACCAAGAC	  Sense	  	   GACGCCGCCCCTGGTGTG	  keratin	  14	   Antisense	   GGTGGCGATCTCCTGCTC	  Sense	  	   CTCTACGTAGTTACCACAACAAT	  keratin	  1	   Antisense	   CAATCCTCTACGTAGACGTA	  Sense	   GGAGGGTAAAATCAAGGAGTGGTA	  keratin	  10	   Antisense	   TCAATCTGCAGCAGCACGTT	  Sense	   CTAGAGGGCATGAGTGTAGTCA	  filaggrin	   Antisense	   CAAGACTGGACAGTTGGCTGG	  Sense	  	   TCACTCATCTTCCCTGGTGCTT	  loricrin	   Antisense	   GTCTTTCCACAACCCACAGGA	  Sense	  	   GAGCTCATTGAATGCTTGGC	  ifn-­γ 	   Antisense	   GCGTCATTGAATCACACCTG	  Sense	  	   ACCTTGACGGTGTTCATACAGT	  il-­4	   Antisense	   CTGCTCCTATTCGACCACTATCT	  Sense	  	   CCCAGGGCGACTGTAACATC	  il-­5	   Antisense	   GCAATGTAGATCCTCATGGCAT	  	  	  
Table	  M3.	  	  
Allele	  Name	   Primer	   Sequence	  (5´-­-­>3´)	  Sense	   GTGACCGTGGGAATGAAGTT	  
C-­FOS	   Antisense	   CCGGGGATAGCCTCTCTTAC	  Sense	   CTGATGGCCCAGAACTCATT	  
MMP10	   Antisense	   ACTGGAACCCTGAACCTGAA	  Sense	  	   CAGGCTTGGCTTGTCAATCT	  
S100A7	   Antisense	   TCATCCTTCTACTCGTGACGC	  Sense	  	   CCTGGCGTCGTGATTAGTGAT	  
HPRT	   Antisense	   AGACGTTCAGTCCTGTCCATAA	  
	  
4.3.	  Genome-­wide	  expression	  analyses	  RNA	   of	   samples	   was	   hybridized	   to	   the	   Illumina	   MouseRef-­‐8	   V2	   R3	   BeadChip	  array	   according	   to	   the	   manufacturer's	   instructions	   (Illumina,	   Inc.,	   San	   Diego,	   CA).	  Microarray	   scanning	  was	  done	  using	   a	  Beadstation	   array	   scanner.	  Data	  preprocessing	  and	   quality	   control	   was	   conducted	   using	   packages	   of	   the	   Bioconductor	   project	  implemented	   at	   DKFZ	   in-­‐house-­‐developed	   ChipYard	   framework	   for	   microarray	   data	  analysis	   (http://www.dkfz.de/genetics/ChipYard/).	   In	   summary,	   microarray	   probes	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were	  annotated	  based	  on	  Ensembl	  (version	  58)	  using	  an	  in	  house	  BLAST-­‐based	  pipeline.	  Before	  normalization	  with	  variance-­‐stabilizing	   transformation	  (VST)	  and	  robust	  spline	  normalization	   (RSN)	   algorithms,	   beads	  with	   signals	   below	   the	   negative	   controls	  were	  removed	  and	  positive	  negative	  and	  hybridization	  controls	  were	  excluded.	  Normalized	   log2	   transformed	  microarray	   data	  were	   used	   to	   calculate	   the	   gene	  fold	   change	   value	   (i.e.	   how	   many	   times	   the	   intensity	   of	   gene	   expression	   changed	  compared	   to	   the	   control).	   FC	   value	   has	   no	   measure	   of	   statistical	   significance,	   but	   is	  biologically	   relevant	   and	   specifically	  usable	   for	  data,	  which	  other	   than	   the	   time	   series	  has	   no	   other	   replication.	   Genes	   were	   ranked	   according	   to	   the	   Euclidian	   distance	  between	   the	   maximum	   expression	   within	   a	   probe	   set	   and	   the	   mean	   expression	   of	   a	  probe	  set	  over	  all	  time	  points	  (as	  show	  in	  (Busch	  et	  al.,	  2008)),	  both	  scaled	  (normalized)	  to	  the	  maximum	  value	  measured	  in	  each	  dataset.	  
	  
5.	  FLOW	  CYTOMETRY	  	  
A	  similar	  protocol	  was	  used	  to	  perform	  Flow	  cytometry	  analyses	  and	  Cell	  Sorting.	  Samples	   were	   taken	   from	   back	   skin	   of	   c-­‐FosEp-­tetON	   mice	   or	   controls	   treated	   with	  doxycycline	  for	  2	  and	  4	  weeks.	  	  Different	  protocols	  were	  used	  to	  homogenize	  back	  skin	  and	  lymph	  nodes.	  
5.1.	  Back	  skin-­specific	  protocol	  Back	   skin	   of	   control	   and	   c-­‐FosEp-­tetON	  mice	   was	   shaved	   and	   removed	   from	   the	  mouse.	   The	   fat	   layer	  was	   eliminated	  using	   a	   scalpel.	   The	   skin	  was	   cut	   in	   small	   pieces	  with	   scissors	   and	   transfered	   to	  MACS	   tubes	   (Miltenyi)	   in	  4ml	  of	   plain	  RPMI	   (Gibco®)	  containing	   120ul	   of	   DNase	   (Sigma-­‐Aldrich®)	   at	   4mg/ml	   diluted	   in	   RPMI.	   200µl	   of	  liberase	  was	  as	  well	  added	  (Roche)	  at	  5mg/ml.	  The	  skin	  was	  incubated	  for	  30	  minutes	  in	  a	  water	  bath	  at	  37C.	  	  Homogenization	  was	  performed	  using	  the	  program	  B01	  in	  a	  MACS	  homogenizer	  twice.	  To	  quench	  the	  enzymatic	  reaction,	  10ml	  of	  10%	  chelated	  FBS-­‐RPMI	  was	  added	   to	   the	  homogenate.	  The	  mix	  was	   filtered	   through	  a	  70µm	  cell	   strainer	  and	  then	  through	  a	  40um	  cell	  strainer.	  Each	  filter	  was	  rinsed	  with	  5ml	  of	  PB	  low-­‐BSA	  buffer	  (2mM	  EDTA,	  0.5%	  BSA,	  PBS)	  to	  collect	  the	  cells	  remaining	  in	  the	  strainer.	  After,	  the	  cell	  
	   Materials	  and	  Methods	   	  
	   60	  
preparation	  was	  spun	  down	  10	  minutes	  at	  300g	  at	  room	  temperature.	  The	  supernatant	  was	   removed	  and	   the	  pellet	  was	   resuspended	   in	  1	  ml	  of	   red	  blood	   cell	   lysing	   (Sigma-­‐Aldrich®)	  buffer.	  The	  cells	  in	  the	  RBC	  lysing	  buffer	  were	  incubated	  for	  5	  min	  the	  fridge.	  5ml	  of	  PB	  buffer	  was	  added	  and	  the	  whole	  mix	  was	  spun	  down	  at	  300g	  for	  5	  minutes	  at	  4C.	  The	  pellet	  was	   resuspended	   in	  300µl	  of	  PB	  high	  BSA	  buffer	   (2mM	  EDTA,	  2%	  BSA,	  PBS).	  Fc	  block	  (BD	  Pharmingen)	  was	  added	  in	  a	  dilution	  of	  1/200	  and	  kept	  30	  minutes	  on	  ice.	  30	  minutes	  after,	  the	  mix	  was	  divided	  into	  different	  conditions	  (depending	  on	  the	  number	  of	  the	  different	  populations	  tested).	  	  
5.2.	  Lymph	  node-­specific	  protocol	  Skin	   draining	   lymph	  nodes	  were	   removed	   from	   the	  mouse	   and	   kept	   in	   5%FBS	  RPMI.	   Lymph	   nodes	   were	   smashed	   with	   a	   plunger	   against	   a	   40µm	   cell	   strainer.	   The	  strainer	  was	  washed	  with	  5%FBS	  RPMI.	  Cells	  were	  spun	  down	  at	  300g	  for	  10	  minutes.	  Finally,	  leukocytes	  were	  resuspended	  in	  PB	  buffer	  low-­‐BSA	  and	  staining	  was	  carried	  out.	  
5.3.	  Flow	  cytometry	  analyses	  For	   flow	   cytometry	   analyses,	   stainings	   were	   performed	   using	   different	  combinations	   of	   the	   following	   antibodies	   depending	   on	   the	   experiment.:	   NK1.1	   PerCP	  Cy5.5	   (1/200)	   (BD	   Pharmingen),	   CD25	   APC	   1/200	   (BD	   Pharmingen),	   CD45.2	   FITC	  1/400	   (BD	   Pharmingen),	   γ/δ	   TCR	   Brilliant	   Violet	   421	   1/200	   (Biolegend),	   CD3	   (BD	  Pharmingen),	  CD4	  PECy7	  1/100	  (BD	  Pharmingen),	  CD8	  (BD	  Pharmingen),	  Gr1	  FITC	  (BD	  Pharmingen),	   CD45	   1/500	   (BD	   Pharmingen),	   	   CD11b	   PErCPCy5.5	   1/200	   (BD	  Pharmingen),	   B220	   PE	   1/200	   (BD	   Pharmingen),	   CD11c	   PE	   1/100c	   (BD	   Pharmingen),	  CD69	  PE	   (BD	  Pharmingen),	   CD44	  APC	  1/200	   (BD	  Pharmingen).	   At	   the	   same	   time	   the	  FMOs	  (Fluoresence	  Minus	  One)	  controls	  were	  prepared.	  In	  these	  controls	  you	  add	  every	  single	  antibody	  in	  the	  antibody	  cocktail	  used	  minus	  one.	  	  The	  antibodies	  were	  incubated	  with	  the	  cells	  for	  30	  minutes	  in	  ice	  protected	  from	  light.	  After	  staining,	  two	  washes	  were	  performed	  with	  PB	  buffer.	  Depending	  on	  the	  group	  of	  fluorophores	  used,	  we	  employed	  either	  DAPI	  (5ul	  of	  a	  stock	  at	  2mg/ml)	  or	  Acqua	  live	  (1/1000	  dilution	  from	  the	  original	  stock	  in	  PB	  buffer).	  Samples	  were	  incubated	  for	  30	  minutes	  at	  room	  temperature	   	  and	  afterwards	  washed	  twice	  with	  PB	  buffer.	  Cells	  were	  fixed	  with	  1%PFA	  in	  PB	  buffer	  in	  a	  final	   volume	   of	   400µl	   for	   30	   min	   in	   the	   fridge.	   Finally,	   cells	   were	   washed	   and	   next	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morning	  samples	  were	  analyzed	  in	  different	  Cell	  Analyzers	  (BD	  FACSCanto™,	  BD	  LSRII	  Fortessa™	  or	  BD	  FACSCalibur™).	  Beads	  from	  BD™	  CompBeads	  were	  used	  to	  compensate	  every	   single	   color	   used	   in	   each	   experiment.	   For	   this	   purpose,	   positive	   beads	   were	  incubated	   separately	  with	   each	   antibody,	   then	  washed	   and	   finally	   the	   negative	   beads	  were	  added.	  Analyses	  were	  performed	  using	  FlowJo	  software.	  
5.4.	  FACS	  sorting	  Cell	  suspensions	  were	  stained	  with	  CD3	  APC	  1/200	  (BD	  Pharmingen),	  CD4	  PECy7	  1/100	   (BD	   Pharmingen),	   and	   Gr1	   FITC	   (BD	   Pharmingen)	   for	   30	  minutes	   in	   ice.	   Cells	  were	  washed	  with	  PB	  buffer	  twice	  and	  right	  before	  sorting,	  5ul	  of	  DAPI	  at	  2mg/ml	  was	  added.	  Cells	  were	  usually	  sorted	  in	  a	  BD	  Influx	  Sorter	  and	  sometimes	  in	  a	  BD	  FACSAria	  III.	  
6.	  CELL	  CULTURE	   	  
6.1.	  Keratinocyte	  primary	  cultures	  
6.1.1.Primary	  keratinocytes	  Isolation	   and	   culture	   of	   primary	   keratinocytes	   were	   performed	   as	   described	  (Zenz	  et	  al.,	  2003).	  Briefly,	  the	  epidermis	  was	  separated	  from	  the	  dermis	  by	  incubation	  in	   0.75%	   trypsin	   (Gibco®)	   at	   37°C.	   60	   min	   later,	   the	   epidermis	   was	   incubated	   in	  medium	  containing	  250µg/ml	  DNase	  (Sigma-­‐Aldrich®)	  for	  30	  min	  in	  a	  water	  bath.	  The	  cell	   suspension	   was	   filtered	   through	   a	   70µm	   cell	   strainer.	   Keratinocytes	   were	   spun	  down	  and	  plated	  in	  coated	  dishes	  (Cascade	  Biologics)	  in	  complete	  MEM	  (8%	  chelated	  fetal	  calf	  serum	  (FCS),	  Gentamycin,	  Penicyllin,	  Streptomycin,	  0.05mM	  Ca2+	  in	  Eagle	  MEM	  (Sigma-­‐Aldrich®).	   Next	   day	   the	   medium	   was	   changed	   to	   serum-­‐free	   keratinocyte	  medium	   (KC-­‐SFM)	   (Gibco®)	   and	   c-­‐Fosfl/fl	  were	   infected	  with	   adenoviruses	   (Ad-­‐Cre	   or	  Adeno-­‐green	  fluorescent	  protein	  (Ad-­‐GFP)	  purchased	  from	  the	  University	  of	  Iowa	  with	  300	   particles	   per	   cell.	   Cells	   were	   collected	   at	   different	   time-­‐points	   post-­‐infection.	   c-­‐FosEp-­tetON	  keratinocytes	  were	  cultured	  in	  KC-­‐SFM	  ±	  1µg/ml	  Dox	  treatment	  starting	  one	  day	   after	   plating	   the	   cells.	   Keratinocytes	   were	   collected	   at	   different	   time	   points.	   TPA	  treatment	  was	  used	  at	  a	  concentration	  of	  10ng/ml	  for	  3,	  5,	  6,	  8,	  12	  hours	  depending	  on	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the	  experiment.	  For	  Calcium	  treatment,	  Ca2+	  was	  diluted	  at	  a	  concentration	  of	  1.8mM	  in	  KC-­‐SFM.	  Keratinocytes	  were	  always	  grown	  at	  32C.	  	  
6.1.3.	  E	  Low	  Calcium	  medium	  Keratinocytes	   used	   for	   colony	   formation	   assays	   were	   kept	   in	   E-­‐Low	   Calcium	  medium.	  This	  media	  was	  prepared	  as	  previously	  described	  (Nowak	  and	  Fuchs,	  2009)	  	  
6.1.4.	  SCC	  cell	  lines	  	   Epidermal-­‐derived	  SCCO9	  cells	  were	  kindly	  provided	  by	  M.	  Sibilia	   (Institute	  for	  Cancer	  Research,	  Vienna,	  Austria);	   SCCO11,	   SCCO22	  were	  kindly	  provided	  by	  G.	  P.	  Dotto	  (University	  of	  Lausanne,	  Lausanne,	  Switzerland);	  These	  cell	  lines	  were	  cultured	  in	  DMEM	  10%FBS.	  
6.1.5.	  Feeders	  	   3T3	   fibroblasts	   or	   feeders	   were	   maintained	   in	   10%	   FBS	   DMEM	   F:12	   (3:1)	  (Gibco)	  with	  sodium	  bicarbonate,	  L-­‐glutamine	  and	  Pen-­‐Strep.	  These	  cells	  were	  never	  passaged	   for	  more	   than	  20	  passages.	  When	   feeders	  were	   ready	   to	   be	   used	   they	  were	  treated	   with	   10ug/ml	   mitomycin	   C	   (stock	   0.5mg/ml,	   dissolved	   in	   H2O)	   in	   complete	  medium	  for	  2	  hours	  at	  37C,	  then	  trypsinized	  and	  replated	  1/3	  of	  their	  saturation	  density	  along	  with	  keratinocytes	  
6.4.	  In	  vitro	  proliferation	  assays	  
6.4.1.	  Cell	  Counts	  	   5x105	   c-­‐FostetON	   keratinocytes	   were	   plated	   in	   triplicate	   on	   six-­‐well	   plates	  coated	  with	  Coating	  Matrix	  and	  grown	  in	  keratinocyte	  serum-­‐free	  media.	  Dox	  treatment	  started	  one	  day	  after	  for	  1,	  2,	  3,	  4,	  and	  5	  days.	  Cells	  were	  trypsinized	  and	  counted	  with	  a	  neubauer	  chamber	  at	  indicated	  times.	  
6.4.2.	  Colony	  formation	  assays	  
	   To	  analyze	   colony	   formation	  properties,	   1500	   cells	  were	  plated	   in	   triplicate	  on	  six-­‐well	   plates	   coated	  with	   coating	  matrix	   on	   top	   of	   feeders.	   Cells	  were	   kept	   in	   E-­‐low	  calcium	  medium	  in	  the	  presence	  or	  absence	  of	  1µg/ml	  of	  Dox.	  	  17	   days	   after	   having	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plated	   the	   keratinocytes,	   the	   culture	   media	   was	   removed	   and	   remaining	   fibroblasts	  were	  washed	  with	  PBS1x	  until	  they	  were	  detached.	  Keratinocyte	  colonies	  were	  fixed	  in	  25%	  glutaraldehyde	  in	  PBS	  1X	  for	  15min	  at	  RT.	  Then,	  glutaraldehyde	  was	  removed	  and	  cells	  were	   stained	  with	   0.05%	  Crystal	   Violet	   in	   distilled	  Water.	   The	   dye	  was	   kept	   for	  30min	   at	   room	   temperature.	   Colonies	   were	   washed	   twice	   with	   water	   and	   left	   them	  inverted	   to	   dry.	   The	   plates	   were	   scanned	   the	   colonies	   were	   quantified	   using	   Axio	  software.	  Colony	  number	  and	  size	  was	  measured.	  
6.4.3.	  EdU	  incoroporation	  assay	  	   c-­‐FostetON	   keratinocytes	   were	   plated	   in	   triplicates	   according	   to	   the	   conditions	  cited	  in	  section	  6.1.	  Cells	  were	  cultured	  in	  KC-­‐SFM	  for	  different	  times ± 1µg/ml	  of	  Dox	  in	  the	   media.	   EdU	   (Click-­‐It-­‐EdU,	   Invitrogen)	   was	   added	   to	   cell	   culture	   media	   at	   a	  concentration	  of	  10µM	  and	  2	  hours	  later	  cells	  were	  carefully	  trypsinized,	  scraped	  from	  the	  plate	  and	  transferred	  FACS	  tubes.	  Keratinocytes	  were	  spun	  down	  at	  500g	  for	  15	  min	  at	  4C	  and	  the	  cell	  pellet	  was	  fixed	  with	  100	  µl	  of	  4%	  PFA	  15	  min	  at	  room	  temperature.	  Cells	  were	  washed	  and	  resuspended	  in	  1%	  BSA/PBSA.	  EdU	  incorporation	  was	  measured	  by	   Flow	   Cytometry	   analyses	   in	   a	   BD	   LSRII	   Fortessa™.	   %EdU	   positive	   cells	   were	  quantified	  using	  FlowJo	  software.	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1.	  INDUCIBLE	  EPIDERMAL	  C-­FOS	  EXPRESSION	  IN	  ADULT	  MICE	  LEADS	  
TO	  EPIDERMAL	  HYPERPLASIA	  WITH	  INCREASED	  PROLIFERATION	  
1.1.	  Inducible	  keratinocyte-­specific	  c-­fos	  expression:	  c-­FosEp-­tetON	  mouse	  model	  Increased	   c-­‐Fos	   levels	   have	   been	   found	   in	   SCC	   tumors	   arising	   in	   different	  stratified	   squamous	   epithelia	   such	   as	   the	   epidermis	   (Guinea-­‐Viniegra	   et	   al.,	   2012;	  Sachdev	   et	   al.,	   2008).	   To	   address	   the	   question	   whether	   keratinocyte-­‐specific	   c-­‐Fos	  expression	  alters	  epidermal	  homeostasis	  and	  is	  sufficient	  to	  promote	  SCC	  development	  in	  the	  skin,	  we	  have	  generated	  a	  doxycycline	  (Dox)	  inducible	  mouse	  model.	  To	  achieve	  inducible	  expression	  of	  c-­fos	  in	  keratinocytes	  in	  vivo,	  we	  crossed	  K5-­‐rtTA	  mice	  to	  colTetO-­











	  (A)	   Schematic	   representation	   of	   the	   c-­‐FosEp-­tetON	   mouse	   model.	   rtTA	   (reverse	   transactivator),	  tetOp	  (tetracycline-­‐regulatable	  operator).	  Dox	  is	  supplied	  either	  in	  the	  drinking	  water	  (0.5mg/l)	  or	  in	  the	  food.	  (B)	  Experimental	  set-­‐up.	  (C)	  Representative	  picture	  of	  a	  control	  and	  a	  c-­‐FosEp-­tetON	  mouse	  model	   treated	  with	  Dox	   in	   the	   food	   for	   4	  weeks.	   Square	   shows	   a	   higher	  magnification	  picture	  of	  the	  back	  skin	  of	  the	  mice	  showing	  the	  macroscopic	  lesions.	  (n=	  8	  controls,	  8	  mutants).	  (D)	  Kaplan-­‐Meier	  survival	  curve	  depicting	  control	  and	  c-­‐FosEp-­tetON	  mice	  	  (n=20/17).	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c-­fos	  expression	  was	  always	  induced	  in	  adult	  c-­‐FosEp-­tetON	  mice	  from	  6	  to	  8	  weeks	  of	   age,	   by	   supplying	   them	  with	  Dox	   (Fig.	   1B).	   c-­‐FosEp-­‐tetON	  adult	  mice	   expressing	   c-­‐Fos	  following	   Dox	   treatment	   for	   4	   weeks	   showed	   reduced	   size	   and	   dramatic	   hair	   loss	  compared	   to	   control	   mice.	   Interestingly,	   the	   skin	   of	   these	   mice	   was	   thickened	   with	  cornified	  epidermis	  appearing	  as	  dry,	   scaly	   lesions	   (Fig.1C).	  About	  50%	  of	   the	  mutant	  mice	  eventually	  had	  to	  be	  euthanized	  due	  to	  ethical	  reasons	  short	  after	  4	  weeks	  of	  Dox	  treatment	  (Fig.	  1D)	  Inducible	  expression	  of	  c-­fos	  was	  detectable	  in	  the	  epidermis	  as	  early	  as	  2	  weeks	  after	  Dox	  induction	  by	  immunohistochemistry	  (IHC)	  and	  RT-­‐qPCR	  (Fig.	  2A	  and	  2B).	  At	  2	  weeks	   expression	   was	   mainly	   localized	   to	   the	   hair	   follicles,	   while	   at	   4	   weeks	   it	   was	  clearly	   visible	   in	   the	   basal	   layer	   of	   the	   epidermis	   and	   outer	   root	   sheath	   of	   the	   hair	  follicles	   (Fig.	   2A,	   arrows).	   Histological	   analyses	   of	   back	   skin	   revealed	   a	   complete	  disruption	   of	   the	   skin	   architecture	   accompanied	   by	   massive	   epidermal	   hyperplasia,	  hyper-­‐	  and	  parakeratosis	  and	  cell	  and	  nuclear	  atypia	  in	  c-­‐FosEp-­‐tetON	  mice	  following	  Dox	  treatment	   for	  4	  weeks.	   	   Strikingly,	  already	  at	  2	  weeks	  after	   inducible	  c-­fos	   expression,	  hair	  follicles	  were	  enlarged	  similar	  to	  the	  hair	  follicles	  in	  anagen	  or	  growing	  phase	  of	  the	  hair	  cycle	  compared	   to	  controls	   (Fig.	  2C,	  arrows).	  At	  4	  weeks,	  most	  hair	   follicles	  were	  absent	  and	  foci	  of	  central	  keratinization	  within	  concentric	  layers	  of	  abnormal	  squamous	  cells	  were	  often	  observed	  (Fig.	  2C).	  These	  cysts	  expressed	  early	  and	  late	  interfollicular	  epidermal	  differentiation	  markers,	  such	  as	  Keratin	  1	  (KI),	  Keratin	  10	  (K10),	  Loricrin	  and	  Filaggrin	  (data	  not	  shown),	  suggesting	  an	  alteration	  of	  the	  differentiation	  program	  of	  the	  hair	  follicle	  upon	  inducible	  c-­fos	  expression.	  Other	   keratin	   5	   (K5)-­‐expressing	   epithelial	   tissues,	   such	   as	   the	   tongue	   and	   the	  forestomach	  expressed	  exogenous	  c-­Fos,	  while	   tissues	   that	  do	  not	  express	  K5,	   such	  as	  spleen	  or	  liver,	  did	  not	  (Fig.	  2D	  and	  data	  not	  shown).	  Altogether,	  these	  data	  indicate	  that	  inducible	   expression	   of	   c-­fos	   in	   the	   epidermis	   alters	   epidermal	   homeostasis	  consequently	  disrupting	  the	  skin	  architecture.	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Figure	  2.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  Histological	  analyses	  of	  c-­‐Fos	  in	  back	  skin	  of	  control	  and	  c-­‐FosEp-­tetON	  mice	  after	  2	  and	  4	  weeks	  on	  Dox.	  (B)	  RT-­‐qPCR	  analyses	  of	  total	  c-­fos	  and	  exogenous	  c-­fos	  (c-­fos-­flag)	  levels.	  (n=4/4/4/4).	  (C)	  H&E	  histological	  analyses	  of	  back	  skin	  of	  c-­‐FosEp-­tetON	  mice	  after	  2	  and	  4	  weeks	  on	  Dox.	  Arrow	  indicates	   hair	   follicle.	   (n=4/4/4/4).	   (D)	  Histological	   analyses	   of	   c-­‐Fos	   in	   stomach,	   tongue	   and	  esophagous	  of	  c-­‐FosEp-­tetON	  mice	  after	  4	  weeks	  on	  Dox.	  (n=3/3).	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1.1.2.	  c-­Fos	  promotes	  proliferation	  in	  vivo	  in	  a	  non-­cell	  autonomous	  manner	  The	   balance	   between	   keratinocyte	   proliferation	   and	   differentiation	   must	   be	  tightly	  controlled	  to	  maintain	  epidermal	  homeostasis.	  A	  disruption	  in	  any	  of	  these	  two	  physiological	  processes	   leads	  to	  development	  of	  diseased	  skin.	  Therefore,	  we	  assessed	  proliferation	  in	  vivo	  by	  measuring	  Ki67	  protein	  levels	  in	  c-­‐FosEp-­tetON	  back	  skin	  samples.	  Interstingly	  Ki67	  IHC	  staining	  revealed	  increased	  proliferating	  cells	  in	  the	  basal	  layer	  of	  the	  epidermis	  upon	  c-­fos	  expression	  as	  early	  as	  2	  weeks	  of	  Dox	  treatment	  (Fig.	  3A	  and	  B).	   To	   evaluate	   whether	   c-­‐Fos	   would	   promote	   keratinocyte	   proliferation	   in	   a	   cell-­‐autonomous	  manner,	  we	  measured	  keratinocyte	  proliferation	  in	  vitro	  by	  using	  primary	  c-­‐FostetON	  keratinocytes	  from	  the	  tail.	  Upon	  Dox	  treatment,	  inducible	  expression	  of	  c-­fos	  
in	  vitro	  was	  detected	  by	  immunoblot	  analyses	  (Fig.	  4A).	  However,	  c-­‐Fos	  did	  not	  promote	  proliferation,	   as	   measured	   by	   keratinocyte	   number	   in	   culture	   (Fig.	   4B),	   EdU	  incorporation	   (Fig.	   4C)	   and	   colony	   formation	   assays	   (Fig.	   4D,	   4E	   and	   4F).	   Altogether,	  these	  data	  indicate	  that	  expression	  of	  c-­fos	  in	  keratinocytes	  is	  not	  sufficient	  to	  promote	  proliferation	  in	  a	  cell	  autonomous	  manner.	  
Figure	  3.	  	   	  	  	  	  	  	  	  	  (A)	  Histological	  analyses	  of	  c-­‐FosEp-­tetON	  back	  skin	  of	  Ki67	  at	  indicated	  times	  on	  Dox	  (w=weeks).	  (B)	  Quantification	  of	  Ki67	  positive	  nuclei	  per	  20x	  field.	  2w/4w:	  2	  and	  4	  weeks	  of	  Dox	  treatment.	  *p<0.05,	  ***p<0.0005.	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  (A)	  Immunoblot	  depicting	  protein	  levels	  of	  total	  c-­‐Fos	  total,	  exogenous	  c-­‐Fos	  and	  vinculin	  in	  c-­‐FostetON	   keratinocytes	   at	   6,	   12,	   24,	   48	   and	   72	   hours	   ±Dox.	   (B)	   c-­‐FostetON	   keratinocyte	   number	  quantification	   in	   cultured	   ±Dox	   for	   0,	   24,	   48,	   72	   and	   	   96h.	   (C)	   EdU	   incorporation	   assay	   in	   c-­‐FostetON	  keratinocyte	  treated	  ±Dox	  for	  6,	  12,	  24	  and	  48	  hours.	  (D)	  Picture	  of	  colonies	  formed	  from	  control	   and	   c-­‐FostetON	   keratinocytes	   treated	   ±Dox	   in	   a	   colony	   formation	   assay.	   Colonies	   are	  stained	  with	  crystal	  violet.	  (E)	  Quantification	  of	  the	  number	  of	  colonies.	  (F)	  Quantification	  of	  the	  colony	  size	  (by	  measuring	  the	  number	  of	  square	  pixels	  of	  each	  colony).	  ns=	  Not	  significant.	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1.1.3.	  Impaired	  differentiation	  upon	  c-­fos	  expression	  in	  vitro	  Previous	  studies	  in	  our	  lab	  have	  shown	  that	  c-­fos	  expression	  in	  keratinocytes	  can	  impair	  the	  differentiation	  program	  by	  repressing	  TACE	  expression	  through	  p53	  (Guinea-­‐Viniegra	   et	   al.,	   2012).	   TACE,	   also	   known	   as	   TNF-­‐α	   Converting	   Enzyme	   (or	   ADAM17),	  activates	   the	   Notch	   signaling	   pathway	   in	   keratinocytes	   by	   cleaving	   the	   extracellular	  domain	  of	  Notch	  (Guinea-­‐Viniegra	  et	  al.,	  2012).	  Upon	  cleavage,	  the	  intracellular	  domain	  of	   Notch	   (NICD)	   translocates	   to	   the	   nucleus	   and	   activates	   several	   genes	   involved	   in	  keratinocyte	  differentiation.	  Epidermal	  differentiation	  marker	  analysis	  in	  vivo	  in	  the	  c-­‐FosEp-­tetON	  mouse	  model	  upon	  4	  weeks	  of	  Dox	  treatment	  revealed	  a	  dramatic	  expansion	  of	  basal	  and	  suprabasal	  epidermal	  layers	  in	  mutant	  mice.	  Multiple	  cell	   layers	  were	  positive	  for	  K5	  (Fig.5A)	  and	  K14	  (not	  shown),	  which	  mark	  the	  basal	  cell	  compartment.	  Similarly,	  the	  spinous	  (K1	  and	  K10)	  and	   the	  granular	   (filaggrin	  and	   loricrin)	   layers	  were	  expanded	   (Fig.	  5A	  and	  data	  not	   shown),	   indicating	   that	   c-­fos	   expression	   affects	   early	   and	   late	   keratinocyte	  differentiation.	  	  To	  assess	  whether	  keratinocyte	  differentiation	  is	  impaired	  upon	  c-­fos	  expression	  
in	  vitro,	  we	  challenged	  primary	  control	  and	  c-­‐FostetON	  keratinocytes	  with	  2mM	  calcium	  to	  induce	   differentiation.	   24h	   after	   calcium	   treatment	   and	   Dox	   treatment,	   the	   levels	   of	  
notch1	  and	  the	  levels	  of	  the	  transcription	  factor	  hes1,	  which	  is	  downstream	  of	  Noctch-­‐1,	  did	  not	   increase	   as	   compared	   to	   controls	   (Fig.	   5C	   and	  5D).	   Furthermore,	   the	   levels	   of	  early	  differentiation	  markers	  keratin10	   and	  keratin1	   (Fig.	  5E	  and	  data	  not	   shown)	  did	  not	   increase	   either.	   Moreover,	   loricrin,	   a	   late	   differentiation	   marker,	   showed	   not	  significant,	  but	   reduced	   levels	  upon	  c-­‐Fos	  expression	  and	  calcium	   treatment	   (data	  not	  shown).	   These	   data	   support	   the	   fact	   that	   c-­‐Fos	   interferes	   with	   keratinocyte	  differentiation	  programs	  as	  previously	  described	  (Guinea-­‐Viniegra	  et	  al.,	  2012).	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Figure	  5.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  Histological	  analyses	  of	  Keratin	  5	  (K5),	  Keratin	  1	  (K1)	  and	  Loricrin	   in	  back	  skin	  of	  c-­‐FosEp-­
tetON	  mice	  after	  4	  weeks	  on	  Dox.	  (n=4).	  (B)(C)(D)(E)	  RT-­‐qPCR	  analyses	  of	  total	  c-­fos,	  notch1,	  hes-­1	  and	   keratin1	   respectively	   mRNA	   levels	   in	   c-­‐FostetON	   keratinocytes	   treated	   ±Dox,	   +0.05/2mM	  Ca2+	  for	  24h.	  *p<0.05,	  ***p<0.0005.	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1.2.	  Inducible	  keratinocyte-­specific	  c-­fos	  expression:	  c-­FosEp-­tetOFF	  mouse	  model	  To	   validate	   the	   findings	   observed	   in	   c-­‐FosEp-­tetON	   mouse	   model	   upon	   inducible	  expression	   of	   c-­fos,	   I	   generated	   another	   inducible	  mouse	   line,	   the	   c-­‐FosEp-­tetOFF	  mouse	  line.	   In	   this	   mouse	   model,	   we	   can	   induce	   expression	   of	   c-­fos	   by	   removing	   the	   Dox	  treatment	  (Fig.	  6).	  In	  our	  experimental	  set-­‐up,	  mice	  are	  kept	  in	  Dox	  until	  their	  6th	  or	  8th	  week	  of	  age,	  when	  they	  are	  adults,	  and	  then	  Dox	  is	  removed	  to	  induce	  c-­fos	  expression	  (Fig.	  7A).	  	  Upon	  c-­fos	  expression	  in	  K5-­‐expressing	  tissues	  using	  the	  tet-­‐OFF	  system,	  the	  same	  features	  were	   recapitulated	   as	   in	   the	   c-­‐FosEp-­tetON	  mouse	  model,	   such	   as	   hair	   loss	   and	  development	  of	  scaly	  plaques	  	  (Fig.	  7B).	  Increased	  c-­‐Fos	  protein	  levels	  were	  detected	  in	  back	   skin	   of	   mice	   by	   immunoblot	   (Fig.	   7C)	   and	   immunohistochemistry	   (Fig.	   7D).	  Histologically,	   18	   weeks	   after	   Dox	   removal,	   the	   skin	   of	   mutant	   mice	   developed	  epidermal	  hyperplasia,	  hair	  follicle	  cysts	  and	  increased	  proliferation	  (Figure	  7E	  and	  data	  not	   shown).	   These	   data	   confirmed	   the	   findings	   obtained	   using	   the	   c-­‐FosEp-­tetON	  mouse	  line.	  However,	   the	  development	  of	   the	  phenotype	  was	  delayed	  and	  the	  mice	  died	   later	  compared	  to	  the	  c-­‐FosEp-­tetON	  mouse	  line,	  probably	  due	  to	  the	  differences	  in	  the	  levels	  of	  inducible	   c-­fos	   expression	   when	   using	   the	   two	   different	   lines	   (K5-­‐tTA	   and	   K5-­‐rtTA	  mouse	  lines).	  
Figure	  6.	  	  	  	  	  	  c-­‐FosEp-­tetOFF	  mouse	  model.	  Dox	  is	  supplied	  in	  food	  pellets.	  Upon	  Dox	  treatment,	  the	  rtTA	  binds	  to	  the	  tetOP	  activating	  the	  expression	  of	  exogenous	  c-­fos	  in	  K5-­‐expressing	  tissues.	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Figure	  7.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  (A)	  Experimental	  set-­‐up	  in	  c-­‐FosEp-­tetOFF	  mice.	  (B)	  Pictures	  of	  c-­‐FosEp-­tetOFF	  mice	  after	  18	  weeks	  off	  Dox.	  (C)	  Immunoblot	  depicting	  c-­‐Fos	  total	   levels	   in	  back	  skin	  extracts	  of	  c-­‐FosEp-­tetON	  mice	  after	  18	  weeks	  off	  Dox.	  (D)	  Histological	  analyses	  of	  c-­‐Fos	  in	  back	  skin	  of	  c-­‐FosEp-­tetOFF	  mice	  after	  4	  and	  18	  weeks	  off	  Dox.	  (n=3/3,	  3/4).	  (E)	  H&E	  stainings	  of	  back	  skin	  of	  c-­‐FosEp-­tetOFF	  mice	  after	  4	  and	  18	  weeks	  off	  Dox.	  (n=3/3,	  3/4)	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1.2.1.	  The	  epidermal	  barrier	  is	  not	  affected	  upon	  c-­fos	  expression	  The	  epidermis	  is	  an	  effective	  barrier	  that	  prevents	  dehydration	  from	  loss	  of	  body	  water,	  poisoning	  from	  the	  absorption	  of	  noxious	  substances	  and	  systemic	  infection	  from	  invading	  surface	  microorganisms	  (Elias,	  2007).	  When	  the	  skin	  barrier	  is	  disrupted,	  the	  body	   is	   more	   susceptible	   to	   infections	   and	   develops	   skin	   inflammatory	   and	  hyperproliferative	  diseases	  such,	  as	  atopic	  dermatitis	  and	  psoriasis	  (Hogan	  et	  al.,	  2012;	  Sonnenberg	  et	  al.,	  2011).	  	  	   We	   therefore	   tested	   whether	   increased	   epidermal	   c-­‐Fos	   levels	   could	  interfere	  with	  the	  proper	  development	  of	  the	  epidermal	  barrier	  by	  performing	  different	  assays.	   	   First,	   I	   tested	   the	   integrity	   of	   the	   outside-­‐in	   barrier.	  We	   used	   P1	   c-­‐FosEp-­tetOFF	  pups,	  which	  were	  bred	  without	  Dox	   (expression	  of	  c-­fos	   is	   induced),	   and	  performed	  a	  toluidine	  blue	  penetration	  assay.	  We	  used	  P1	  c-­‐FosEp-­tetOFF	  pups,	   since	  at	   this	   stage	   the	  pups	  have	  no	  hair	  and	  the	  procedure	  is	  easily	  performed.	  However,	  we	  did	  not	  observe	  any	   penetration	   of	   the	   dye	   in	   the	   skin	   of	   the	   pups	   (Fig.	   8A),	   as	   it	   occurs	   when	   the	  integrity	  of	  the	  barrier	  is	  disrupted	  and	  the	  dye	  penetrates	  the	  skin.	  Interestingly,	  these	  mice	  displayed	  open	   eyes	   at	   birth	   (Fig.	   8A,	   arrows).	   The	   same	  phenotype	   is	   observed	  when	  the	  expression	  of	  other	  AP-­‐1	  members	  in	  the	  epidermis,	  such	  as	  c-­‐Jun	  and	  JunB,	  is	  perturbed	  (Zenz	  et	  al.,	  2003;	  Guinea-­‐Viniegra	  et	  al.,	  2009).	  The	   second	   most	   commonly	   used	   method	   to	   measure	   the	   integrity	   of	   the	  epidermal	  barrier	  is	  to	  test	  the	  quantity	  of	  water	  that	  evaporates	  from	  inside	  of	  the	  body	  through	   the	   epidermal	   layer	   to	   the	   outside	   of	   the	   body	   and	   this	   test	   is	   called	  Transepidermal	   Water	   Loss	   (TEWL)	   (Verdier-­‐Sevrain	   and	   Bonte,	   2007).	   When	   the	  barrier	  is	  disrupted,	  increased	  evaporation	  is	  measured.	  I	  performed	  this	  test	  using	  P1	  c-­‐FosEp-­tetOFF	   pups,	   which	   were	   bred	   without	   Dox	   and	   we	   did	   not	   observe	   significant	  differences	  between	  controls	  and	  mutants	  (Fig.	  8B).	  An	  additional	  method	  to	  assess	  the	  integrity	  of	  the	  epidermal	  barrier	  is	  to	  assess	  the	  lipid	  matrix	  deposition	  in	  the	  epidermis.	  For	  this	  purpose,	  we	  used	  the	  c-­‐FosEp-­tetON	  mouse	   model.	   	   Frozen	   back	   skin	   sections	   from	  mice	   kept	   on	   Dox	   for	   4	   weeks	   were	  stained	  with	  Nile	  Red	  dye.	  	  Nile	  Red	  is	  a	  dye	  that	  fluoresces	  yellow-­‐gold	  in	  the	  presence	  of	  neutral	  lipids	  (found	  in	  the	  stratum	  corneum)	  and	  red	  in	  the	  presence	  of	  polar	  lipids	  (found	   in	   the	   granular	   and	   spinous	   layer).	   No	   significant	   changes	   in	   the	   lipid	   content	  
	   Results	   	  	  
	   77	  
were	  observed	  between	  controls	   and	  c-­‐FosEp-­tetON	  mice	   (Fig.	  8C).	  Altogether	   these	  data	  indicate	  that	  increased	  levels	  of	  c-­‐Fos	  either	  during	  development	  or	  during	  adulthood	  do	  not	   interfere	   with	   the	   development	   or	   impair	   the	   integrity	   of	   the	   epidermal	   barrier	  function.	  
Figure	  8.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  Picture	  depicting	  5	  P1	  pups	  (3	  controls	  and	  2	  c-­‐FosEp-­tetOFF)	  after	  toluidine	  blue	  penetration	  assay.	   Arrows	   indicate	   open	   eyes	   at	   birth	   and	   tail	   clip	   as	   a	   positive	   control.	   (n=10/5).(B)	  Transepidermal	   Water	   Loss	   (TEWL)	   measurements	   in	   P1	   control	   and	   c-­‐FosEp-­tetOFF	   pups.	  (n=10/5).	   (C)	  Nile	  Red	  staining	   to	  measure	   lipid	  deposition	   in	   the	  epidermis.	  Red	  color:	  polar	  lipids.	  Yellow	  color:	  non	  polar	  lipids.	  (n=4).	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2.	   Mmp10	   AND	   s100a7a15	   ARE	   TWO	   NOVEL	   TRANSCRIPTIONAL	  
TARGET	  GENES	  OF	  c-­FOS	  
2.1.	   Genome-­wide	   expression	   analyses	   revealed	   novel	   target	   genes	   of	   c-­Fos	   in	  
keratinocytes	  	  To	   molecularly	   understand	   the	   phenotype	   developed	   upon	   inducible	   c-­fos	  expression	   in	   the	   epidermis,	   primary	   in	   vitro	   cultured	   c-­‐FostetON	   keratinocytes	   were	  employed	  for	  identification	  of	  novel	  transcriptional	  targets	  in	  keratinocytes.	  	  Genome-­‐wide	   expression	   analyses	   using	   mutant	   primary	   keratinocytes	   were	  performed	   in	   collaboration	   with	   Peter	   Angel	   (DKFZ,	   Germany)	   to	   compare	   c-­fos	  expressing	   versus	   non-­‐expressing	   keratinocytes	   (±Dox)	   for	   6,	   12,	   24,	   48	   and	   72h.	  Interestingly,	  no	  major	  changes	   in	   the	  expression	  of	  genes	   involved	   in	  proliferation	  or	  differentiation	  were	   observed.	  However,	   among	   a	   number	   of	   c-­‐Fos-­‐induced	   genes,	  we	  found	  two	  consistently	  up-­‐regulated	  genes,	  mmp10,	  a	  matrix	  metalloprotease	   involved	  in	   extracellular	   matrix	   remodeling	   and	   s100a7a15,	   a	   chemo-­‐attractant	   molecule	   for	  CD4+T	  lymphocytes	  as	  well	  as	  granulocytes	  (Fig.	  9A).	  	  
2.2.Validation	  of	  c-­Fos	  target	  genes	  in	  vitro	  The	  expression	  of	  these	  two	  novel	  potential	  target	  genes,	  identified	  by	  means	  of	  genome-­‐wide	  expression	  analyses,	  was	  validated	  at	  the	  RNA	  and	  protein	  level	  in	  vitro.	  A	  significant	   increase	   in	   the	   levels	   of	   mRNA	   (Fig.	   9B)	   and	   protein	   by	   immunoblot	   and	  ELISA,	  (Fig.	  9C,	  D)	  of	  mmp10	  and	  of	  s100a7a15	  was	  observed	  upon	  of	  c-­fos	  induction	  in	  
vitro.	  	   To	  confirm	  that	  these	  genes	  are	  putative	  c-­‐Fos	  target	  genes,	  I	  tested	  expression	  of	  both	   genes	   in	   c-­fos-­‐deficient	   keratinocytes.	   First,	   I	   stimulated	   keratinocytes	  with	   TPA	  (12-­‐O-­‐Tetradecanoylphorbol	  13-­‐acetate),	  an	  AP-­‐1	  agonist,	  to	  induce	  expression	  of	  c-­fos,	  and	  a	  significant	  increase	  in	  the	  expression	  of	  both	  mmp10	  and	  s100a7a15	  was	  detected.	  However,	   this	   increase	  was	   reduced	   in	   c-­‐Fos-­‐deficient	   keratinocytes	   (Fig.	   9E	   and	   9F).	  These	   data	   suggest	   that	   mmp10	   and	   s100a7a15	   are	   likely	   to	   be	   transcriptionally	  regulated	  by	  c-­‐Fos.	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Figure	  9.	  
	  	  	  	  	  	  	  	  	  	  	  	  (A)	  Genome-­‐wide	   expression	   analyses	   showing	   2	   consistently	   up-­‐regulated	   genes	   in	   c-­‐FostetON	  keratinocytes	  comparing	  cells	  treated	  ±Dox	  (±c-­fos	  expression)	  after	  6	  to	  72	  hours	  of	  culture.	  (B)	  RT-­‐qPCR	  analyses	   of	   c-­‐fos,	  mmp10	   and	   s100a7a15	   expression	   in	   c-­‐FostetON	   keratinocytes	   ±Dox	  after	   6	   to	   72hours	   of	   Dox	   treatment.	   (C)	   Immunoblot	   of	   S00a7a15,	   MMP10	   and	   the	   house	  keeping	   genes,	   GAPDH	   and	   Vinculin	   after	   24h	   ±Dox	   treatment	   in	   c-­‐FostetON	   keratinocytes.	   (D)	  S100a7a15	  protein	  levels	  measured	  in	  supernatants	  of	  c-­‐FostetON	  keratinocytes	  treated	  for	  12,	  24	  and	  48	  hours	  ±	  Dox.	  	  (E,F)	  In	  vitro	  mRNA	  analyses	  of	  mmp10	  (E)	  and	  s100a7a15	  (F)	  levels	  in	  c-­‐Fosfl/fl	  keratinocytes	  treated	  either	  with	  Ad-­‐Cre	  (blue	  bar)	  o	  Ad-­‐GFP	  (black	  bar).	  
	  
2.3.	  Validation	  of	  c-­Fos	  target	  genes	  in	  vivo	  We	   next	   assessed	   the	   expression	   of	  mmp10	   and	   s100a7a15	   in	   the	   back	   skin	   of	  control	   and	   c-­‐FosEp-­tetON	   mice.	   We	   detected	   increased	   mmp10	   and	   s100a7a15	   mRNA	  levels	  in	  the	  epidermis	  of	  c-­‐FosEp-­tetON	  mice	  after	  4	  weeks	  of	  c-­fos	  induction,	  as	  analyzed	  by	  RT-­‐qPCR	  (Fig.	  10A).	  Moreover,	   increased	  levels	  of	  MMP10	  protein	  were	  detected	  in	  the	  sera	  of	  c-­‐FosEp-­tetON	  mice	  measured	  by	  ELISA	  at	  2	  weeks	  of	  Dox	  treatment	  (Fig.	  10B).	  Histological	   (IHC	  and	   immunofluorescence)	   analyses	   also	   confirmed	  elevated	   levels	   of	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these	  two	  proteins	  in	  the	  back	  skin	  of	  c-­‐FosEp-­tetON	  mice	  after	  2	  and	  4	  weeks	  of	  inducible	  
c-­fos	  expression	  (Fig.	  10C,	  10D).	  These	  data	  suggest	  that	  c-­‐Fos	  could	  be	  a	  transcriptional	  regulator	  of	  mmp10	  and	  s100a7a15.	  	  
Figure	  10.	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  RT-­‐qPCR	  analyses	  of	  c-­fos,	  mmp10	  and	  s100a7a15	  expression	  of	  back	  skin	  of	  control	  and	  c-­‐FosEp-­tetON	  mice	   after	   4	  weeks	   of	  Dox	   treatment.	   (B)	  MMP10	   levels	   in	   the	   serum	  of	   c-­‐FosEp-­tetON	  mice	  after	  4	  weeks	  of	  Dox	   treatment.	   (C)	   Immunofluorescence	  analyses	  of	   S100a7a15	   in	  back	  skin	  of	  c-­‐FosEp-­tetON	  mice	  after	  4	  weeks	  of	  Dox	  treatment.	   (D)	   Immunohistochemical	  analyses	  of	  MMP10	  in	  the	  back	  skin	  of	  control	  and	  c-­‐FosEp-­tetON	  mice	  after	  2	  and	  4	  weeks	  of	  Dox	  treatment.	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2.4.	  Mmp10	  and	  s100a7a15	  promoter	  analyses	  To	   ascertain	   whether	   c-­‐Fos	   transcriptionally	   controls	   mmp10	   and	   s100a7a15	  expression,	   I	   assessed	   c-­‐Fos	   recruitment	   to	   their	   promoters	   by	   chromatin	  immunoprecipitation	   (ChIP)	   assays.	   The	   promoter	   regions	   of	   mmp10	   and	   s100a7a15	  contain	  12-­‐O-­‐tetradecanoylphorbol-­‐13-­‐acetate	  (TPA)	  response	  elements	  (TRE)	  to	  which	  AP-­‐1	  family	  of	  transcripction	  factors	  can	  bind.	  c-­‐Fos	  was	  found	  bound	  to	  both	  mmp10	  as	  well	   as	   s100a7a15	   promoters	   in	   primary	   c-­‐FosEp-­tetON	   keratinocytes,	   when	   c-­fos	  expression	   was	   induced	   by	   Dox	   treatment	   for	   24h	   (Fig.	   11A).	   Furthermore,	   ChIP	  analyses	   using	   c-­fosfl/fl	   keratinocytes	   transduced	   with	   Adenoviral-­‐Cre	   (termed	   as	   c-­‐Fos∆Kc)	  or	  Adenoviral-­‐GFP	  (termed	  as	  c-­‐Fosfl/fl)	  and	  induced	  with	  TPA	  (an	  AP-­‐1	  agonist)	  for	  3	  hours	  were	  performed.	  We	  observed	  that	  upon	  in	  vitro	  c-­fos	  deletion,	  no	  binding	  to	  
mmp10	   and	  s100a7a15	  promoters	  was	  detected	   (Fig.	  11B).	  These	  results	   indicate	   that	  
mmp10	  and	  s100a7a15	  are	  direct	  transcriptional	  targets	  of	  c-­‐Fos.	  








	  (A)	  Chromatin	  immunoprecipitation	  (ChIP)	  of	  c-­‐Fos	  at	  the	  mmp10	  (left)	  and	  s100a7a15	  (right)	  promoters.	   Endpoint	  RT-­‐qPCR-­‐fragments	   are	   shown	   together	  with	   the	   representation	  of	  %	  of	  binding	  of	  c-­‐Fos	  to	  mmp10	  and	  s100a7a15	  promoters.	  Chromatin	  was	  immunoprecipitated	  using	  c-­‐Fos	   antibody	   from	   c-­‐FostetON	   keratinocytes	   treated	   ±Dox	   for	   24h.	   (B)	   ChIP	   of	   c-­‐Fos	   at	   the	  
mmp10	   and	   s100a7a15	   promoters.	   Endpoint	   qPCR-­‐fragments	   are	   shown	   together	   with	   the	  representation	   of	   %	   of	   binding	   of	   c-­‐Fos	   to	  mmp10	   (left)	   and	   s100a7a15	   (right)	   promoters.	  Chromatin	  was	  immunoprecipitated	  using	  c-­‐Fos	  antibody	  in	  c-­‐Fosfl/fl	  and	  c-­‐Fos∆Ep	  keratinocytes	  treated	  for	  3h	  with	  TPA.	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3.	  c-­fos	  EXPRESSION	  INDUCES	  SKIN	  INFLAMMATION	  CHARACTERIZED	  
BY	  CHRONIC	  CD4	  T	  CELL	  RECRUITMENT	  S100a7a15	  has	  been	  shown	  to	  be	  involved	  in	  the	  recruitment	  of	  CD4	  T	  cells	  and	  granulocytes	  (Wolf	  et	  al.,	  2008).	  MMP10	  can	  also	  facilitate	  the	  recruitment	  of	  leukocytes	  from	   the	   bloodstream	   by	   degrading	   components	   of	   the	   extracellular	   matrix	   and	   by	  modulating	   cytokine	   and	   chemokine	   activity	   (Elkington	   et	   al.,	   2005).	   Moreover,	  inflammatory	   cells	   invade	   tumors,	   and	   these	   cells	   are	   a	   source	   of	   growth	   factors	   and	  cytokines	   that	   facilitate	   tumorigenesis	   (Coussens	   et	   al.,	   1999;	   Hanahan	   and	   Coussens,	  2012).	  We	  therefore	  examined	  the	  presence	  of	  inflammatory	  cells	  in	  the	  skin	  of	  c-­‐FosEp-­
tetON	   and	  control	  mice	  over	   time	   that	  would	  explain	   the	  preneoplastic	  phenotype	  since	  proliferation	  occurred	  in	  a	  non-­‐cell	  autonomous	  manner.	  	  Flow	  cytometry	  analyses	  of	  back	  skin	  at	  2	  weeks	  after	  inducible	  expression	  of	  c-­‐Fos	  revealed	  no	  significant	  changes	   in	  total	   leukocyte	   infiltration,	  as	  analyzed	  with	  the	  pan	   leukocyte	  marker	  CD45.	  However,	   CD4	  T	   cell,	   as	  well	   as	  Gr1	  granulocyte	  number	  were	   already	   significantly	   increased	   at	   this	   time	   point	   (Fig.	   12A).	   No	   changes	   were	  observed	  in	  the	  infiltration	  of	  macrophages,	  B	  cells	  and	  CD8	  T	  cells	  (Fig.	  12A).	  Moreover,	  at	  4	  weeks,	  when	  the	  epidermis	  is	  already	  hyperplastic,	  we	  found	  substantial	  leukocyte	  infiltration	  (assessed	  by	  CD45	  staining)	  (Fig.	  12B).	  Interestingly,	  there	  was	  a	  chronic	  and	  pronounced	  accumulation	  of	  CD4	  T	  cells	  in	  the	  skin	  of	  mutant	  mice	  at	  this	  time	  point	  but	  no	   changes	   in	   Gr1+	   cell	   number	   was	   observed	   (Fig.	   12B).	   These	   cells	   expressed	   high	  levels	  of	  CD44	  protein,	  a	  marker	  of	  CD4	  T	  cell	  activation	  (Fig.	  13A).	  These	  data	  indicate	  that	   chronic	   recruitment	   of	   CD4	   T	   cells	   could	   be	   detrimental	   for	   the	   epidermal	  homeostasis	   and	   could	   likely	   be	   the	   cause	   of	   the	   phenotype	   developed	   upon	   c-­fos	  expression	  in	  the	  epidermis.	  	  Analyses	   of	   the	   activation	   status	   of	   CD4	   T	   cells	   in	   the	   draining	   lymph	   nodes	  revealed	   increased	   CD4+CD44high	   cells	   in	   c-­‐FosEp-­tetON	  mice	   compared	   to	   control	  mice	  (Fig.	  13B).	  Therefore,	  the	  accumulation	  of	  CD4	  T	  cells	  in	  the	  skin	  of	  mutant	  mice	  is	  likely	  the	  result	  of	  the	  recruitment	  of	  activated	  CD4	  T	  cells	  from	  draining	  lymph	  nodes,	  instead	  of	  an	  expansion	  of	  resident	  CD4	  T	  cells	  in	  the	  homeostatic	  skin.	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Figure	  12.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  Flow	  cytometry	   analyses	  of	   the	   skin	   immune-­‐cell	   infiltrate	   in	  6-­‐8	  week-­‐old	   control	   and	   c-­‐FosEp-­tetON	  mice	  (n=6/9)	  after	  2	  weeks	  of	  ectopic	  c-­fos	  expression.	  (B)	  Flow	  cytometry	  analyses	  of	  the	   skin	   immune-­‐cell	   infiltrate	   in	   6-­‐8	  week-­‐old	   control	   (n=6)	   and	   c-­‐FosEp-­tetON	   (n=9)	  mice	   at	   4	  weeks	  of	  ectopic	  c-­fos	  expression.*p<0.05,	  **p<0.005,	  ***p<0.0005.	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To	  analyze	  which	   type	  of	   effector	  CD4	  T	   cells	  penetrate	   the	   skin	  of	   c-­‐FosEp-­tetON	  mice,	  CD4+CD3+	  T	  cells	  were	  FACS	  sorted	  from	  the	  skin	  after	  4	  weeks	  of	  inducible	  c-­fos	  expression.	  I	  examined	  the	  expression	  of	  INF-­‐γ,	  as	  a	  functional	  marker	  for	  Th1	  cells,	  IL-­‐4	  and	   IL-­‐5	   as	   markers	   of	   the	   Th2	   lineage,	   IL-­‐17,	   as	   a	   marker	   of	   the	   Th17	   cell	   lineage,	  FoxP3,	  as	  a	  marker	   for	  Treg	  cells,	  and	  IL-­‐22,	  as	  a	  marker	  of	   the	  Th22	  cell	   lineage	  (Fig.	  13C).	   Overall	   there	   were	   no	   significant	   changes	   in	   the	   expression	   levels	   of	   most	  cytokines.	   Interestingly,	   there	   was	   a	   marginal	   increase	   in	   the	   levels	   of	   Fox	   P3	   and	   a	  striking	   elevation	   of	   IL-­‐22	   expression	   in	   CD4	   T	   cells	   from	  mutant	   mice	   compared	   to	  controls.	  	  
Figure	  13.	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  Flow	  cytometry	  analyses	  of	  the	  immune-­‐cell	  infiltrate	  in	  the	  skin	  of	  6-­‐8	  week-­‐old	  control	  and	  c-­‐FosEp-­tetON	  (n=3)	  mice	  at	  2	  weeks	  of	  ectopic	  c-­‐fos	  expression.	  (B)	  Flow	  cytometry	  analyses	  of	  the	  immune-­‐cell	  infiltrate	  in	  the	  draining	  lymph	  nodes	  of	  6-­‐8	  week-­‐old	  control	  and	  c-­‐FosEp-­tetON	  (n=3)	  mice	   at	   2	   weeks	   of	   ectopic	   c-­‐fos	   expression.	   (C)	   RT-­‐qPCR	   Expression	   analyses	   of	   CD3+CD4+	  sorted	  T	   lymphocytes	   from	  the	  back	  skin	  of	  6-­‐8	  week-­‐old	  control	  and	  c-­‐FosEp-­tetON	  mice	  after	  4	  weeks	  of	  inducible	  c-­fos	  expression	  (n=3).	  *P<0.05	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IL-­‐22	  has	  been	  implicated	  in	  the	  control	  of	  tumor	  growth	  and	  progression	  (Liu	  et	  al.,	  2012;	  Curd	  et	  al.,	  2012)	  as	  well	  as	   in	  skin	   inflammatory	  diseases,	  such	  as	  psoriasis	  (Pan	   et	   al.,	   2012).	   IL-­‐22	   signals	   through	   activation	   of	   STAT3	   and	   gp130,	   a	   signal	  transducer	   associated	   with	   IL-­‐22	   receptor.	   Analysis	   of	   activation	   of	   STAT3	   by	   IHC	  showed	  activated	  STAT3	  (Y705P-­‐STAT3)	  in	  the	  epidermis	  of	  c-­‐FosEptetON	  mice	  compared	  to	  control	  mice	  2	  weeks	  after	  inducible	  c-­fos	  expression	  (Fig.	  14).	  Thus,	  IL-­‐22	  supplied	  by	  infiltrating	  CD4	  T	  cells	  and	  recruited	  as	  a	  consequence	  of	  increased	  levels	  of	  MMP10	  and	  S100a7a15,	  may	  contribute	  to	  keratinocyte	  survival	  and/or	  proliferation,	  eventually	  leading	  to	  epidermal	  hyperplasia	  as	  shown	  upon	  inducible	  c-­fos	  expression.	  These	  data	  suggest	   a	   novel	   mechanism	   by	   which	   c-­‐Fos-­‐induced	   infiltration	   of	   CD4	   T	   cells	   in	   the	  “primed”	   skin,	   leads	   to	   the	   release	   of	   specific	   cytokines,	   such	   as	   IL-­‐22,	   which	   by	  activation	  of	  specific	  pathways	  in	  keratinocytes	  promote	  cell	  survival	  and	  proliferation.	  	  
Figure	  14.	  	  	  	  	  	  	  	  	  	  	  p-­‐STAT3	   (Y705)	   immunostaining	   in	  back	   skin	  of	   control	   and	  c-­‐FosEp-­tetON	  mice	  after	  2	  and	  4	  of	  weeks	  ectopic	  c-­fos	  expression	  (n=4/4/4/4).	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4.	  INTERFERING	  WITH	  CD4	  T	  CELL	  RECRUITMENT	  SIGNIFICANTLY	  
IMPAIRS	  c-­FOS-­MEDIATED	  EPIDERMAL	  HYPERPLASIA	  
	   Previous	  studies	  by	  Coussens	  et	  al	  have	  shown	  that	  CD4	  T	  cells	  heavily	  infiltrate	  preneoplastic	   lesions	   and	   SCC	   in	   the	   K14-­‐HPV	   mouse	   model	   (Junankar	   et	   al.,	   2006).	  Moreover,	  genetic	  depletion	  of	  CD4	  T	  cells	  in	  the	  same	  tumor-­‐prone	  mouse	  model	  (K14-­‐HPV)	  leads	  to	  a	  delayed	  neoplastic	  progression	  and	  a	  lower	  incidence	  of	  tumors	  (Daniel	  et	   al.,	   2003).	   Since	   chronic	   recruitment	   of	   CD4	   T	   cells	   upon	   c-­fos	   expression	   was	  observed,	   we	   genetically	   depleted	   this	   population	   of	   immune	   cells	   by	   crossing	   the	   c-­‐FosEp-­tetON	  mouse	  model	   to	   the	  RAG1-­‐/-­‐	  mice	  (Mombaerts	  et	  al.,	  1992).	  RAG1	  and	  RAG2	  (recombination-­‐activating	  gene)	  are	  two	  proteins	  necessary	  for	  immunoglobulin	  and	  T-­‐cell	   receptor	   gene	   recombination.	  	   RAG1	   and	   RAG2	  work	   closely	   together	   in	   receptor	  gene	  recombination	  and	  they	  are	  both	  necessary	  for	  V(D)J	  recombination	  (Schatz	  and	  Ji,	  2011).	  Interestingly,	  upon	  RAG1	  deletion,	   in	   the	  absence	  of	  mature	  T	  and	  B	  cells,	   c-­‐FosEp-­tetON	  mice	   developed	   significantly	   smaller	   lesions	   (Fig.	   15A),	   while	   some	   mice,	   displayed	  defined	   isolated	   regions	   of	   mild	   hyperplasia.	   	   Moreover,	   we	   assessed	   the	   levels	   of	  lymphocytes	   by	   performing	   CD3	   immunostainings.	   As	   expected,	   no	   CD3+	   cells	   were	  observed	   in	   RAG1	   deficient	   mice	   (Fig.	   15B).	   Interestingly,	   in	   c-­‐FosEp-­tetON;	   Rag-­/-­	   mice,	  keratinocyte	  proliferation,	  assessed	  by	  Ki67	  immunostaining,	  and	  p-­‐STAT3,	  a	  marker	  for	  keratinocyte	   survival,	  were	   significantly	   reduced	   (Fig.	   15C,D).	   These	   data	   confirm	  our	  hypothesis	   that	   CD4+T	   cells	   are	   important	   mediators	   in	   the	   development	   of	  preneoplastic	  lesions.	  	  	  	  
	  
	  
	  	  	  
	   Results	   	  	  












	  	  	  (A,B,C,D)	   Immunohistochemical	   analyses	   depicting	   H&E,	   CD3,	   Ki67,	   and	   pSTAT3	  immunostainings,	  respectively,	  of	  back	  skin	  of	  control	  (Col-­‐Fos	  (+/+);	  K5rtTA	  (+/+);	  Rag	  (-­‐/-­‐)),	  c-­‐FosEp-­tetON	   (Col-­‐Fos	   (+/KI);	   K5rtTA	   (+/T);	   Rag	   (+/+))	   an7	   c-­‐FosEp-­tetON	   Rag-­‐/-­‐	   mice	   (Col-­‐Fos	  (+/KI);	  K5rtTA	  (+/T);	  Rag	  (-­‐/-­‐)	  mice	  on	  Dox	  for	  4	  weeks	  (n=7/4/10,	  males).	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5.	   BROAD	   MMP	   INHIBITION	   PREVENTS	   THE	   DEVELOPMENT	   OF	  
PRENEOPLASTIC	   LESIONS	   UPON	   C-­FOS	   EXPRESSION	   IN	   c-­FOSEp-­tetON	  
MICE	  	  	   After	   confirming	   direct	   binding	   of	   c-­‐Fos	   to	   the	   mmp10	   promoter	   and	  corroborating	   that	   mmp10	   is	   a	   direct	   transcriptional	   target	   of	   c-­‐Fos,	   a	   broad	   MMP	  inhibitor	  (TAPI-­‐1)	  was	  used	  in	  vivo	  to	  block	  MMP10	  activity.	  The	  inhibitor	  was	  used	  as	  a	  preventive	  treatment	  and	  it	  was	  administered	  intraperitonally	  (IP)	  three	  times	  a	  week	  in	  parallel	  to	  the	  Dox	  treatment	  (Fig.	  16).	  As	  assessed	  by	  H&E	  immunostainings,	  c-­‐FosEp-­
tetON	  treated	  with	  the	  MMP	  inhibitor	  showed	  significant	  prevention	  in	  the	  development	  of	  the	   preneoplastic	   lesions	   (Fig.17).	   However,	   even	   though	   TAPI-­‐1-­‐treated	   c-­‐FosEp-­tetON	  mice	   did	   not	   show	   a	   dramatic	   hyperplasia,	   they	   presented	   other	   features	   commonly	  developed	   by	   c-­‐FosEp-­tetON	  mice,	   such	   as	   hair	   follicle	   cysts	   (Fig.	   17).	  While	   c-­‐FosEp-­tetON	  mice	  still	  expressed	  high	  MMP10	  protein	  levels	  upon	  TAPI-­‐1	  treatment,	  they	  showed	  no	  recruitment	  of	  T	  lymphocytes.	  Keratinocyte	  proliferation	  and	  survival,	  assessed	  by	  ki67	  and	  p-­‐STAT3	   immunostaining	   respectively,	  were	   reduced	  compared	   to	  vehicle-­‐treated	  mice.	   Nevertheless,	   MMP10	   activity	   assays	   of	   epidermal	   protein	   lysates	   should	   be	  performed	   to	   assess	   the	   efficiency	   of	   this	   drug	   to	   reach	   the	   epidermis.	   These	   results	  indicate	   that	   inhibition	   of	   MMP	   signaling	   ameliorates	   the	   pathological	   features	  developed	   by	   the	   c-­‐FosEp-­tetON	  mice.	   However,	   not	   only	   a	   specific	   inhibitor	   should	   be	  developed	   but	   also	   further	   analyses	   should	   be	   performed	   to	   supply	   the	   drug	  subcutaneously	  and	  avoid	  systemic	  secondary	  effects.	  	  
Figure	  16.	  	  	  	  
	  
	  
	  Experimental	  set-­‐up.	  	  Control	  and	  c-­‐FosEp-­tetON	  mice	  were	  treated	  with	  Dox	  and	  with	  vehicle	  or	  10mg/kg	  of	  TAPI-­‐1	  injected	  IP	  three	  times	  a	  week	  for	  4	  weeks.	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6.	  c-­FOS-­DEPENDENT	  SKIN	  PHENOTYPE	  IS	  LARGELY	  REVERSIBLE	  To	   determine	   whether	   sustained	   expression	   of	   c-­fos	   is	   required	   to	   maintain	  epidermal	  hyperplasia	  upon	  inducible	  c-­fos	  expression,	  I	  made	  use	  of	  the	  switchable	  c-­‐FosEp-­tetON	  mouse	  model	  by	  removing	  Dox	  treatment.	  c-­fos	  expression	  was	  induced	  for	  4	  weeks	  until	  the	  mice	  developed	  visible	  lesions	  at	  which	  point	  inducible	  c-­fos	  expression	  was	   stopped	   for	   either	   4	   or	   16	   weeks	   (Fig.	   18A).	   4	   weeks	   after	   switching	   off	   c-­fos	  expression,	   c-­‐FosEp-­tetON	  mice	   almost	   fully	   recovered	  macroscopically,	   although	  30%	  of	  the	  c-­‐FosEp-­tetON	  mice	   still	   contained	  areas	  where	  hair	  was	  absent	   (Fig.	  18B).	  16	  weeks	  after	   stopping	   inducible	   c-­fos	   expression,	   all	   mice	   had	   completely	   reverted	   the	  phenotype	  (Fig.	  18C).	  Histologically,	   about	  50%	  of	   the	  mice	  still	   showed	  areas	  of	  mild	  dysplasia	  as	  well	  as	  hair	  follicle	  cysts	  at	  4	  weeks,	  but	  not	  at	  16	  weeks	  (Fig.	  18C,	  arrow).	  	  	   IHC	   analyses	   were	   performed	   to	   analyze	   protein	   levels	   of	   c-­‐Fos	   (not	  shown),	   Ki67	   and	  MMP10	   protein,	   which	   levels	   were	   still	   observed	   in	   the	   remaining	  dysplastic	   areas	   and	   in	   the	   cysts	   at	   4	   weeks	   after	   having	   stopped	   inducible	   c-­fos	  expression,	  probably	  due	  to	  a	  slow	  turnover	  of	  the	  epidermis	  (Fig	  19A,B).	  However,	  no	  expression	   of	   these	   markers	   was	   observed	   at	   16	   weeks	   (Fig.	   19A,B).	   These	   results	  suggest	  an	  addictive	  effect	  of	  the	  epidermis	  to	  constant	  c-­‐Fos	  signaling.	  Expression	   analyses	   of	   total	   skin	   revealed	   that	   c-­fos	   and	   mmp10,	   but	   not	  
s100a7a15	  levels,	  remained	  high	  4	  weeks	  after	  stopping	  inducible	  c-­fos	  expression	  (Fig.	  19C)	   correlating	   with	   visible	   signs	   of	   epidermal	   architectural	   disruption.	   	   A	   slight	  increase,	  but	  not	  significant,	  in	  total	  leukocyte	  as	  well	  as	  CD4	  T	  lymphocyte	  infiltration	  analyzed	   by	   flow	   cytometry	  was	   observed	   also	   4	  weeks	   after	   stopping	   inducible	   c-­fos	  expression,	  but	  not	  after	  16	  weeks	  (Fig.	  19D).	  These	  results	  indicate	  a	  clear	  dependence	  of	   c-­fos	   expression,	   with	   CD4	   T	   cell	   infiltration	   and	   the	   epidermal	   hyperproliferative	  status.	  Upon	  16	  weeks	  of	   inducible	  c-­‐Fos	  removal,	  CD4	  T	  cells	  are	  no	   longer	  recruited	  and	   as	   a	   consequence,	   keratinocyte	   proliferation	   is	   halted,	   as	   seen	   by	   Ki67	   and	  phosphorylation	  of	  STAT3	  (Fig.	  19A	  and	  data	  not	  shown).	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Figure	  18.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  Experimental	  set-­‐up.	  Control	  and	  c-­‐FosEp-­tetON	  mice	  are	  kept	  on	  Dox	  for	  4	  weeks	  and	  then	  the	  Dox	  treatment	  is	  removed	  for	  4	  or	  16	  weeks.	  (B)	  Picture	  of	  control	  and	  c-­‐FosEp-­TetON	  female	  mice	  after	  4	  weeks	  of	  Dox	  and	  4	  or	  16	  weeks	  off	  Dox	  administration.	  (C)	  H&E	  staining	  of	  normal	  skin	  from	  control	  and	  c-­‐FosEp-­TetON	   female	  on	  Dox	  for	  4	  weeks	  and	  Off	  Dox	  for	  4	  or	  16	  weeks	  of	  Dox	  administration.	  (n	  “4	  weeks”=4/3,	  n	  “16	  weeks”=	  3/3).	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Figure	  19.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  Immunohistochemical	  analyses	  depicting	  Ki67	  immunostainings	  of	  back	  skin	  of	  control	  and	  c-­‐FosEp-­tetON	  mice	  treated	  on	  Dox	  for	  4	  weeks	  and	  kept	  without	  Dox	  for	  4	  or	  16	  weeks.	  (n=4/4).	  (B)	   Immunohistochemical	  analyses	  depicting	  MMP10	   immunostainings	  of	  back	  skin	  of	   control	  and	   c-­‐FosEp-­tetON	   mice	   treated	   on	   Dox	   for	   4	   weeks	   and	   kept	   without	   Dox	   for	   4	   or	   16	   weeks.	  (n=4/4).	  (C)	  RT-­‐qPCR	  expression	  c-­fos,	  mmp10	  and	  s100a7a15	  of	  back	  skin	  of	  c-­‐FosEp-­tetON	  mice	  treated	  on	  Dox	  for	  4	  weeks	  and	  left	  without	  Dox	  for	  4	  or	  16	  weeks.	  (n=4/4).	  (D)	  Flow	  Cytometry	  analyses	  of	  the	  skin	  immune	  infiltrate	  of	  control	  c-­‐FosEp-­tetON	  mice	  treated	  on	  Dox	  for	  4	  weeks	  and	  left	  without	  Dox	  for	  4	  or	  16	  weeks.	  (n=4/4).	  *p<0.05,	  **p<0.005.	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7.	   DMBA-­INDUCED	   PAPILLOMA	   AND	   SCC	   DEVELOPMENT	   IS	  
ACCELERATED	  BY	  c-­FOS	  
7.1.	  c-­FosEp-­tetON	  mice	  develop	  invasive	  SCCs	  upon	  DMBA	  	  To	  investigate	  the	  contribution	  of	  c-­‐Fos	  to	  papilloma	  and	  tumor	  development,	  we	  applied	  an	  adapted	  version	  of	  the	  two-­‐step	  skin	  carcinogenesis	  protocol	  (DMBA/TPA)	  to	  the	   c-­‐FosEp-­tetON	  mice	   (Kemp,	   2005).	  H-­‐Ras	  mutations	  were	   induced	  with	  DMBA	   in	   the	  back	   skin	   of	   adult	  mice	   and	   instead	  of	  TPA,	   c-­fos	   expression	  was	   switched	  on	  1	  week	  later	   using	   a	   low	   dose	   of	   Dox	   (0.25g/l)	   (to	   slower	   the	   development	   of	   the	   skin	  phenotype	   and	   prevent	   lethality)	   (Fig.	   20A).	   After	   8	   weeks	   of	   Dox	   treatment,	   mice	  developed	  papillomas	  (Fig.	  20C)	  and	  at	  11	  weeks	  these	  lesions	  were	  identified	  as	  SCCs,	  whereas	  control	  mice	  did	  not	  develop	  any	   lesion	  (Fig.	  20B,	  C,	  D).	  The	  tumor	  promoter	  TPA	  was	  included	  in	  a	  small	  number	  of	  animals	  that	  were	  also	  treated	  with	  DMBA	  and	  were	   given	  Dox	   treatment,	   as	   a	  positive	   control.	   In	   contrast,	   control	  mice	   after	  DMBA	  and	  11	  weeks	  of	  TPA	  developed	  benign	  papillomas	  (Fig.	  20F).	  	  	  Histologically	   SCCs	   invaded	   the	   adjacent	   dermal	   and	   fat	   layers	   and	   presented	  features	   of	   SCCs,	   such	   as	   aberrant	   mitosis,	   cell	   and	   nuclear	   atypia,	   prominent	  intercellular	  bridges	  and	  keratin	  pearls	  (Fig.	  21A).	  IHC	  analyses	  revealed	  that	  expression	  of	  c-­‐Fos	  was	  present	  in	  the	  tumor	  (Fig.	  21B).	  Furthermore,	  the	  tumors	  expressed	  levels	  of	   high	   keratin	   6,	   a	   keratin	   expressed	   by	   proliferating	   keratinocytes	   (Fig.	   21C).	   	   In	  addition,	   these	   SCCs	   also	   expressed	   important	   markers	   associated	   with	   cancer	   cell	  migration	   and	   invasiveness,	   such	   as	   podoplanin,	   a	   direct	   c-­‐Fos	   target	   gene	  (Durchdewald	  et	  al.,	  2008),	  which	  was	  upregulated	  in	  the	  invading	  front	  of	  the	  c-­‐FosEp-­
tetON	  SCC	  (Fig.	  21D).	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Figure	  20.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  Experimental	  set-­‐up.	  0.5%	  DMBA	  diluted	  in	  acetone	  is	  applied	  in	  the	  back	  skin	  of	  c-­‐FosEp-­tetON	  mice	   at	   5-­‐7	  weeks	   of	   age.	   One	  week	   after,	   Dox	   treatment	   starts	   either	   in	   the	   drinking	  water	  (2.5g/l)	  or	   in	   the	   food	  pellets	   for	  11	  weeks.	  TPA	   is	  applied	  at	   the	  same	  time	  as	  Dox	   in	  certain	  mice.	   (B)	   Picture	   of	   control	   and	   c-­‐FosEp-­TetON	   female	   mice	   after	   DMBA	   and	   11	   weeks	   of	   Dox	  administration.	   (C)	  Representation	  of	   the	  number	  of	   lesions	  per	  mouse	   in	  control	  and	  c-­‐FosEp-­
tetON	  mice	  after	  DMBA	  and	  8	  weeks	  of	  Dox	  administration.	  Mean	  ±SD	  of	  all	  the	  lesions	  developed	  in	   males	   (n=3)	   and	   females	   (n=3).	   nd=	   not	   detected.	   No	   lesions	   found	   in	   control	   mice.	   (D)	  Representation	   of	   the	   lesion	   size	   in	   c-­‐FosEp-­tetON	   female	   (n=3/3)	   and	  male	   (n=3/3)	   mice	   after	  DMBA	  and	  11	  weeks	  of	  Dox.	  Mean	  ±SEM.	  (E)	  H&E	  staining	  of	  normal	  skin	  from	  control	  mouse	  and	   SCC	   in	   c-­‐FosEp-­tetON	   female	   mouse	   after	   DMBA	   application	   and	   11	   weeks	   of	   Dox	  administration	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Figure	  21.	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  H&E	   staining	   in	   papilloma	   from	   control	  mouse	   and	   SCC	   in	   c-­‐FosEp-­tetON	  mouse	   after	  DMBA	  application	   and	   11	  weeks	   of	  Dox	   and	  TPA	   administration.	   (n=3/3).	   (B)	   Immunohistochemical	  analyses	  of	  c-­‐Fos	  in	  the	  back	  skin	  from	  control	  mouse	  and	  SCC	  in	  c-­‐FosEp-­tetON	  mouse	  after	  DMBA	  application	  and	  11	  weeks	  of	  Dox.	  (n=3/3).	  (C)	  Immunohistochemical	  analyses	  of	  keratin	  6	  in	  the	  back	   skin	   from	   control	   mouse	   and	   SCC	   in	   c-­‐FosEp-­tetON	  mouse	   after	   DMBA	   application	   and	   11	  weeks	  of	  Dox.	  (n=3/3).	  (D)	  Immunohistochemical	  analyses	  of	  Podoplanin	  in	  the	  back	  skin	  from	  control	   mouse	   and	   SCC	   in	   c-­‐FosEp-­tetON	   mouse	   after	   DMBA	   application	   and	   11	   weeks	   of	   Dox.	  Arrows	  indicate	  invading	  front	  of	  the	  tumor.	  (n=3/3).	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Expression	   analyses	   of	   the	   whole	   tumor	   revealed	   increased	   mRNA	   levels	   of	  
mmp10	  as	  well	  as	  s100a7a15	  compared	  to	  control	  skin	  (Fig.22A).	  Furthermore,	  MMP10	  protein	  levels	  were	  increased	  in	  the	  sera	  and	  in	  the	  SCCs	  of	  c-­‐FosEp-­tetON	  mice,	  as	  assessed	  by	   ELISA	   and	   by	   immunostaining	   respectively	   (Fig.	   22B,	   22C).	   	   Moreover,	  immunofluorescence	  stainings	  revealed	  increased	  levels	  of	  S100a7a15	  in	  the	  epidermis	  of	  c-­‐FosEp-­tetON	  mice	  4	  weeks	  after	  inducible	  expression	  of	  c-­fos.	  
Figure	  22.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  RT-­‐qPCR	  analyses	  of	  c-­fos,	  mmp10	  and	  s100a7a15	  expression	  of	  back	  skin	  of	  control	  and	  SCC	  of	  c-­‐FosEp-­tetON	  mice.	  (n=4).	  (B)	  MMP10	  levels	  in	  the	  serum	  of	  control	  and	  c-­‐FosEp-­tetON	  mice	  bearing	  an	  SCC.	  (n=3).(C)	  Immunohistochemical	  analyses	  of	  MMP10	  of	  the	  back	  skin	  of	  control	  and	  SCC	  of	  c-­‐FosEp-­tetON	  mice.	  (n=3).	  **p<0.005.	  ***p<0.005.	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7.2.	  c-­FosEp-­tetOFF	  mice	  develop	  highly	  invasive	  SCCs	  upon	  DMBA	  To	   confirm	   our	   finding	   suggesting	   that	   c-­‐Fos	   acts	   as	   a	   tumor	   promoter	   in	   the	  development	  of	  SCCs,	  we	  carried	  out	  the	  same	  adapted	  version	  of	  the	  DMBA/TPA	  skin	  carcinogenesis	  protocol	  to	  the	  c-­‐FosEp-­tetOFF	  mouse	  line	  (Fig.	  23).	  	  Control	   and	   c-­‐FosEp-­tetOFF	  mice	   were	   subjected	   to	   a	   single	   dose	   of	   0.5%	   DMBA	  topically	  applied	  to	  the	  back	  skin	  of	  these	  mice	  (at	  5-­‐6	  weeks	  of	  age)	  and	  one	  week	  later	  Dox	  was	  removed	  to	  induce	  c-­fos	  expression	  for	  18	  weeks.	  c-­‐FosEp-­tetOFF	  mice	  developed	  invasive	  SCCs.	  These	  results	  confirm	  the	  results	  obtained	  by	  using	  the	  c-­‐FosEp-­tetON	  mouse	  line.	   However,	   the	   development	   of	   the	   SCCs	   occurred	   with	   a	   7-­‐week	   difference	  compared	  to	  the	  c-­‐FosEp-­tetON	  mouse	  line,	  possibly	  due	  to	  differences	  in	  the	  K5	  transgenic	  mouse	  line	  or	  c-­fos	  induction	  levels.	  
Figure	  23.	  	  	  	  	  Experimental	   set-­‐up.	   Adapted	   skin	   carcinogenesis	   protocol.	   0.5%	  DMBA	   diluted	   in	   acetone	   is	  applied	  in	  the	  back	  skin	  of	  c-­‐FosEp-­tetOFF	  mice	  at	  5-­‐7	  weeks	  of	  age.	  One	  week	  after,	  Dox	  treatment	  is	  removed	  from	  the	  food.	  Mice	  are	  killed	  and	  analyzed	  18	  weeks	  later.	  (n=11/13).	  	  	  Histological	  analyses	  of	  back	  skin	  and	  SCCs	  revealed	  highly	  invasive	  SCCs,	  as	  seen	  by	  H&E.	  These	  SCCs	  expressed	  c-­‐Fos	  protein	  as	  well	  as	  markers	  expressed	  by	  invasive	  and	   proliferative	   keratinocytes	   such	   as	   podoplanin	   and	   K6.	   Moreover,	   islets	   of	   K5-­‐expressing	   keratinocytes	   were	   observed	   invading	   the	   neighboring	   dermis	   (Fig.	   24).	  These	  data	   indicate	   that	   sustained	   increased	   levels	   of	   c-­‐Fos	   in	   the	   epidermis	  promote	  epidermal	  carcinogenesis	  after	  DMBA	  treatment.	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Figure	  24.	  	  	  	  	  	  	  
Immunohistochemical	  analyses	  (H&E,	  Keratin	  5	  (K5),	  c-­‐Fos,	  Flag)	  of	  back	  skin	  of	  control	  and	  SCC	  c-­‐FosEp-­tetOFF	  mice	  treated	  with	  0.5%	  DMBA	  and	  18	  weeks	  off.	  (n=3/3).	  	  
7.3.	  Impaired	  mmp10	  and	  s100a7a15	  expression	  in	  c-­fos	  deficient	  K5-­SOS+	  tumor-­
prone	  mice	  Previous	   work	   from	   our	   group	   revealed	   an	   important	   role	   of	   c-­‐Fos	   in	   the	  development	  of	  skin	  tumors	  (Guinea-­‐Viniegra	  et	  al.,	  2012).	  In	  these	  experiments,	  the	  K5-­‐SOS+	  papilloma-­‐prone	  mouse	  model,	  which	  develop	  big	  papillomas	  in	  the	  tail	  skin	  due	  to	  a	   hyperactivation	   of	   the	   Ras	   signaling	   pathway,	   was	   used	   (Sibilia	   et	   al.,	   2000).	   In	  epidermis-­‐specific	  c-­fos-­‐deficient	  K5-­‐SOS+	  mice	  (K5-­‐SOS+;	  c-­‐Fos∆Ep),	  tumor	  development	  is	   suppressed	   due	   to	   a	   hyperactivation	   of	   the	   p53/TACE-­‐dependent	   Notch	   signaling	  pathway	   that	   promotes	   irreversible	   keratinocyte	   differentiation	   leading	   to	   tumor	  suppression.	  We	   employed	   this	  mouse	  model	   (K5-­‐SOS+;	   c-­‐Fos∆Ep)	   to	   assess	   the	   levels	   of	   the	  two	  novel	  targets	  (MMP10	  and	  S100a7a15).	  Expression	  of	  mmp10	  and	  s100a7a15	  was	  decreased	  in	  K5-­‐SOS+;	  c-­‐Fos∆Ep	  mice	  compared	  to	  K5-­‐SOS+;c-­‐Fosfl/fl	  papillomas	  (Fig,	  25A).	  As	  a	  control,	  we	  employed	  another	  mouse	  model,	  the	  K5-­‐SOS+;	  c-­‐Jun∆Ep.	  These	  mice	  also	  develop	   smaller	   papillomas	   in	   the	   absence	   of	   c-­‐Jun,	   another	   well-­‐known	   AP-­‐1	   family	  member	   (Zenz	   et	   al.,	   2003).	   Therefore,	   we	   decided	   to	   assess	   whether	   the	   levels	   of	  expression	  of	  mmp10	  and	  s100a7a15	  are	  altered	   in	  the	  absence	  of	  c-­‐Jun.	  However,	   the	  levels	   of	   these	   two	   targets	   remained	   intact,	   suggesting	   that	   c-­‐Jun	   does	   not	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transcriptionally	  control	  the	  expression	  of	  these	  two	  novel	  target	  genes	  (Fig,	  25B).	  
Figure	  25.	  	  	  	  	  	  	  	  
(A)	   RT-­‐qPCR	   analyses	   of	  mmp10	   and	   s100a7a15	   expression	   in	   tumor-­‐prone	  K5-­‐SOS+;	   c-­‐Fosfl/fl	  mice	  and	  in	  K5-­‐SOS+;	  c-­‐Fos∆Ep	  mice	  at	  4	  weeks	  of	  age.	  (n=3/3).	  (B)	  RT-­‐qPCR	  analyses	  of	  mmp10	  and	  s100a7a15	  expression	  in	  tumor-­‐prone	  K5-­‐SOS+;	  c-­‐Junfl/fl	  mice	  and	  in	  K5-­‐SOS+;	  c-­‐Jun∆Ep	  mice	  at	  4	  weeks	  of	  age.	  (n=3/3).	  	  
7.4.	  Sulindac	  treatment	  reduces	  SCC	  size	  and	  number	  	  To	  test	  the	  hypothesis	  that	  c-­‐Fos	  indirectly	  promotes	  epidermal	  proliferation	  and	  subsequently	  SCC	  development	  due	  to	  the	  recruitment	  of	  inflammatory	  cells,	  specifically	  CD4	   T	   cells,	   we	   aimed	   to	   inhibit	   inflammation	   by	   using	   Sulindac.	   This	   Non-­‐Steroidal-­‐Anti-­‐Inflammatory-­‐Drug	   (NSAID)	   specifically	  blocks	  COX1/2	  activity	   and	   consequently	  impairs	  prostaglandin	  synthesis	  and	  inflammatory	  processes.	  Sulindac	  has	  been	  widely	  used	   to	   treat	   patients	   with	   inflammatory	   diseases,	   such	   as	   rheumatoid	   arthritis	   and	  ankylosing	  spondylitis	  as	  well	  as	  it	  is	  being	  used	  in	  phase	  II	  clinical	  trials	  for	  lung	  cancer	  chemoprevention	  (Limburg	  et	  al.,	  2012).	  We	   performed	   our	   adapted	   version	   of	   the	   2-­‐step	   carcinogenesis	   protocol	  comparing	  sulindac-­‐treated	  vs	  sulindac-­‐untreated	  c-­‐FosEp-­tetON	  DMBA-­‐treated	  mice	  (Fig.	  26A.).	  After	  one	  dose	  of	  topical	  DMBA	  and	  7	  weeks	  of	  inducible	  c-­fos	  expression,	  mutant	  mice	  developed	  skin	   tumors	   (Fig.	  26B).	   Interestingly,	  Sulindac-­‐treated	  mice	  developed	  fewer	  tumors	  and	  the	  ones	  developed	  were	  significantly	  smaller	  (Fig.	  26C	  and	  26D).	  We	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therefore	  conclude	  that	  c-­‐Fos	  is	  sufficient	  to	  promote	  SCC	  development	  by	  promoting	  a	  microenvironment	   infiltrated	   by	   inflammatory	   cells	   and	   that	   prevention	   of	  inflammatory	  responses	  diminishes	  SCC	  incidence	  in	  c-­‐FosEp-­tetON	  mice.	  	  
Figure	  26.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (A)	  Experimental	  set-­‐up.	  0.5%	  DMBA	  diluted	  in	  acetone	  is	  applied	  in	  the	  back	  skin	  of	  c-­‐FosEp-­tetON	  mice	   at	   6-­‐8	   weeks	   of	   age.	   One	   week	   after,	   Dox	   treatment	   starts	   in	   the	   food	   and	   sulindac	   is	  supplied	  in	  the	  drinking	  water	  at	  a	  concentration	  of	  180mg/L.	  7	  weeks	  after	  mice	  are	  sacrificed	  and	  analyzed.	  (n=16/8/19/14).	  (B)	  Picture	  of	  c-­‐FosEp-­tetON	  mice	  after	  DMBA	  and	  7	  weeks	  of	  Dox	  ±sulindac.	   	   (C)	  Representation	   of	   the	   number	   of	   lesions	   per	  mouse	   in	   control	   and	   c-­‐FosEp-­tetON	  mice	   after	   DMBA	   and	   7	   weeks	   of	   Dox	   administration.	   Mean	   ±SD.	   (n=16/8/19/14).	   (D)	  Representation	  of	  the	  number	  of	  lesions	  per	  mouse	  in	  control	  and	  c-­‐FosEp-­tetON	  mice	  after	  DMBA	  and	  7	  weeks	  of	  Dox	  administration.	  Mean	  ±SD.	  (n=16/8/19/14).	  *p<0.05,	  **p<0.005.	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8.	  HUMAN	  SCCS	  EXPRESS	  HIGH	  C-­FOS	  PROTEIN	  LEVELS	  CORRELATING	  
WITH	  HIGH	  MMP10	  BUT	  NOT	  WITH	  S100A7	  EXPRESSION	  LEVELS	  
	   In	  order	  to	  address	  whether	  the	  findings	  observed	  in	  the	  c-­‐FosEp-­tetON	  and	  c-­‐FosEp-­
tetOFF	  mouse	   models	   were	   applicable	   to	   human,	   we	   tested	   mRNA	   expression	   levels	   of	  MMP-­‐10	  and	  S100A7	  by	  RT-­‐qPCR	  using	  human	  epidermal	  primary	  keratinocytes	  (HEKs)	  that	   overexpressed	   c-­‐FOS.	   These	  HEKs	   had	   been	   previously	   infected	  with	   lentiviruses	  containing	  either	  empty	  vector	  or	  c-­FOS	  over-­‐expressing	  vector	  under	  the	  control	  of	  the	  ubiquitous	   CMV	   promoter.	   Upon	   c-­FOS	   expression,	   we	   observed	   an	   upregulation	   of	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  (A)	   RT-­‐qPCR	   analyses	   of	   c-­FOS	   and	   MMP10	   Human	   Epidermal	   keratinocytes	   infected	   with	  lentiviruses	  containing	  empty	  vector	  or	  with	  a	  vector	  to	  overexpress	  c-­‐FOS	  (c-­‐FOS	  O/V).	  (B)	  RT-­‐qPCR	   analyses	   of	   MMP10	   and	   S100A7	   Squamous	   Cell	   Carcinoma	   Cell	   lines	   treated	   with	   c-­‐FOS/AP-­‐1	  inhibitor	  or	  with	  vehicle	  (DMSO).	  
	  
8.1.	  SCCs	  but	  not	  BCCs	  express	  c-­Fos	  and	  this	  correlates	  with	  MMP10	  expression	  
	   To	  determine	  the	  relevance	  of	  our	  findings	  to	  human	  Non-­‐Melanoma	  Skin	  Cancer	  (NMSC),	  in	  collaboration	  with	  Peter	  Petzelbauer	  (Medical	  University	  of	  Vienna,	  Austria),	  we	   examined	   c-­‐FOS,	   MMP10	   and	   S100A7	   expression	   in	   human	   epidermal	   tumors.	  Sections	   from	   85	   basal	   cell	   carcinomas	   (BCC)	   and	   96	   SCCs	   patients,	   as	   well	   as	   20	  perilesional	  skin	  samples,	  were	  analyzed	  by	  IHC	  (Figure	  24A).	  	  	  	   In	   BCCs,	   none	   of	   the	   samples	   expressed	   c-­‐FOS	   protein,	   correlating	   with	   no	  MMP10	   expression	   (Fig.	   28A).	   In	   contrast,	   75%	  of	   SCC	   samples	   expressed	   high	   c-­‐FOS	  protein	   levels,	   perfectly	   correlating	  with	  MMP10	  expression.	  25%	  percent	  of	   the	  SCCs	  that	   expressed	   low	   c-­‐FOS	   levels	   correlated	  with	   low	   or	   inexistent	  MMP10	   levels	   (Fig.	  28B).	  However,	  we	  found	  no	  correlation	  between	  c-­‐FOS	  and	  S100A7	  protein	  levels	  in	  the	  same	   set	   of	   samples.	   R.	  Wolf	   et	   al	   previously	   described	   that	   in	   human	   there	   are	   two	  genes	   and	   consequently	   two	   proteins	   (S100A7	   and	   S100A15)	   compared	   to	   mouse,	  which	  only	  has	  one	  s100a715	  gene	  (Wolf	  et	  al.,	  2011).	  S100A7	  and	  S100A15	  are	  highly	  homologous,	   but	   distinct	   in	   regulation	   and	   function,	   and	   are	   exclusively	   expressed.	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S100A7	   mainly	   expressed	   in	   differentiated	   cells	   within	   the	   epidermis	   and	   S100A15	  expressed	   in	   basal	   keratinocytes.	   We	   are	   currently	   performing	   immunostainings	   for	  S100A15	  to	  evaluate	  whether	  c-­‐Fos	  correlates	  with	  S100A15	  expression.	  These	  findings	  suggest	   MMP10	   is	   likely	   a	   direct	   transcriptional	   target	   of	   c-­‐FOS	   in	   human	   and	   both	  proteins	   could	   be	   useful	   targets	   to	   treat	   SCCs	   of	   the	   skin	   by	   means	   of	   inhibitory	  molecules	  as	  a	  preventive	  approach.	   	  
Figure	  28.	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  Immunohistochemical	  analyses	  of	  c-­‐FOS,	  MMP10	  and	  S100A7	  in	  human	  perilesional	  skin,	  BCC,	  SCC	  (low	  and	  high	  levels	  of	  c-­‐Fos).	  (”perilesional	  skin”	  n=10,	  BCC=216,	  SCC=96).	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Figure	  29.	  	  
	  	  	  
	  
	  Graph	  depicting	  the	  correlation	  between	  c-­‐FOS	  and	  MMP10	  staining	  in	  human	  SCCs.	  (n=42).	  
	  
8.2.	  c-­FOS	  protein-­expressing	  SCCs	  present	  CD4	  T	  lymphocyte	  infiltrates	  	  We	   have	   shown	   that	   c-­‐Fos	   transcriptionally	   controls	   S100a7a15	   and	   MMP10	  expression	  in	  mice	  and	  we	  have	  also	  observed	  a	  strong	  correlation	  between	  c-­‐FOS	  and	  MMP10	   expression	   in	   human	   SCCs.	   Moreover,	   S100a7a15	   has	   been	   shown	   to	   be	  involved	   in	   the	   recruitment	   of	   CD4	   T	   cells	   and	   granulocytes	   (Wolf	   et	   al.,	   2008)	   and	  MMP10	   can	   also	   facilitate	   the	   recruitment	   of	   leukocytes	   from	   the	   bloodstream	   by	  degrading	   components	   of	   the	   extracellular	   matrix	   and	   by	   modulating	   cytokine	   and	  chemokine	  activity	  (Elkington	  et	  al.,	  2005).	  Therefore,	  we	  evaluated	  the	  levels	  of	  CD4	  T	  cell	  infiltrates	  by	  performing	  immunostainings	  of	  CD4	  T	  cells	  in	  human	  SCCs	  and	  BCCs.	  The	   levels	  of	  CD4	  T	  cell	   infiltrates	  were	  assessed	  by	   immunostaining	  on	  human	  samples.	   Interestingly,	   73%	   of	   those	   c-­‐FOS-­‐expressing	   SCCs	   showed	   CD4	   T	   cell	  infiltrates	  (Fig.	  30).	  Moreover,	  since	  CD4	  is	  also	  a	  marker	  for	  dendritic	  cells	  in	  the	  skin,	  we	  also	  tested	  the	   levels	  of	  CD3	  in	  the	  same	  samples	  and	  observed	  similar	  patterns	  of	  expression	  as	  CD4	  (data	  not	  shown),	  suggesting	  these	  CD4	  positive	  cells	  are	  likely	  to	  be	  mainly	   CD4	   T	   Lymphocytes	   and	   not	   dendritic	   cells.	   However,	  we	   plan	   to	   perform	   co-­‐stainings	  of	  both,	  CD3	  and	  CD4	  markers.	  These	  data	  show	  a	  strong	  correlation	  between	  c-­‐FOS	  expression	  in	  human	  SCCs	  with	  the	  levels	  of	  CD4	  T	  cell	  infiltrates.	   	  Therefore	  we	  propose	  that	  targeting	  chronic	  CD4	  T	  cell	   infiltrates	  could	  be	  of	  therapeutic	   interest	  to	  treating	  SCCs	  by	  using	  anti-­‐inflammatory	  compounds.	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1.	  c-­FOS	  IN	  EPIDERMAL	  HOMEOSTASIS	  	  Many	  of	  the	  insights	  regarding	  specific	  functions	  of	  c-­‐Fos	  protein	  in	  development	  and	   disease	   have	   been	   obtained	   from	   genetically	   modified	   mice	   and	   cells	   derived	  thereof.	  c-­‐Fos	   is	  dispensable	  for	  skin	  homeostasis,	  since	  global	  or	  keratinocyte-­‐specific	  deletion	  of	  c-­fos	  does	  not	  reveal	  a	  skin	  phenotype	  (Wang	  et	  al.,	  1992;	  Guinea-­‐Viniegra	  et	  al.,	   2012).	   	   However,	   under	   stress	   conditions,	   such	   as	   UV-­‐light,	   Ras/SOS	   activating	  mutations,	  TPA	  or	  calcium,	  c-­fos	  is	  up-­‐regulated	  and	  phosphorylated.	  Guinea-­‐Viniegra	  et	  
al	  demonstrated	  an	  active	  role	  of	  c-­‐Fos	  in	  mediating	  stress	  responses	  and	  showed	  that	  epidermal	   c-­fos	   deletion	   in	   mouse	   tumor	   models	   or	   pharmacological	   FOS/AP-­‐1	  inhibition	  in	  human	  SCC	  cell	  lines	  induced	  epidermal	  cell	  differentiation	  and	  skin	  tumor	  suppression	   by	   inducing	   p53	   and	   subsequently	   TACE	   (TNFα	   converting	   enzyme)	  expression.	  TACE,	  in	  turn,	  promotes	  keratinocyte	  differentiation	  by	  activating	  the	  Notch	  signaling	   pathway	   (Guinea-­‐Viniegra	   et	   al.,	   2012).	   Additionally,	   c-­‐Fos-­‐phoshorylation	  knock-­‐in	   mice,	   in	   which	   c-­‐Fos	   phosphorylation	   sites	   have	   been	   substituted	   by	   non-­‐phosphorylatable	   alanines,	   show	   reduced	   papilloma	   formation	   in	   a	   papilloma-­‐prone	  backgroud	   (K5-­‐SOS)	   (Bakiri	   et	   al.,	   2011).	   In	   contrast,	   overexpression	   of	   the	   viral	  homolog	  of	   c-­‐Fos	   (v-­‐Fos)	   in	   the	   spinous	   layer	   leads	   to	   long	   latency,	  wound-­‐associated	  epidermal	  hyperplasia	  (Greenhalgh	  et	  al.,	  1995).	  Altogether,	   these	  data	   indicate	  that	  c-­‐Fos	  is	  necessary	  for	  efficient	  papilloma	  formation.	  I	  have	  generated	  two	  mouse	  models	  to	  inducibly	  express	  c-­fos	  under	  the	  control	  of	   the	  keratin	  5	  promoter,	  which	   is	   expressed	   in	  basal	   keratinocytes	   as	  well	   as	   in	   the	  basal	   layer	   of	   other	   stratified	   epithelia,	   to	   assess	   specific	   functions	   of	   c-­‐Fos	   in	   the	  epidermis.	  Expressing	  c-­fos	   in	   the	  basal	   layer	  of	   the	  epidermis	   leads	   to	  a	  disruption	  of	  the	   epidermal	   architecture	   with	   the	   development	   of	   preneoplastic	   lesions	   by	   four	   or	  sixteen	   weeks	   of	   inducible	   c-­fos	   expression	   in	   c-­‐FosEp-­tetON	   and	   c-­‐FosEp-­tetOFF	   mice,	  respectively.	  These	   lesions	  most	   likely	  did	  not	   fully	  convert	   into	  SCCs	  due	   to	   the	  early	  death	  of	  these	  mice	  before	  the	  tumors	  developed.	  Moreover,	  other	  features	  such	  as	  hair	  loss,	   hyperkeratosis	   (thickening	   of	   the	   stratum	   corneum),	   parakeratosis	   (retention	   of	  nuclei	   in	   the	   stratum	   corneum)	   as	   well	   as	   follicular	   cysts	   (follicles	   in	   which	   there	   is	  proliferation	   and	   accumulation	   of	   keratin	   into	   a	   cystic	  mass	   that	   invaginates	   into	   the	  dermis)	  were	  observed.	  The	  features	  observed	  in	  this	  mouse	  model	  are	  often	  present	  in	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certain	   inflammatory	   skin	   diseases	   such	   as	   Psoriasis,	   Atopic	   Dermatitis	   and	   Actinic	  Keratosis	   (AK)	  (Bovenschen	  et	  al.,	  2005;	  Berhane	  et	  al.,	  2002),	  which	  are	  described	  as	  preneoplastic	  lesions	  and	  these	  lesions	  often	  develop	  to	  SCCs	  (Mortier	  et	  al.,	  2002).	  The	  disruption	  of	  epidermal	  homeostasis	  promoting	  hyperplasia	  can	  happen	  as	  a	  consequence	   of	   an	   imbalance	   in	   different	   cellular	   processes,	   proliferation	   and	  differentiation,	  or	  can	  also	  develop	  as	  a	  consequence	  of	  the	  epithelial	  barrier	  disruption	  (Hsu	  and	  Fuchs,	  2012).	  Upon	  inducible	  c-­fos	  expression	   in	  vivo,	   increased	  proliferation	  was	  observed	  by	  performing	  Ki67	   immunostainings.	   Interestingly,	  no	  cell	  autonomous	  changes	   in	   proliferation	   were	   observed	   upon	   c-­fos	   expression	   in	   primary	   c-­‐FostetON	  keratinocytes,	  as	  assessed	  by	  three	  independent	  methods.	  Thus,	  these	  data	  suggest	  that	  increased	   proliferation	   in	   vivo	   must	   occur	   from	   changes	   arising	   in	   the	   stroma	   of	   the	  preneoplastic	  lesion,	  probably	  due	  to	  paracrine	  signaling	  of	  growth	  factors	  or	  cytokines	  from	  stromal	   cells.	  These	   results	   are	   in	   line	  with	  previous	   findings	   showing	   that	  mice	  lacking	  epidermal	  c-­‐Fos	  do	  not	  develop	  any	  alteration	  in	  proliferation	  neither	  in	  vivo	  nor	  
in	   vitro	   (Guinea-­‐Viniegra	   et	   al.,	   2012).	  However,	   the	   impact	  of	  c-­fos	   expression	  on	   cell	  proliferation	   is	   cell-­‐type-­‐specific,	   since	   it	   can	   promote	   cell	   cycle	   progression	   in	  osteoblasts	  and	  in	  mouse	  embryonic	  fibroblasts	  (MEFs)	  by	  activating	  the	  expression	  of	  Cyclins	  D1,	  A	  and	  E	  (Sunters	  et	  al.,	  1998).	  	  	  Furthermore,	   epidermal	   differentiation	   was	   assessed	   in	   vivo	   by	   performing	  immunostainings	   of	   early	   and	   late	   differentiation	   markers	   of	   backskin	   of	   c-­‐FosEp-­tetON	  mice	   and	   controls	   after	   inducible	   expression	   of	   c-­fos.	   A	   delay	   in	   keratinocyte	  differentiation	   was	   clearly	   observed,	   since	   basal	   keratinocytes	   expanded	   from	   one	   to	  several	   layers	   of	   keratinocytes.	   Interestingly,	   a	   similar	   defect	   was	   observed	   when	   c-­‐FostetON	  keratinocytes	  were	  primed	  to	  differentiate	   in	  vitro	  upon	  Ca2+	  treatment,	  where	  keratinocytes	   expressing	   inducible	   c-­fos	   failed	   to	   properly	   differentiate.	   mRNA	  expression	   analyses	   revealed	   impaired	   expression	   of	   early	   and	   late	   differentiation	  markers	   as	   well	   as	   impaired	   activation	   of	   the	   differentiation-­‐promoting	  p53/TACE/Notch-­‐signaling	   pathway.	   These	   findings	   are	   in	   line	   with	   previously	  published	   data	   showing	   that	   a	   reduction	   in	   c-­‐Fos	   levels	   in	   keratinocytes	   or	   c-­fos-­‐deficient	   keratinocytes	   undergo	   premature	   differentiation	   upon	   certain	   stress	  responses,	  such	  as	  Ca2+	  and	  TPA	  in	  a	  p53	  and	  TACE	  dependent	  manner	  (Guinea-­‐Viniegra	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et	   al.,	   2012).	   Therefore,	   and	   since	   keratinocyte	   differentiation	   is	   impaired	   upon	   c-­‐Fos	  expression	  in	  vitro,	  I	  evaluated	  the	  integrity	  of	  the	  epidermal	  barrier,	  which	  can	  occur	  as	  a	  consequence	  of	   impaired	  differentiation	  due	   to	  reduced	  Notch	  signaling	   (Demehri	  et	  al.,	  2009).	  No	  epidermal	  barrier	  defects	  were	  observed	  upon	  c-­‐Fos	  expression	  in	  c-­‐FosEp-­
tetOFF	  pups	  or	   in	  back	   skin	  of	   c-­‐FosEp-­tetON	  mice	  by	  performing	   inside-­‐out	   and	  outside-­‐in	  epidermal	  barrier	  permeability	  tests.	  These	  results	  exclude	  the	  possibility	  of	  the	  barrier	  defect	   being	   a	   direct	   cause	   promoting	   keratinocyte	   proliferation	   and	   the	   subsequent	  development	  of	  the	  “preneoplastic	  lesions”	  even	  though	  Notch	  signaling	  is	  reduced.	  	  Tet-­‐ON	  and	  tet-­‐OFF	  mouse	  models	  allow	  spatiotemporal	  modulation	  of	  inducible	  gene	  expression.	  I	  exploited	  this	  feature	  to	  address	  the	  question	  whether	  the	  observed	  preneoplastic	  lesions	  are	  dependent	  on	  constitutive	  c-­fos	  expression	  and	  whether	  upon	  cessation	  of	  c-­fos	  expression,	  the	  lesions	  would	  regress.	   I	  analyzed	  the	  "reverted"	  mice	  after	  switching	  off	  c-­fos	  expression	  once	  the	   lesions	  had	  already	  developed.	   I	  observed	  an	  improvement	  in	  the	  back	  skin	  of	  these	  mice.	  Overall,	  no	  epidermal	  hyperplasia	  was	  observed	   even	   though	   some	   follicular	   cysts	   still	   remained.	   This	   suggests	   that	   hair	  follicles,	  once	  they	  loose	  their	  fate,	  cannot	  regenerate	  their	  structure	  thus	  leading	  to	  hair	  loss.	  Moreover,	  some	  isolated	  patches	  still	  presented	  mild	  hyperplasia	  and	  these	  areas	  coincided	  with	  still	  enhanced	  expression	  of	  c-­fos.	  Overall,	  these	  findings	  suggest	  that	  the	  preneoplastic	   lesion	   requires	   constant	   c-­fos	   signaling	   to	   maintain	   these	   pathological	  features.	  	  
2.	  c-­FOS	  TRIGGERS	  INFLAMMATORY	  PROCESSES	  IN	  THE	  SKIN	  THAT	  
LEAD	  TO	  THE	  DEVELOPMENT	  OF	  PRENEOPLASTIC	  LESIONS	   	  Immune	  responses	  in	  the	  skin	  are	  a	  crucial	  component	  of	  the	  peripheral	  immune	  system	   to	   protect	   against	   pathogens	   to	   obtain	   information	   for	   the	   immune	   system	   to	  initiate	   specific	   and	   long-­‐term	   immunity	   and	   finally	   to	   repair	   damaged	   tissue.	   Acute	  inflammation	  is	  a	  rapid	  self-­‐limiting	  process,	  however,	  it	  does	  not	  always	  resolve	  quickly	  and	   may	   be	   maintained	   for	   a	   prolonged	   time	   and	   become	   chronic	   due	   to	   constant	  infection.	  There	  is	  increasing	  evidence	  that	  chronic	  inflammation	  is	  at	  the	  basis	  of	  many	  of	  the	  diseases	  of	  advanced	  age,	  such	  as	  cancer	  (Berhane	  et	  al.,	  2002).	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Here,	   I	  have	  described	  a	  new	  role	  of	   c-­‐Fos	   in	  promoting	   immune-­‐cell-­‐mediated	  preneoplastic	  lesions	  in	  the	  epidermis.	  Flow	  Cytometry	  analyses	  of	  back	  skin	  revealed	  a	  transient	   granulocyte	   and	   chronic	   CD4+T	   cell	   recruitment	   following	   inducible	   c-­fos	  expression.	   	  These	  infiltrates	  were	  present	  in	  the	  skin	  of	  c-­‐FosEp-­tetON	  mice	  compared	  to	  controls	   after	   inducible	   c-­fos	   expression,	   when	   no	   visible	   lesions	   in	   the	   skin	   had	  developed,	  indicating	  that,	  recruitment	  of	  these	  cells	  preceded	  the	  development	  of	  focal	  preneoplastic	   lesions.	   Interestingly,	   the	  AP-­‐1	   family	  of	   transcription	   factors	   (mainly	   c-­‐Jun,	   JunB	  and	  Fra2)	  has	  also	  been	  previously	   involved	   in	  mediating	  skin	   inflammatory	  processes	  by	  inhibiting	  the	  expression	  of	  cytokines	  such	  as	  G-­‐CSF,	  IL-­‐6,	  IL-­‐17,	  TNFα	  or	  TSLP	  (Zenz	  et	  al.,	  2005;	  Meixner	  et	  al.,	  2008;	  Guinea-­‐Viniegra	  et	  al.,	  2009;	  Schonthaler	  et	  al.,	  2009)	  (Wurm	  and	  Wagner,	  unpublished).	  	  Using	   FACS	   (Fluorescent-­‐activated	   cell	   sorting)	   sorting	   followed	   by	   mRNA	  expression	  analyses,	  I	   identified	  Interleukin-­‐22	  (IL-­‐22)	  as	  the	  main	  cytokine	  expressed	  by	  CD4	  T	  cells	  that	  infiltrate	  c-­‐FosEp-­tetON	  preneoplastic	  lesions.	  IL-­‐22	  is	  a	  member	  of	  the	  IL-­‐10	   family,	   which	   includes	   IL-­‐19,	   IL-­‐20,	   IL-­‐24	   and	   IL-­‐26.	   This	   cytokine	   is	   mainly	  expressed	   by	   Th17	   cells	   at	   barrier	   surfaces	   (Liang	   et	   al.,	   2006).	   IL-­‐22	   expression	   is	  restricted	   to	   cells	   of	   lineages	   of	   the	   innate	   and	   adaptive	   immune	   responses,	   whereas	  expression	   of	   the	   functional	   IL-­‐22R	   seems	   to	   be	   restricted	   to	   the	   non-­‐hematopoietic	  cells	  of	  the	  skin,	  pancreas,	  intestine,	  liver,	  lung	  and	  kidney	  (Tachiiri	  et	  al.,	  2003;	  Wolk	  et	  al.,	   2004).	   IL-­‐22-­‐IL-­‐22R	   interactions	   can	   induce	   the	   expression	   of	   genes	   encoding	  molecules	  involved	  in	  tissue	  inflammation,	  immunesurveillance	  and	  homeostasis	  (Liang	  et	  al.,	  2006).	  One	  of	   the	  signaling	  pathways	  activated	  upon	  IL-­‐22	  IL-­‐22R	  ligation	   is	   the	  JAK-­‐STAT3	  pathway,	  which	  is	  involved	  in	  keratinocyte	  survival	  and	  proliferation	  (Zhang	  et	  al.,	  2012).	  Consistent	  with	   this,	  deregulated	  expression	  of	   IL-­‐22	  or	   IL-­‐22R	  has	  been	  reported	  in	  certain	  human	  diseases,	  such	  as	  psoriasis	  (Pan	  et	  al.,	  2012),	  and	  studies	  in	  mouse	  models	  have	   identified	  crucial	  roles	   for	  IL-­‐22–IL-­‐22R	  in	  regulating	  homeostasis	  of	  epithelial	  cells	  at	  barrier	  surfaces.	  I	  propose	  here	  an	  important	  contribution	  of	  CD4	  T	  cell	  secreted	  IL-­‐22	  in	  promoting	  keratinocyte	  survival	  and	  proliferation	  thus	  priming	  the	  keratinocytes	  towards	  uncontrolled	  proliferation	  that	  may	  eventually	  lead	  to	  cancer.	  Interestingly,	   activation	   of	   STAT3	   and	   NF-­‐κB	   pathways	   was	   observed	   upon	  inducible	  c-­fos	  expression	  in	  c-­‐FosEp-­tetON	  mice.	  Both	  pathways	  are	  usually	  not	  expressed	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during	   epidermal	   homeostasis,	   however	   these	   are	   activated	   upon	   inflammatory	  processes	   and	   cancer	   (You	   et	   al.,	   2012).	   The	   activation	   of	   STAT3	   pathway	   is	   likely	   a	  consequence	  of	  IL-­‐22	  signaling	  from	  the	  infiltrating	  CD4	  T	  lymphocytes.	  To	  ask	  whether	  the	  preneoplastic	  lesions	  observed	  upon	  c-­fos	  expression	  require	  the	  presence	  of	  CD4	  T	  cells,	  mature	  T	  and	  B	  cells	  were	  depleted	  by	  crossing	  the	  c-­‐FosEp-­
tetON	  mouse	  model	  to	  a	  Rag1-­‐/-­‐	  mouse.	  Interestingly,	  80%	  of	  the	  mice	  in	  a	  Rag1-­‐deficient	  background	   showed	   either	   no	   lesions	   or	   the	   lesions	  were	   significantly	   smaller.	   These	  results	   clearly	   point	   to	   the	   relevance	   of	   CD4	   T	   cells	   in	   the	   development	   of	   skin	  preneoplastic	  lesions.	  This	  results	  support	  previous	  evidence	  in	  which	  there	  is	  reduced	  incidence	  of	  development	  of	  SCCs	  in	  the	  skin	  in	  K14-­‐HPV	  skin	  tumor	  prone	  mouse	  in	  a	  Rag1-­‐	  or	  CD4	  T	  cell-­‐deficient	  background	  was	  found	  (Daniel	  et	  al.,	  2003;	  de	  Visser	  and	  Coussens,	  2005).	  	  Moreover,	   flow	   Cytometry	   analyses	   performed	   after	   switching	   off	   c-­fos	  expression	  revealed	  a	  mild,	  but	  not	  significant	   increase	  in	  the	  CD4	  T	  cell	  population	  in	  the	   back	   skin	   of	   c-­‐FosEp-­tetON	   mice	   compared	   to	   controls.	   These	   results	   confirm	   the	  studies	   describing	   that	   in	   inflamed	   skin,	   due	   to	   UV	   light	   exposure	   or	   infection,	   some	  infiltrated	  CD4	  T	  cells,	  remain	  in	  the	  peripheral	  tissue	  waiting	  for	  a	  second	  infection	  or	  injury	  where	  inflammatory	  processes	  are	  triggered.	  c-­‐Fos	  also	  contributes	  to	  the	  development	  of	  other	  inflammatory	  diseases	  such	  as	  arthritis	  (Shiozawa	  and	  Tsumiyama,	  2009).	  Aikawa	  and	  colleagues,	  by	  using	  a	  collagen-­‐induced	   arthritis	   mouse	   model	   (Brand	   et	   al.,	   2007),	   showed	   that	   treatment	   with	   a	  specific	   c-­‐Fos/AP-­‐1	   inhibitor	   (T5224)	   before	   the	   onset	   of	   arthritis	   inhibited	   the	  development	   of	   this	   inflammatory	   disease.	   Interestingly,	   in	   91%	   of	   the	   cases	   joint	  destruction,	  was	   inhibited	   in	   treated	  mice	  compared	   to	   controls	   (Aikawa	  et	  al.,	   2008).	  This	  inhibitor	  was	  also	  used	  as	  a	  therapeutic	  treatment	  once	  the	  arthritis	  had	  developed.	  However,	  this	  regimen	  did	  not	  cause	  a	  substantial	  improvement	  in	  joint	  destruction,	  but	  there	  was	  an	  improvement	  in	  the	  indices	  of	  cell	  infiltration,	  neutrophil	  infiltration,	  and	  synovial	   cell	   proliferation.	   Mechanistically,	   the	   authors	   identified	   a	   pro-­‐inflammatory	  cytokine	   IL-­‐1β	   and	  MMP-­‐3	   to	   be	   significantly	   lowered	   in	   the	   serum	   of	   T5224-­‐treated	  mice,	   but	   did	   not	   provide	   further	   evidence	   of	   the	   cellular	   source	   of	   these	   molecules	  (Aikawa	  et	  al.,	  2008).	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Depending	   on	   the	   cell	   context,	   c-­‐Fos	   can	   also	   exert	   anti-­‐inflammatory	   effects.	  Upon	   LPS	   (Lipopolysaccharyde)	   treatment,	   complete	   c-­‐Fos	   knock-­‐out	   mice	   showed	  increased	  expression	   levels	  of	   IL-­‐6,	  TNFα,	   IL-­‐12p40	   in	   their	  spleens	  (Ray	  et	  al.,	  2006).	  This	   was	   due	   to	   increased	   NF-­‐κB	   levels	   and	   activity	   in	   the	   absence	   of	   c-­‐Fos	   in	  macrophages.	  In	  line	  with	  these	  findings,	  the	  same	  group	  observed	  that	  c-­‐Fos	  knock-­‐out	  mice	   were	   more	   susceptible	   to	   DSS-­‐induced	   colitis	   without	   defining	   the	   molecular	  mechanism	   underlying	   this	   phenotype	   (Takada	   et	   al.,	   2010).	   Moreover,	   Koga	   and	  colleagues	   further	   demonstrated	   by	   silencing	   c-­fos	   expression	   in	   dendritic	   and	  macrophage	   cell	   lines	   that	   c-­‐Fos	   physically	   interacts	   with	   p65	   and	   impairs	   c-­‐AMP-­‐induced,	   p65-­‐mediated	   TNFα	   expression	   (Koga	   et	   al.,	   2009).	   This	   direct	   interaction	  between	   c-­‐Fos	   and	   p65/NF-­‐κB	   could	   likely	   explain	   the	   findings	   observed	   by	   Ray	   and	  colleagues	   in	  which	  upon	  c-­‐Fos	  deficiency	   in	  macrophages,	  NF-­‐κB	   levels	  and	  signaling	  are	  increased	  (Ray	  et	  al.,	  2006).	  	  Overall,	   it	   is	  known	  that	  c-­‐Fos	  can	  exert	  pleiotropic	  roles	  depending	  on	   the	  cell	  context.	  	  c-­‐Fos	  knock-­‐out	  mice	  show	  reduced	  B-­‐cell	  numbers	  in	  the	  spleen,	  lymph	  nodes	  and	   peripheral	   blood	   due	   to	   a	   marked	   reduction	   in	   the	   number	   of	   B-­‐cell	   precursors	  (Okada	   et	   al.,	   1994).	   Moreover,	   c-­‐Fos	   knock-­‐out	   mice	   also	   showed	   a	   considerable	  inhibition	   of	   early	   T	   cell	   development	   with	   a	   significant	   lower	   thymocyte	   number	  compared	  to	  wild-­‐type	  mice	  (Wang	  et	  al.,	  1992).	  This	  phenotype	  is	  a	  consequence	  of	  an	  unexpected	   function	  of	   c-­‐Fos	   as	   a	  direct	   regulator	  of	  T	   cell	   antigen	   recpetor-­‐β	   (TCRβ)	  recombination	  by	   binding	   to	   an	  AP-­‐1	  binding	   site	   in	   a	   recombination	   signal	   sequence	  and	  physical	  interaction	  with	  RAG	  recombinases	  (Wang	  et	  al.,	  2008).	  Contrary	  to	  c-­‐Fos	  knock-­‐out	  mice	  that	  display	   impaired	  B	  and	  T	  cell	  development,	  c-­‐Fos	  transgenic	  mice	  have	   impaired	   T	   cell	   function.	   This	   effect	   is	   indirectly	   mediated	   by	   c-­‐Fos	   expression	  inducing	  increased	  proliferation	  of	  thymic	  epithelial	  cells,	  which	  indirectly	  affects	  T	  cell	  development	  (Ruther	  et	  al.,	  1988).	  In	   summary,	   the	   transcription	   factor	   c-­‐Fos,	   exerts	   pleiotropic	   roles,	   which	   are	  cell-­‐	   and	   context-­‐specific.	   I	   have	   shown	   that	   c-­‐Fos	   promotes	   inflammatory	   responses	  when	  inducibly	  expressed	  in	  the	  epidermis	  of	  c-­‐FosEp-­tetON	  mice	  even	  though	  in	  other	  cell	  types,	  such	  as	  macrophages,	  upon	  stimulus,	  it	  can	  inhibit	  expression	  of	  certain	  cytokines	  (Ray	  et	  al.,	  2006).	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3.	   c-­FOS	   TRANSCRIPTIONALLY	   CONTROLS	   mmp10	   AND	   s100a7a15	  
EXPRESSION	   	  In	   order	   to	   identify	   novel	   transcriptional	   targets	   of	   c-­‐Fos	   in	   keratinocytes	   that	  could	  provide	  mechanistic	  insights	  in	  the	  phenotype	  developed	  in	  c-­‐FosEp-­tetON	  mice,	  we	  performed	  genome-­‐wide	  expression	  analyses	   in	  collaboration	  with	  Peter	  Angel	   (DKFZ,	  Heidelberg).	   These	   analyses	   revealed	   no	   major	   changes	   in	   the	   expression	   of	   genes	  involved	   in	   keratinocyte	   differentiation	   neither	   in	   proliferation	   upon	   inducible	   c-­fos	  expression.	  However,	  5	  consistently	  up-­‐regulated	  target	  genes	  were	  identified	  (mmp10,	  
tgfbi,	  eef2,	  ngf	  and	  s100a7a15).	  Amongst	  these	  genes,	  further	  characterization	  of	  mmp10	  and	   s100a7a15	  was	   performed	   due	   to	   their	   implication	   in	   inflammatory	   responses	   as	  well	  as	  in	  skin	  cancer.	  I	  validated	  the	  expression	  of	  these	  two	  candidate	  genes	  by	  mRNA	  and	  protein	  analyses	  in	  c-­‐FostetON	  keratinocytes	  in	  vitro	  as	  well	  as	  in	  the	  back	  skin	  of	  c-­‐FosEp-­tetON	  and	  control	  mice	   induced	  with	  Dox.	  Moreover,	  Chromatin	   IP	  (ChIP)	  analyses	  revealed	  direct	  binding	  of	   c-­‐Fos	   to	   the	  promoters	  of	   these	  genes,	   indicating	   that	   c-­‐Fos	  transcriptionally	   regulates	   expression	   of	   these	   two	   novel	   target	   genes.	   Furthermore,	  TPA-­‐treated	  control	  and	  c-­fos-­deficient	  keratinocytes	  were	  used	  as	  a	  control	  to	  directly	  show	  impaired	  expression	  of	  mmp10	  and	  s100a7a15	  	  upon	  c-­‐Fos	  deficiency.	  MMP10,	   matrix	   metalloprotease	   10,	   also	   known	   as	   Stromelysin	   2,	   plays	  important	  roles	   in	  physiological	  processes,	  such	  as	  embryonic	  development	  and	  tissue	  remodeling	   and	   cancer	   (Kessenbrock	   et	   al.,	   2010).	   The	   MMP	   family	   of	   proteins	  comprises	   20	   human	   MMP	   members	   divided	   in	   five	   main	   groups	   according	   to	   their	  structure	   and	   substrate	   specificity:	   collagenases,	   gelatinases,	   membrane	   type,	  stromelysins	   and	   matrilysins	   (Bourboulia	   and	   Stetler-­‐Stevenson,	   2010).	   Stromelysins	  cleave	   similar	   substrates	   (collagens	   III,	   IV	   and	   V,	   fibronectin,	   elastin)	   and	   also	   these	  enzymes	  cleave	  other	  MMPs,	  which	  are	  secreted	  as	  inactive	  enzymes	  or	  zymogens,	  such	  as	   proMMP-­‐1,	   proMMP-­‐7,	   proMMP-­‐8	   and	   proMMP-­‐9	   (Parks	   et	   al.,	   2004).	   In	   the	  epidermis,	   MMP10	   is	   usually	   expressed	   at	   low	   levels,	   but	   only	   upon	   wounding	   it	   is	  upregulated	  at	  the	  tip	  of	  the	  migrating	  epithelial	  tongue,	  similar	  to	  what	  we	  observe	  in	  c-­‐FosEp-­tetON	  mice	  comparing	  early	  and	   late	   stages	  of	  phenotype	  development	   (Saarialho-­‐Kere	   et	   al.,	   1994;	  Madlener	   et	   al.,	   1996).	  Moreover,	   the	   group	   of	  Werner	   generated	   a	  transgenic	  mouse	  model	  constitutively	  expressing	  active	  MMP10	  in	  keratinocytes.	  These	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animals	   had	   no	   alterations	   in	   the	   skin	   architecture,	   although	   upon	   wounding,	  keratinocytes	   at	   the	   migrating	   epidermal	   tip	   were	   scattered	   and	   there	   was	   reduced	  deposition	  of	  new	  matrix	  (Krampert	  et	  al.,	  2004).	  These	  results	  suggest	  that	  MMP10	  is	  important	   in	   the	   epidermis	   during	   wound	   healing	   processes.	   Interestingly,	   several	  MMPs	  (MMP-­‐1,	  MMP-­‐3	  and	  MMP-­‐13)	  have	  AP-­‐1	  binding	  sites	  and	  are	  regulated	  by	  AP-­‐1	  family	  of	  transcription	  factors	  (Tuckermann	  et	  al.,	  2001;	  Eferl	  and	  Wagner,	  2003).	  I	  have	  attempted	  to	  inhibit	  MMP	  signaling	  by	  using	  a	  broad	  MMP	  inhibitor	  (TAPI-­‐1)	  in	  vivo	  (due	  to	  the	  absence	  of	  specific	  MMP10	  inhibitors)	  supplied	  systemically	  to	  c-­‐FosEp-­tetON	   mice.	   Preliminary	   analyses	   revealed	   a	   delay	   in	   the	   development	   of	   the	  phenotype	   in	   c-­‐FosEp-­tetON	   mice	   treated	   with	   TAPI	   compared	   with	   mice	   treated	   with	  vehicle.	   Further	   experiments	   will	   be	   necessary	   to	   prove	   a	   	   clear	   impact	   of	   MMP10	  signaling	   in	   the	   recruitment	   of	   CD4	   T	   cells	   and	   in	   the	   development	   of	   preneoplastic	  lesions.	   Furthermore,	   other	   paths	   of	   delivery,	   such	   as	   topical	   administration	   will	   be	  tested.	  	  
s100a7a15	   gene	   belongs	   to	   the	   S100	   protein	   family	   of	   small	   calcium-­‐binding	  proteins	   involved	   in	  epithelial	  host	  defense.	  Whereas	   in	  mouse	  there	   is	  only	  one	  gene,	  
s100a7a15,	   in	   human	   there	   are	   two	   different	   genes	   S100A7	   and	   S100A15	   (Wolf	   et	   al.,	  2006).	   Genomic	   analyses	   of	   the	   S100A7	   and	   S100A15	   encoding	   chromosomal	   regions	  revealed	  that	  both	  likely	  evolved	  by	  gene	  duplications	  during	  primate	  evolution,	  forming	  an	   innate	   subfamily	   in	   human	   (Kulski	   et	   al.,	   2003).	   The	   S100A7/A15	   proteins	   are	   of	  major	   interest	   because	   of	   their	   differential	   expression	   and	   putative	   functional	   role	   in	  epidermal	   cell	   maturation,	   tumorigenesis	   and	   inflammation	   (Broome	   et	   al.,	   2003)	  (Eckert	  et	  al.,	  2004).	  The	  human	  calcium-­‐binding	  protein	  S100A7	  was	  first	  identified	  as	  a	  protein	  upregulated	  in	  inflamed	  hyperplastic	  psoriatic	  skin	  (Madsen	  et	  al.,	  1991).	  The	  highly	  homologous	  human	  S100A15	  was	  recently	  identified	  in	  psoriasis	  and	  found	  also	  to	   be	   upregulated	   in	   lesional	   skin	   (Wolf	   et	   al.,	   2003).	   Moreover,	   S100a7a15	   induces	  leukocyte	   chemotaxis	   by	   binding	   to	   RAGE	   (Wolf	   et	   al.,	   2010).	   Inducible	   expression	   of	  
s100a7a15	   in	   the	  basal	   layer	  of	   the	  epidermis	  predisposes	  mice	   to	  develop	   “psoriasis-­‐like”	  phenotype	  with	  recruitment	  of	  Gr1+	  and	  CD4	  T	  cells	  (Wolf	  et	  al.,	  2010).	  In	  line	  with	  these	   results,	   genomic	   and	   proteomic	   analyses	   performed	   in	   another	   psoriasis	  mouse	  model	   (c-­‐Jun/JunB	   epidermal	   deletion)	   also	   showed	   increased	   S100a7a15	  mRNA	   and	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protein	   levels	   in	   psoriatic	   mouse	   skin	   (Zenz	   et	   al.,	   2005)(Schönthaler	   and	   Wagner,	  unpublished).	   Since	   S100a7a15	   is	   expressed	   in	   the	   preneoplastic	   lesions	   developed	  upon	  c-­fos	  expression	  and	  it	  exerts	  chemoattractive	  functions	  for	  CD4	  T	  and	  Gr1+	  cells,	  we	  plan	  to	  inhibit	  this	  protein	  in	  vivo	  by	  either	  using	  a	  blocking	  antibody	  or	  by	  testing	  an	  inhibitor,	  which	  is	  specific	  for	  S100A9	  protein	  (Kallberg	  et	  al.,	  2012).	  In	  conclusion,	  the	  contribution	   of	   S100a7a15	   to	   the	   development	   of	   preneoplastic	   lesions	   is	   not	   yet	  defined.	  
4.	   c-­FOS	   FUNCTIONS	   IN	   SKIN	   CANCER	   DEVELOPMENT	   AND	  
PROGRESSION	   	  Our	  studies	  demonstrate	  that	   following	  DMBA-­‐induced	  Ha-­‐Ras	  mutations,	  c-­‐Fos	  overexpression	   in	   the	   epidermis	   is	   sufficient	   to	   promote	   SCC	   development	   in	   both	   c-­‐FosEp-­tetON	  and	  c-­‐FosEp-­tetOFF	  mouse	  lines.	  These	  epithelial	  tumors	  were	  highly	  proliferative	  and	   invaded	   the	   surrounding	   dermis	   and	  muscle	   layer,	   as	   assessed	   by	   Keratin	   6	   and	  Keratin	  5	  immunostaining.	  Our	   findings	   confirm	   previous	   data	   indicating	   that	   overexpression	   of	   the	   viral	  homolog	  of	  c-­‐Fos	  (v-­‐Fos)	   in	   the	  spinous	   layer	   leads	   to	   long	   latency,	  wound	  associated,	  epidermal	  hyperplasia	  (Greenhalgh	  et	  al.,	  1993).	  In	  addition,	  c-­fos	  ubiquitous	  expression	  (under	  the	  control	  of	  the	  H2K	  promomter)	  following	  DMBA-­‐topical	  applications,	  lead	  to	  the	  development	  of	  SCCs	  (Sakai,	  1990).	  Conversely,	  experiments	  performed	  with	  c-­‐Fos	  knock-­‐out	  mice	  have	  shown	  that	  c-­‐Fos	  is	  essential	  for	  the	  progression	  from	  papillomas	  to	  SCCs	  (Saez	  et	  al.,	  1995).	  Furthermore,	   recent	  data	   from	  our	   lab	  demonstrate	   that	  c-­‐Fos	   is	   required	   for	   efficient	   papilloma	   and	   SCC	   formation	   (Durchdewald	   et	   al.,	   2008;	  Guinea-­‐Viniegra	  et	  al.,	  2012).	  In	  this	  study,	  the	  authors	  demonstrate	  that	  the	  absence	  of	  c-­‐Fos	   in	   keratinocyte-­‐specific	   c-­fos-­‐deficient	   mice	   and	   upon	   stress	   (Ras	   signaling,	  calcium	   or	   TPA)	   or	   in	   human	   SCC	   cell	   lines	   treated	   with	   the	   c-­‐Fos/AP-­‐1	   inhibitor	  (T5224)	  promotes	  premature	  keratinocyte	  differentiation	  in	  a	  p53	  and	  TACE-­‐dependent	  manner	  (Guinea-­‐Viniegra	  et	  al.,	  2012).	  	   Mechanistically,	   c-­‐FosEp-­tetON	   epidermal	   tumors	   also	   expressed	   both	   novel	   c-­‐Fos	  target	  genes	  mmp10	  and	  s100a7a15	  as	  assessed	  by	  mRNA	  and	  protein	   levels.	  There	   is	  increasing	   evidence	   that	   both	   targets	   are	   directly	   linked	   to	   cancer.	   In	   mice,	   genetic	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depletion	  of	  MMP10	  in	  a	  KRas-­‐mediated	  lung	  cancer	  model	  leads	  to	  the	  development	  of	  fewer	  and	  smaller	  tumors,	  and	  overall	  decrease	  in	  tumor	  burden	  compared	  to	  controls.	  However,	   there	   are	   no	   studies	   performed	   in	   mice	   implicating	   an	   functional	   role	   of	  MMP10	   in	   SCC	   development.	   It	   would	   be	   of	   interest	   to	   genetically	   deplete	  mmp10	   to	  address	   its	   functional	  contribution	  to	  the	  development	  of	  preneoplastic	   lesions	  as	  well	  as	  to	  the	  development	  of	  SCCs.	  	   In	   human,	   increased	   MMP10	   protein	   levels	   are	   expressed	   in	   some	   epithelial	  tumors	   such	   as	   esophageal	   or	   oral	   SCCs	   (Liu	   et	   al.,	   2011;	   Stott-­‐Miller	   et	   al.,	   2011).	   A	  strong	   correlation	   between	   MMP10	   levels	   and	   invasiveness	   is	   observed	   in	   head	   and	  neck	   tumor	   samples	   as	  well	   as	   in	   cell	   lines	   (Deraz	  et	   al.,	   2011).	   Interestingly,	   tumoral	  and	   salivary	  MMP10	   levels	   are	  being	  used	  as	  markers	  of	   oral	   SCCs	   (Stott-­‐Miller	   et	   al.,	  2011).	  Moreover,	  MMP10	  is	  highly	  expressed	  in	  different	  cancers	  like	  lung	  cancers,	  oral	  SCC,	   esophageal	   cancer	   and	   it	   has	   been	   shown	   to	   promote	   invasion	   of	   head	   and	  neck	  cancer	  (Frederick	  et	  al.,	  2008).	  In	  collaboration	  with	  Peter	  Petzelbauer	  (Medical	  School	  University	  of	  Vienna,	  Austria)	  we	  found	  a	  strong	  correlation	  between	  the	  expression	  of	  c-­‐FOS	  and	  MMP10	  in	  SCCs,	  but	  not	  in	  BCCs.	  80%	  of	  the	  SCCs	  analyzed	  expressed	  c-­‐FOS	  as	  well	  as	  MMP10,	  but	  none	  of	  the	  BCCs	  expressed	  these	  two	  proteins,	  suggesting	  that	  these	   proteins	   are	   important	   mediators	   in	   SCC.	   	   These	   results	   suggest	   that	   c-­‐FOS	   in	  human,	   most	   likely	   transcriptionally	   controls	   the	   expression	   of	   MMP10	   as	   we	   have	  described	   in	   mouse.	   However,	   chromatin	   immunoprecipitation	   analyses	   to	   assess	  binding	  of	  c-­‐FOS	  to	  the	  MMP10	  promoter	  should	  be	  performed	  to	  address	  this	  specific	  question.	  	  there	   is	   little	  evidence	   linking	  S100a7a15	  protein	   to	  cancer.	  Studies	  performed	  in	  mice,	  where	  orthotopic	  implantation	  of	  MVT-­‐1	  breast	  tumor	  cells	  into	  the	  mammary	  glands	   of	   mice	   inducibly	   expressing	   s100a7a15	   under	   the	   control	   of	   the	   Mouse	  Mammary	   Tumor	   Virus	   (MMTV)	   promoter,	   showed	   enhanced	   tumor	   growth	   and	  metastasis(Nasser	   et	   al.,	   2012).	   The	   authors	   claim	   that	   upon	   inducible	   s100a7a15	  expression,	  ductal	  hyperplasia	  occurs	  and	  subsequently	  cytokines	  and	  chemoattractant	  molecules	   are	   released	   to	   recruit	   macrophages,	   which	   in	   turn	   promote	   tumor	  development	  (Nasser	  et	  al.,	  2012).	  In	  human	  there	  are	  two	  genes	  S100A7	  and	  S100A15,	  whereas	  in	  mice	  there	  is	  only	  one	  s100a7a15.	  Several	  studies	  have	  shown	  upregulation	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of	  S100A7	  in	  several	  types	  of	  cancer,	  such	  as	  breast,	  laringeal	  carcinoma,	  skin	  SCC,	  lung	  SCC,	   ductal	   carcinoma	   and	   prostate	   cancer	   and	   it	   has	   been	   shown	   to	   have	   a	   role	   in	  promoting	  endothelial	  cell	  proliferation	  as	  well	  as	  SCC	  cell	  migration	  (Al-­‐Haddad	  et	  al.,	  1999).	   No	   studies	   have	   been	   performed	   so	   far	   to	   address	   the	   levels	   of	   S100A15	   in	  human	  cancer.	   I	  have	  used	  the	  same	  set	  of	  samples	  provided	  by	  Peter	  Petezelbauer	  to	  meassure	   the	   levels	   of	   S100A7	  protein.	   Even	   though	   increased	   levels	   of	   S100A7	  were	  observed	  in	  cutaneous	  SCCs	  compared	  to	  perilesional	  skin	  or	  to	  BCCs,	  c-­‐FOS	  and	  S100A7	  expression	  patterns	  seemed	  to	  be	  exclusive.	  S100A15	  protein	  levels	  will	  be	  assessed	  in	  these	  samples.	  These	  results	  suggest	   that	   there	   is	  evidence	  that	  S100A7	  and	  S100A15,	  even	  though	  they	  are	  very	  similar	  in	  structure,	  they	  are	  different	  in	  function.	  To	   address	   the	   question	  whether	   inflammation	   promotes	   skin	   tumorigenesis,	   I	  used	  a	  Cyclooxygenase	  1	  and	  2	  (COX1/COX2)	  inhibitor	  (Sulindac).	   Interestingly,	  tumor	  number,	   size	   and	   burden	   were	   significantly	   reduced.	   	   COX1	   and	   COX2	   are	   enzymes	  responsible	   for	   the	  synthesis	  of	   important	  biological	  mediators	  called	  prostanoids	  and	  play	  divergent	  roles.	  In	  the	  gastrointestinal	  tract,	  COX-­‐1	  maintains	  the	  normal	  lining	  of	  the	   stomach.	   The	   enzyme	   is	   also	   involved	   in	   kidney	   and	   platelet	   function.	  Cyclooxygenase-­‐2	  (COX-­‐2)	  is	  primarily	  present	  at	  sites	  of	   inflammation.	  Recent	  studies	  have	  demonstrated	  high	  COX-­‐2	  levels	  in	  several	  types	  of	  cancers	  (Eberhart	  et	  al.,	  1994),	  including	  skin	  cancer	  (Buckman	  et	  al.,	  1998;	  Muller-­‐Decker,	  2011;	  An	  et	  al.,	  2002;	  Smith	  et	  al.,	  2012).	  In	  fact,	  immunostaining	  of	  biopsies	  from	  SCCs	  show	  more	  intense	  staining	  for	   COX-­‐2	   protein,	   compared	   to	   normal	   skin	   (Buckman	   et	   al.,	   1998).	   In	   line	  with	   our	  results,	   Wilgus	   et	   al	   showed	   that	   topical	   treatment	   with	   a	   specific	   COX2	   inhibitor	  (Celecoxib)	   prevented	   the	   formation	  of	   papillomas	   after	   continuous	   exposure	   to	  UV-­‐B	  light	   (Wilgus	  et	  al.,	  2000;	  Wilgus	  et	  al.,	  2003).	  These	  results	   indicate	   that	   inhibition	  of	  inflammation	   could	   be	   therapeutically	   beneficial	   to	   prevent	   the	   development	   of	  cutaneous	  SCCs.	  
In addition, CD4 T cell infiltrates were found in	   human	   SCC,	   but	   not	   BCCs	   as	  assessed	  by	  CD4	  immunostaining.	  Interestingly,	  70%	  of	  the	  SCCs	  expressing	  high	  levels	  of	   c-­‐FOS	   showed	   infiltration	   of	   CD4	   T	   cells.	   This	   suggests	   that	   expression	   of	   c-­‐Fos	   in	  human	  SCC	   could	   also	  promote	   infiltration	  of	   CD4	  T	   cells.	   Further	   analyses	   should	  be	  performed	  to	  assess	  whether	  the	  presence	  of	  these	  cells	  could	  be	  used	  as	  a	  prognostic	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marker	   in	   cutaneous	   SCCs.	   In	   contrast	   to	   our	   results,	   where	   we	   propose	   a	   tumor-­‐promoting	   role	   of	   the	   CD4	   T	   cell	   population,	   it	   is	   widely	   accepted	   that	  immunocompromised	  patients	  that	  undergo	  organ	  transplantation	  are	  prone	  to	  develop	  cutaneous	  SCCs	  (Muellenhoff	  and	  Koo,	  2012).	  These	  patients	  are	  commonly	  treated	  with	  Calcineurin	   inhibitors	   such	   as	   cyclosporine	   A	   (Costanzo,	   2001).	   	   Interestingly,	   recent	  studies	   have	   indicated	   that	   the	   effect	   of	   these	   inhibitors	   may	   not	   only	   impact	   on	   T	  lymphocytes,	  but	  may	  also	  have	  an	  impact	  on	  other	  cell	  types	  such	  as	  keratinocytes.	  Wu	  and	   colleagues	   demonstrated	   that	   genetic	   and	   pharmacological	   suppression	   of	  calcineurin/NFAT	  function	  promoted	  tumor	  formation	  in	  mouse	  skin	  and	  in	  xenografts	  by	  activating	  expression	  of	  ATF-­‐3	   in	  keratinocytes	   (Wu	  et	  al.,	  2010).	  Further	  evidence	  also	  suggests	  that	  cyclosporine	  A	  can	  also	   inhibits	  DNA	  repair	  thus	   increasing	  the	  skin	  cancer	   risk	   (Kuschal	   et	   al.,	   2012).	   However,	   other	   immunesupressive	   drugs	   are	   being	  tested	  to	  avoid	  using	  cyclosporine	  A	  inhibitors	  (Euvrard	  et	  al.,	  2012).	  	  Therefore,	  my	  studies	  have	  helped	  to	  better	  understand	  the	  contribution	  of	   the	  CD4	  T	  cells	  in	  the	  development	  of	  preneoplastic	  lesions	  and	  SCCs	  in	  the	  skin	  and	  suggest	  that	  the	  use	  of	  antiinflammatory	  drugs	  may	  be	  beneficial	  to	  prevent	  development	  of	  skin	  cancer.	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Conclusions	  for	  objective	  #1	  1. Inducible	  c-­fos	  expression	  in	  the	  basal	  layer	  of	  the	  epidermis	  of	  c-­‐FosEp-­tetON	  and	  c-­‐FosEp-­tetOFF	  mice	  leads	  to	  the	  development	  of	  preneoplastic	  lesions.	  These	  lesions	  are	  characterized	  by	  increased	  proliferation,	  hyper-­‐	  and	  parakeratosis,	  cell	  atypia	  and	  infiltration	  of	  inflammatory	  cells.	  
2. Inducible	   expression	   of	   c-­fos	   in	   the	   basal	   layer	   of	   the	   epidermis	   promotes	  keratinocyte	   proliferation	   in	   vivo,	   but	   not	   in	   vitro.	   Moreover,	   epidermal	  differentiation	   is	   partly	   delayed,	   since	   Notch	   signaling	   pathway	   activation	   is	  impaired.	  3. Upon	   inducible	   c-­fos	   expression	   in	   the	   epidermis,	   transient	   and	   chronic	  infiltration	  of	  Gr1+	  and	  CD4+	  T	  cells,	  respectively,	  is	  observed	  by	  Flow	  Cytometry	  analyses.	   Moreover,	   FACS	   sorting	   of	   CD4	   T	   cells	   from	   backskin	   of	   c-­‐FosEp-­tetON	  mice	  revealed	  dominant	  expression	  of	  the	  pro-­‐inflammatory	  cytokine	  IL-­‐22.	  	  	  4. Inducible	  expression	  of	  c-­fos	  is	  not	  required	  to	  sustain	  the	  preneoplastic	  lesions	  since	  upon	  c-­fos	  switching	  off,	  preneoplastic	  lesions	  regress	  and	  the	  epidermis	  is	  restored	  to	  a	  homeostatic	  condition.	  	  5. Inducible	   c-­fos	   expression	   after	   a	   single	   dose	   of	  DMBA	   is	   sufficient	   to	   promote	  development	  of	  invasive	  SCCs	  in	  c-­‐FosEp-­tetON	  and	  c-­‐FosEp-­tetOFF	  mice.	  	  6. Tumor	   burden,	   number	   and	   size	   of	   invasive	   SCCs	   in	   c-­‐FosEp-­tetON	   were	   reduced	  when	   the	   DMBA/c-­‐Fos	   treatment	   was	   combined	   with	   the	   application	   of	   a	  COX1/COX2	  inhibitor.	  
	  
Conclusions	  for	  objective	  #2	  7. Genome-­‐wide	   expression	   analyses	   using	   primary	   c-­‐FostetON	   keratinocytes	  identified	   mmp10	   and	   s100a7a15	   as	   two	   putative	   target	   genes	   of	   c-­‐Fos.	  Furthermore,	   chromatin	   immunoprecipitation	   analyses	   revealed	   direct	   binding	  of	  c-­‐Fos	  to	  mmp10	  and	  s100a7a5	  promoters	  thus	   indicating	  that	  they	  are	  direct	  transcriptional	  targets	  of	  c-­‐Fos/AP-­‐1.	  MMP10	  and	  S100a7a15	  proteins	  are	  likely	  responsible	  for	  immune	  cell	  recruitment.	  8. Inhibition	  of	  MMP10	  signaling	  ameliorates	  the	  development	  of	  the	  preneoplastic	  lesions	  upon	  inducible	  c-­fos	  expression	  in	  c-­‐FosEp-­tetON	  mice.	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9. Depletion	  of	  mature	  B	  and	  T	  cells	  by	  crossing	  c-­‐FosEp-­tetON	  mice	  to	  a	  Rag1	  deficient	  background	  prevents	  the	  development	  of	  preneoplastic	  lesions.	  
	  
Conclusions	  for	  objective	  #3	  10. Immunostainings	  in	  paraffin	  embedded	  human	  samples	  demonstrated	  that	  80%	  of	   human	   SCCs	   expressed	   c-­‐FOS	   protein	   compared	   to	   helathy	   skin	   whereas	   in	  BCCs	   no	   c-­‐FOS	   expression	   was	   detected.	   Moreover,	   70%	   of	   the	   SCCs	   showed	  coexpression	  of	  both	  c-­‐FOS	  and	  MMP10.	  However,	  no	  coexpression	  of	  c-­‐FOS	  with	  S100A7	  was	  observed.	  Furthermore,	  70%	  of	  the	  SCCs	  expressing	  high	  levels	  of	  c-­‐FOS	  presented	  CD4	  T	  cell	  infiltrates.	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Conclusiones	  del	  objetivo	  #1	  1. La	  expresión	  inducible	  de	  c-­fos	  en	  el	  capa	  basal	  de	  la	  epidermis	  en	  los	  ratones	  c-­‐FosEp-­tetON	  y	  c-­‐FosEp-­tetOFF	  promueve	  el	  desarrollo	  de	  lesiones	  preneoplásicas.	  Estas	  lesiones	   se	   caracterizan	   por	   ser	   altamente	   proliferativas,	   presentar	   hiper-­‐	   y	  paraqueratosis,	  atipia	  celular	  e	  infiltración	  de	  células	  inmunes.	  
2. La	   expresión	   inducible	   de	   c-­fos	   en	   la	   capa	   basal	   de	   la	   epidermis	   promueve	  proliferación	   en	   los	   queratinocitos	   in	   vivo,	   pero	   no	   in	   vitro.	   Además,	   la	  diferenciación	   epidérmica	   se	   retrasa	   parcialmente	   dado	   que	   la	   vía	   de	  señalización	  de	  Notch	  está	  inactivada.	  3. Los	  ensayos	  de	  citometría	  de	  flujo	  revelan	  infiltración	  transitoria	  de	  células	  Gr1+	  e	   infiltración	   crónica	   de	   linfocitos	   T	   CD4+	   en	   la	   piel	   de	   los	   ratones	   c-­‐FosEp-­tetON.	  Además,	  el	  aislamiento	  de	  los	  linfocictos	  T	  CD4	  de	  la	  piel	  de	  los	  ratones	  c-­‐FosEp-­
tetON	  	  mediante	  FACS	  reveló	  expresión	  dominante	  de	  la	  citoquina	  IL-­‐22.	  4. Las	   lesiones	   preneoplásicas	   desarrolladas	   en	   la	   piel	   de	   los	   ratones	   c-­‐FosEp-­tetON	  	  	  revierten	   y	   la	   epidermis	   vuelve	   a	   una	   situación	   homeostática	   al	   apagar	   la	  expresión	  inducible	  de	  c-­fos.	  5. La	  expresión	  inducible	  de	  c-­fos	  después	  de	  la	  aplicación	  de	  DMBA	  en	  la	  piel	  de	  los	  ratones	   c-­‐FosEp-­tetON	   y	   c-­‐FosEp-­tetOFF	   promueve	   el	   desarrollo	   de	   carcinomas	  epidermoides	  invasivos	  en	  los	  ratones.	  6. El	  uso	  del	  inhibidor	  de	  las	  enzimas	  COX1/COX2	  en	  combinación	  con	  la	  aplicación	  de	  DMBA	  y	   la	   expresión	   inducible	  de	  c-­fos	   reduce	   la	   carga	   tumoral	   así	   como	  el	  número	  y	  tamaño	  de	  los	  carcinomas	  epidermoides	  en	  los	  ratones	  c-­‐FosEp-­tetON.	  
	  
Conclusiones	  del	  objetivo	  #2	  7. Análisis	   masivos	   de	   expresión	   génica	   utilizando	   queratinocitos	   primarios	  aislados	  de	  ratones	  c-­‐FostetON	  identificaron	  dos	  genes	  cuya	  expresión	  incrementó	  al	   inducir	   expresión	   de	   c-­fos.	   Además,	   análisis	   de	   immunoprecipitación	   de	  cromatina	   revelan	   la	   unión	   de	   c-­‐Fos	   a	   los	   promotores	   de	  mmp10	   y	   s100a7a15	  indicando	   que	   c-­‐Fos	   controla	   transcripcionalmente	   la	   expresión	   de	   estos	   dos	  genes.	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8. La	   inhibición	  de	   la	   actividad	  de	   la	   proteína	  MMP10	   reduce	   el	   desarrollo	   de	   las	  lesiones	   preneoplásicas	   al	   inducir	   la	   expresión	   de	   c-­fos	   en	   la	   capa	   basal	   de	   la	  epidermis	  en	  los	  ratones	  c-­‐FosEp-­tetON.	  9. La	   depleción	   de	   linfocitos	  maduros	  B	   y	   T	   al	   cruzar	   el	   ratón	   c-­‐FosEp-­tetON	   con	   un	  ratón	  knock-­‐out	  de	  Rag1	  previene	  el	  desarrollo	  de	  las	  lesiones	  preneoplásicas.	  
	  
Conclusiones	  del	  objetivo	  #3	  10. 	  Las	  inmunotinciones	  en	  tejido	  embebido	  en	  parafina	  demuestran	  que	  el	  80%	  de	  los	   carcinomas	   epidermoides	   humanos	   analizados	   expresan	   altos	   niveles	   de	   c-­‐FOS	  comparado	  con	   la	  piel	  adyacente	  al	   tumor	  mientras	  que	  en	   los	  carcinomas	  basales	   no	   se	   detectó	   expresión	   de	   c-­‐FOS.	   Además,	   el	   70%	   de	   los	   carcinomas	  epidermoides	   coexpresan	   ambas	   proteinas,	   c-­‐FOS	   y	  MMP10	   pero	   no	   se	   obervó	  coexpresión	   entre	   c-­‐FOS	   y	   S100A7.	   Finalmente,	   el	   70%	   de	   los	   carcinomas	  epidermoides	   que	   expresan	   niveles	   altos	   de	   c-­‐FOS	   presentaban	   infiltración	   de	  linfocitos	  T	  CD4+.	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AP-­1	  Protein	   Phenotype	   Affected	  organs/cells	   Reference	  
TRANSGENIC	  
H2Kb-­Jun	   None	   H2Kb-­‐Jun	   	  (Grigoriadis	  et	  al.,	  1993)	  
UBC-­JunB	   Increased	  bone	  mass	   Thymus,	  CD4	  thymocytes	  	  (Schorpp	  et	  al.,	  1996)	  
CD4-­JunB	  
Enhanced	  Thelper	  cell	  2	  maturation	   Thymus,	  CD4	  thymocytes	  	  (Li	  et	  al.,	  1999)	  
UBC-­JunD	  
Peripheral	  T	  cells	  and	  B	  cells	  reduced	   Lymphocytes	   	  (Meixner	  et	  al.,	  2004)	  
H2Kb-­Fos	   Osteosarcoma	   Bone,	  osteoblasts	   	  (Grigoriadis	  et	  al.,	  1993)	  
H2Kb-­c-­
Fos/Rsk-­2-­/y	   Reduced	  osteosarcoma	   Bone,	  osteoblasts	   	  (David	  et	  al.,	  2005)	  
H2Kb-­FosB	   None	   Bone	   	  (Grigoriadis	  et	  al.,	  1993)	  
TCRb-­ΔFosB	  
Impaired	  T	  cell	  differentiation	   Thymus,	  immature	  thymocytes	   	  (Carrozza	  et	  al.,	  1997)	  
NSE-­DFosB	   Osteosclerosis	   Bone,	  osteoblasts	   	  (Sabatakos	  et	  al.,	  2000)	  
H2Kb-­Fra-­1	   Osteosclerosis	   Bone,	  osteoblasts	   	  (Jochum	  et	  al.,	  2000)	  
CMV-­Fra-­2	  
Increased	  bone	  mass,	  fibrosis	   Bone,	  internal	  organs,	  skin	   	  (McHenry	  et	  al.,	  1998)	  
H2Kb-­Fra-­2	  
Lung	  fibrosis,	  Osteosclerosis	   Lung,	  Bone,	  osteoblasts	   	  (Eferl	  et	  al.,	  2008)	  
KNOCK-­OUT	  
c-­Jun	  
Embryonic	  lethal	  at	  E12.5	   Liver,	  heart,	  neural	  crest	   (Hilberg	  et	  al.,	  1993;	  Johnson	  et	  al.,	  1993;	  Johnson	  et	  al.,	  1993)	  
JunB	  
Embryonic	  lethal	  at	  E10	   Extraembryonic	  tissues	   (Schorpp-­‐Kistner	  et	  al.,	  1999)	  
JunD	   Male	  sterility	   Testis,	  spermatides	   (Thepot	  et	  al.,	  2000)	  
c-­Fos	   Osteopetrosis	   Bone,	  osteoclasts	   (Wang	  et	  al.,	  1992)	  
FosB	   Nurturing	  defect	   Brain,	  hypothalamus	   (Gruda	  et	  al.,	  1996;	  Brown	  et	  al.,	  1996)	  
Fra-­1	  
Embryonic	  lethal	  at	  E9.5	   Exraembryonic	  tissue	   (Schreiber	  et	  al.,	  2000)	  
Fra-­2	   Lethal	  after	  birth	   Bone,	  osteoclasts	   (Eferl	  et	  al.,	  2007)	  
CONDITIONAL	  
Alfp-­cre	  c-­Jun	  
Liver	  regeneration	  defect	   Liver,	  hepatocytes	   	  (Behrens	  et	  al.,	  2002)	  
Alfp/Mx-­cre	  c-­Jun	  
+DEN	  
c-­‐Jun	  required	  for	  liver	  initiation	  tumorigenesis	   Liver,	  hepatocytes	   (Min	  et	  al.,	  2012)	  
Col2a1-­cre	  c-­Jun	   Scoliosis	   Bone,	  notochonrdal	  cells	   (Behrens	  et	  al.,	  2003)	  
Nestin-­cre	  c-­Jun	  
Axonal	  regeneration	  defect	   Central	  nervous	  system,	  motoneurons	   (Raivich	  et	  al.,	  2004)	  
MORE-­cre	  JunB	   Osteopenia	   Bone,	  osteoclasts,	  osteoblasts	   	  (Kenner	  et	  al.,	  2004)	  
MORE-­cre	  Fra-­1	   Osteopenia	   Bone,	  osteoblasts	   	  (Eferl	  et	  al.,	  2004)	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Nestin-­cre	  Fos	   Learning	  defects	   Bran,	  hippocampal	  neurons	   	  (Fleischmann	  et	  al.,	  2003a)	  
K5-­cre	  c-­Jun	  
Eyes	  open	  at	  birth,	  reduced	  skin	  tumors	   Keratinocytes	   (Zenz	  et	  al.,	  2003)	  
K5-­cre	  c-­Jun,	  K5-­
SOS	   	  	   	  	   (Zenz	  et	  al.,	  2003)	  
K5-­cre	  Fra-­2	  
Epidermal	  hyperplasia	  and	  inflammation	   Keratinocytes	   Wurm,	  unpublished	  
K5-­cre	  JunB	  
Myeloproliferative	  disease,	  bone	  loss,	  epidermal	  hyperplasia	  and	  inflammation	   	  Keratinocytes	  	   	  (Meixner	  et	  al.,	  2008)	  
K5-­cre	  c-­Fos	   None	   Keratinocytes	   (Guinea-­‐Viniegra	  et	  al.,	  2012)	  
K5-­cre	  Fos,	  K5-­SOS	  
Reduced	  papilloma	  size	  with	  increased	  differentiation	   Keratinocytes	   (Guinea-­‐Viniegra	  et	  al.,	  2012)	  
K5-­cre	  JunB,	  c-­Jun	  
Systemic	  inflammatory	  response	  with	  cachexia	   Keratinocytes	   (Guinea-­‐Viniegra	  et	  al.,	  2009)	  
INDUCIBLE	  
K5-­creERTJunB	  +	  
Jun	   Psoriasis-­‐like	  disease	  Skin,	  joints,	  keratinocytes	  	  (Zenz	  et	  al.,	  2005)	  
K5-­creERTFos;	  K5	  
SOS	  
Reduced	  papilloma	  size	   Keratinocytes	   	  (Guinea-­‐Viniegra	  et	  al.,	  2012)	  
	  	   	  	   	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
